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Abstract 
 
Three enzymes – One substrate 
Regulation of carbon flux through a “non-canonical” metabolic branchpoint 
Audrey Crousilles 
 
Pseudomonas aeruginosa is a common opportunistic pathogen. Recent work indicates that in many 
infection scenarios, P. aeruginosa exhibits an exquisite predilection for metabolizing fatty acids to 
yield acetyl-CoA. In most higher organisms, acetyl-CoA cannot be used for biomass production 
because the two carbon atoms which enter the TCA cycle are lost as CO2. However, many bacteria 
are able to bypass these oxidative decarboxylation steps, allowing them to conserve carbon for 
gluconeogenesis. They perform this by using the “glyoxylate shunt”. Here, isocitrate is cleaved by 
isocitrate lyase (ICL) to yield succinate and glyoxylate (which, in a subsequent reaction, is combined 
with a further acetyl-CoA unit to yield the gluconeogenic precursor, malate). However, ICL has to 
compete with the TCA cycle enzyme, isocitrate dehydrogenase (ICD), for the available isocitrate, 
and it is the outcome of this “metabolic tussle” which dictates the flux of carbon through the 
glyoxylate shunt. In E. coli, ICD is inactivated by AceK-dependent phosphorylation, allowing flux 
through the glyoxylate shunt. However, P. aeruginosa is “wired up” differently because it employs 
not one, but two highly-expressed isocitrate dehydrogenases (ICD and IDH). For this PhD project, I 
focused on these three enzymes (ICD, IDH and ICL). I cloned, overexpressed and purified them at 
high yield to perform a thorough investigation of their kinetics, regulation and more interestingly 
crystal structures. I found that only one of these (the E. coli-like ICD) is regulated by AceK-mediated 
phosphorylation. The other, IDH, is allosterically regulated, as is the isocitrate lyase. These findings 
demonstrate that in P. aeruginosa the rerouting of the carbon flux through the glyoxylate shunt is 
delicately regulated via allostery mainly. The conditions in which the cells grow and access to either 
poor or rich carbon sources heavily influence the partitioning of the central metabolism. In P. 
aeruginosa, the TCA cycle remains more active (than in E. coli for example) even during growth on 
poor nutrient and this is probably an important aspect to manage oxidative stress accompanying 
growth. Finally, I have solved the x-ray crystal structures of ICD, IDH and ICL. These are entirely 
novel structures that have not been defined previously and are new entries to the Protein Data Bank. 
The structure solving work highlighted very interesting peculiarities to these enzymes when compared 
with other bacterial pathogens. This emphasizes the growing idea that Pseudomonas aeruginosa is a 
unique bacterium that cannot be modelled by the well-studied Escherichia coli. All this work 
crystallizes the knowledge to build up a picture of how flux is likely to be regulated at this “non-
canonical” metabolic branchpoint and features new interesting directions for downstream applications 
such as drug-design.  
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 1 
1. Introduction 
1.1. Pseudomonas aeruginosa 
1.1.1. Generalities 
Pseudomonas aeruginosa is a Gram-negative, rod-shaped and mono-flagellated bacterium of 
the Pseudomonadaceae family. Pseudomonads are renowned for their metabolic versatility and their 
widespread distribution. P. aeruginosa is defined as a ubiquitous microorganism; it can grow in soil 
and coastal marine habitats but also on plant and animal tissues1. It is capable of forming biofilms 
as a trait to grow on wet surfaces including rocks and soil2. Pseudomonas was initially an 
environmental organism, but it evolved to colonise and establish infections in more complex hosts 
including humans, animals and plants3. 
In humans, P. aeruginosa is an opportunistic pathogen of immunocompromised or 
immunodeficient individuals. It accounts for around 10% of all nosocomial infections in hospitals in 
the European Union4, and in February 2017, made it to the top-three priority pathogens list for new 
antibiotics R&D after reports of carbapenem-resistant strains5,6. So, P. aeruginosa is a significant 
source of bacteraemia in burns victims, urinary-tract infections in catheterized patients and hospital-
acquired pneumonia treated with respirators7. The ubiquitous trend stems from an array of abilities 
to facilitate adaptation and survival in diverse ecological niches. P. aeruginosa has broad capabilities 
to transport, metabolize and grow on organic substances. It is well equipped to export compounds 
(antibiotics included) with a large number of pumps and efflux systems8. Furthermore, P. aeruginosa 
has the ability to form adhesive communities known as biofilms and possesses an impressive arsenal 
of virulence factors9,10. More specifically, the metabolic versatility is provided by genes encoding not 
only the enzymes participating in metabolic pathways, but also a surprisingly large number of 
transcriptional regulators. With more than 500 regulatory genes, P. aeruginosa is particularly complex 
and demonstrates fine regulation of multiple pathways11. This PhD project will highlight one of them 
and its consequences for carbon management in the cell. 
Another interesting aspect of Pseudomonas aeruginosa is its genome. It has one of the largest 
and most complex genomes among bacteria. Within the species, the size varies between 5.5 and 7 
Mbp and the G-C content fluctuates around 65-67%. The genome itself is made up of a single circular 
chromosome and a variable number of plasmids12. The divergence in genome size is explained by its 
structure, there is the core genome and the accessory genome. The latter increments the variable 
length. The conserved core component of the genome is largely collinear among P. aeruginosa 
strains13. Ongoing genome projects indicate that the core genome consists of somewhat more than 
4,000 genes. It is highly conserved among divergent strains within the species, and overall shows very 
low interclonal sequence diversity of 0.5 –  0.7 %. Very few loci in the core genome are subject to 
diversifying selection. As an example of the integrity of this genome, a study performed on a subset 
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of characterized clinical strains identified 5,021 genes that are conserved across all five genomes, with 
at least 70% sequence identity. This set of genes was therefore indicative of the core genome. Among 
these, more than 90% of them shared at least 98% sequence identity14. Furthermore, a similar study 
analysed twenty clinical isolates and concluded that 89 to 97% of the PAO1 open reading frames 
(ORFs) were detected revealing a conserved pattern of genome mosaicism. However, the variable 
genomic regions appeared as 38 islands dispersed in the chromosome. These sites of dispersion of 
additional genetic information remain complex and very variable, they participate in the genome 
mosaicism of P. aeruginosa and explain its intrinsic capability to adapt so easily and perfectly to its 
environment15.  
The accessory genome on the other hand consists of fragments of DNA from a few hundreds 
to 200 kbp long. The minimum size of an accessory element was defined to be at least four contiguous 
ORFs. These so-called regions of genome plasticity (RGP) add about a further 10,000 or so genes to 
the whole genome. The actual number of accessory elements diverges in length and number which 
leads to the greatest variability between clones of the same species, but overall there are between 38 
and 53 islands that have been identified between all strains. As an example, the laboratory strain 
PAO1 exhibits very little accessory element with only one RGP while another laboratory strain PA14 
exhibits seven of them14. The usual definition of an RGP refers to a horizontally acquired genetic 
element present in the chromosome of individual strains. Very often phages, transposons or insertion 
sequences make up these RGP and indicate how mobile these DNA elements are; they have been 
acquired then kept by the host strain. Many elements were eventually fixed by secondary mutation 
or deletion, but a few of them remain mobile and are passed on to a new host. The accessory genome 
is central to P. aeruginosa biology. The horizontal transfer of these elements implements the genome 
evolution of the species and more importantly it also confers specific phenotypes that are 
advantageous in selective conditions16. Overall, the accessory genome encodes genes involved in the 
pathogenicity with lipopolysaccharide (LPS) O antigen, pyoverdine, pili and even flagellum17– 20. These 
are great assets for the persistence of the species by encoding virulence factors21 and resistance to 
antibiotics22. 
1.1.2. Infections scenario 
1.1.2.1. Acute infections 
P. aeruginosa is an opportunistic pathogen, infections occur in hospitalised patients, 
immunocompromised hosts and patients with cystic fibrosis. Patients with a greater risk of infection 
include individuals with acquired immunodeficiency syndrome (AIDS) or cancer23,24. Perhaps, one of 
the most evident infections following an immunocompromising event is in burns victims. Extensive 
breaches in the skin barrier open a door to opportunistic pathogens; and the environmental occurrence 
of P. aeruginosa makes it a prime candidate. Treating these infections is difficult and the mortality 
rate among the patients is likely to reach up to 40-50%. It is then urgent to prevent the spread of the 
pathogen from the environment or between patients25. This example illustrates how most acute 
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infections are nosocomial in nature. Out of all hospital-acquired infections caused by Gram-negative 
bacilli, P. aeruginosa ranks as the second cause associated with nosocomial infection26. However, 
among the anatomic sites of P aeruginosa infection, the lung is associated with the highest mortality 
rate. Respiratory tract infections by P. aeruginosa remain the most frequent, they include hospital-
acquired and ventilator-associated pneumonia27. The evolution of such infections is characterized by 
haemorrhagic and necrotizing lung pathology with vasculitis (inflammation of the blood vessels) and 
microabcesses28,29. The case of ulcerative keratitis of the cornea exemplifies the versatility of the 
microorganism. Without necessarily a point of entry into the body, these infections became common 
in users of extended-wear soft contact lenses30,31. The intrinsic change of the tears composition as a 
consequence of use of the lenses promotes the adhesion and colonisation of the cornea by P. 
aeruginosa. The transenveloppe apparatus of the microorganism (flagellum and pili) play an 
important role for the adhesion to the host tissue. Following that, P. aeruginosa is then capable of 
producing several exotoxin proteins and proteases that are important virulence factors in keratitis. 
These products include exotoxin A, phospholipase C, elastase (LasB), alkaline protease and the LasA 
protease (endopeptidase); and eventually degrade the corneal tissue32,33. Bloodstream infections by P. 
aeruginosa persist in patients admitted in intensive care units because of the multiple point of entries 
into the body. Surgical site infections fall into this category. However, the prognosis of P. aeruginosa 
bacteraemia remains poor with a mortality exceeding 38%34,35. Finally, urinary tract infections (UTIs) 
remain the most common bacterial infections an individual will encounter. In this case, P. aeruginosa 
ranks as the third species to cause hospital-acquired catheter-associated UTIs36,37. 
1.1.2.2. Chronic infections 
The chronic, long-term infections associated with P. aeruginosa generally occur in the lungs 
of patients who exhibit subjacent respiratory conditions. The most common of these conditions is 
cystic fibrosis that we will investigate in the next section. However, there are many cases of chronic 
infections in patients with bronchiectasis or chronic obstructive pulmonary disease (COPD). 
Bronchiectasis is defined by the presence of permanent and abnormal dilation of the bronchi. The 
inflammatory process commences in the small airways, releases mediators such as proteases which 
damage the large airways. With progression of the disease, the follicles enlarge in size and cause 
airflow obstruction to the small airways38– 41. COPD is characterised by poorly reversible airflow 
obstruction and an abnormal inflammatory response in the lungs. The airflow is limited due to an 
abnormal inflammatory response of the lungs to noxious chemicals (particles, gases, cigarette 
smoking)42. These three diseases show a similar pattern of accumulation of mucus in the lungs due to 
poor mucosal clearance and this results in the formation of a favourable environment for the 
establishment of Pseudomonas43– 45. Additionally, chronic infections with P. aeruginosa are associated 
with high-density bacterial assemblages, such as biofilms that favour the emergence of variants mostly 
arising through homologous recombination, recombinatorial DNA repair, and DNA mismatch repair 
deficiency46,47. 
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1.1.2.3. Cystic fibrosis (CF) 
Cystic fibrosis is an autosomal recessive disease caused by mutations in the gene encoding the 
cystic fibrosis transmembrane conductance regulator (CFTR). This gene is located on the human 
chromosome 7 and encodes a cyclic adenosine monophosphate-regulated chloride channel found at 
the apical surface of epithelial cells. So far, more than 500 mutations of the CFTR gene have been 
identified which showcases the complexity of the disease and its causes. In the lungs, inactive or 
inefficient functioning CFTR results in impaired chloride transport and enhanced sodium absorption 
across airway epithelial cells. This leads to a net increase in water absorption. Alternatively, the 
volume of the liquid that sits on the outer surface of the airway epithelium is reduced (due to hyper 
absorption by the cells) and the mucus eventually becomes thicker. Because of this thick mucus, 
ciliary clearance is impaired which provides a favourable environment for bacteria to proliferate. 
There is no longer a threat that would expulse them out of the lungs48– 54. The widespread presence of 
CFTR throughout the body helps to explain the actual pleiotropic effect of this genetic condition. 
Other organs such as the liver, pancreas, intestines and bones will eventually develop signs of 
complication55,56. In terms of figures, in the European Union, CF affects on average 1 in 3,000 births57. 
It is the most common genetic disease within the Caucasian population and it is the leading cause to 
premature respiratory failure. There are approximately 60,000 individuals currently living with CF 
in North America and Europe, 40% of whom are adults58. 
Although the survival of CF patients has significantly improved in the past decades, CF 
remains a life-limiting condition. The median survival age ranges from 23 to 40 years old in Europe 
depending on the country studied. One aspect of the condition is its impact on the nutrition and 
growth rate of the individuals. Due to pancreatic malfunction, CF leads to malnutrition which would 
eventually impact the overall health of the patient. Compared to the early recognized cases of CF in 
the forties, medical care and antibiotic treatment improved to extend the survival as we know it 
nowadays59– 62. However, the consequence is now that morbidity and mortality is caused by recurrent 
and chronic bacterial infections. Colonization of the lungs by a polymicrobial population leads to 
complicated situations with advanced 
respiratory failure and infections63– 65. 
The CF airways accumulate 
thick mucus which provides an 
environment highly susceptible to 
colonization by opportunistic 
pathogens, including bacteria, fungi 
and viruses. Bacterial colonization is 
probably promoted by the unique 
composition of the sputum. It is 
particularly rich in mucin, lipids, 
Figure 1: Prevalence of the bacterial population in cystic fibrosis 
lungs per age cohort. For the first 12 years of the patient life, the 
bacterial population in the CF airways is diverse with S. aureus 
dominance. Then, it appears clearly that by the age of 18, P. 
aeruginosa population becomes more prominent (Figure adapted 
from Paranjape et Mogayzel, 201471). 
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proteins, amino acids, ions and DNA released by the host’s neutrophils66– 70. The life of a CF individual 
will inevitably be marked by the colonization of the lungs by successive bacterial species. In the early 
stages, as seen in figure 1 (adapted from Paranjape et Mogayzel71), Staphylococcus aureus and 
Haemophilus influenza dominate. Then, by the age of 18, Pseudomonas aeruginosa takes over and 
typically becomes predominant. Other species remain steady, such as S. aureus, Burkholderia cepacia 
and Stenotrophomonas maltophilia72. The complexity of the bacterial population encourages contact 
and interaction between bacterial cells themselves and between bacterial and the host’s cells via cell-
to-cell signalling molecules, via notably quorum sensing in the former or TLR5-activated cascade by 
flagellin in the latter73,74. 
1.1.3. Antibiotic resistance 
Pseudomonas aeruginosa is intrinsically resistant to a variety of antimicrobials and 
consequently has joined the category of “superbugs” due to its capacity to develop antibiotic 
resistance. The bacterium constitutively demonstrates decreased susceptibility to most antibiotics 
including aminoglycosides, fluoroquinolones and b-lactams. This is because of low outer membrane 
permeability which prevents the penetration of these molecules into the cells due to inefficient porins 
as an uptake route for antibiotics. This then allows secondary adaptive mechanisms to work more 
efficiently, including increased efflux and enzymatic antibiotic modifications (e.g. b-lactamase). Like 
immunity in humans, antibiotic resistance is either intrinsic or acquired75– 77. 
1.1.3.1. Intrinsic resistance 
The outer membrane permeability plays a major role in P. aeruginosa resistance. It 
constitutes a semi-permeable barrier for the uptake of small molecules. However, the uptake of 
hydrophilic molecules such as b-lactams is limited to the use of water-filled channels of porin proteins 
which prevent the movement of such molecules into the cell. This is a characteristic of all Gram-
negative bacteria but this is particularly true for P. aeruginosa as it has up to a 100-fold lower outer 
membrane permeability compared with E. coli78. The major porin in P. aeruginosa is OprF and 
accounts for up to 65% of nonspecific permeation through the outer membrane. Smaller channel 
proteins, OprD and OprB, mediate the movement of other antibiotic-like molecules. Despite the high 
number of copies of OprF, it remains an inefficient antibiotic uptake route because of either 
heterogeneous formation (only a very small proportion of porins form large channels)79 or inefficient 
architecture (the porins have been reported to be extremely narrow)80. That means that the remaining 
35% of nonspecific permeation is guided by the other channels, which are intrinsically less efficient as 
porins. Specific channels are responsible for the uptake of carbapenem b-lactams, such as OprD. Loss 
of OprD is frequently associated with resistance to imipenem81,82. And more recently, OprD impaired 
strains of P. aeruginosa have been detected. A point mutation leading to an amino acid substitution 
at codon 170 gives the advantage of escaping the last line of antibiotic treatment83,84. 
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P. aeruginosa is geared up with efflux pumps that will eventually extrude any molecule that 
has been taken up via the porins. The systems are composed of three protein components: an energy-
dependent pump in the cytoplasmic membrane (Mex component), an outer membrane porin (Opr 
component) and a linker protein, also a Mex component, which couples the two previous together85. 
These pumps belong to the resistance-nodulation-cell division (RND) superfamily of transporters. To 
date 12 out of 17 sequenced RND have been characterized in P. aeruginosa. Four of them have been 
studied in depth and these are MexAB-OprM, MexXY-OprM, MexCD-OprJ and MexEF-OprN86. 
MexAB-OprM is responsible for extrusion of b-lactams, quinolones and a range of disinfectants. 
MexXY-OprM extrudes aminoglycosides while MexEF-OprN extrudes carbapenems and quinolones. 
Finally, MexCD-OprJ accommodates a variety of macrolides, tetracycline and some b-lactams87. 
P. aeruginosa typically carries two endogenous b-lactamases: cephalosporinase, AmpC and 
an oxacillinase, PoxB. AmpC is well known and is commonly linked to b-lactam resistance in clinical 
isolates. AmpC is not unique to P. aeruginosa, it is common to a large number of Gram-negative 
bacteria. It is inducible by a number of b-lactam antibiotics and thus contributes to the intrinsic 
resistance of P. aeruginosa. The right amount of antibiotic will trigger the up-regulation of the 
enzyme. Resistance to b-lactams is further improved by mutational derepression of ampC gene 
providing a quicker response in case of selective pressure from the environment. More b-lactamases 
have been acquired as the antibiotic treatment became harsher, as an example this includes the 
extended-spectrum b-lactamase (ESBL) enzymes capable of hydrolysing a broader range of b-
lactams82,88. 
1.1.3.2. Acquired resistance 
There are two types of acquired resistance that implement the intrinsic resistance of P. 
aeruginosa to become even less susceptible to antibiotics. These are horizontal transfer of genetic 
elements and mutational resistance. DNA elements such as plasmids, transposons, integrons or 
resistance islands can be acquired by conjugation, transformation or transduction. This promotes 
antibiotic resistance acquisition and multi-drug resistance as some plasmids can potentially carry 
multiple antibiotic cassettes. Such horizontal transfer has been mainly reported in cases of 
aminoglycoside and b-lactam resistance89,90. Another mechanism for acquired resistance is mutational 
resistance. The normal mutation rate (10– 6 to 10– 9 per nucleotide per generation for individual 
antibiotics) can significantly increase under selective conditions. For example, the frequency of 
selection of ciprofloxacin-resistant mutants of P. aeruginosa increased 100-fold when the organism 
was grown as a biofilm in comparison with free-living cells91. The hypermutators represent this 
extreme adaptation of P. aeruginosa that can acquire resistance to several different antibiotics. These 
strains contain mutations in genes involved in the repair of damaged DNA and they are frequently 
found in CF airways47,92. 
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1.1.4. Virulence factors 
The opportunistic profile of P. aeruginosa is recognisable for having an arsenal of virulence 
factors that help to facilitate successful infection and colonisation across a wide range of environments. 
The established versatility of its genome justifies how the bacterium is able to exploit any niche it 
colonizes. P. aeruginosa utilizes the secretion of compounds, toxins and proteins as virulence factors. 
This can occur via simple transport or using a complete machinery dedicated to the transport of 
extracellular virulence factors. Alternatively, the bacteria are capable of adapting their type of growth, 
from free cells to biofilms, introducing an alternative pathogenesis. The production and regulation of 
these virulence factors is under the control of quorum sensing (QS)93– 95. The production of extracellular 
compounds includes exotoxin A and exoenzyme S. Exotoxin A leads to the inhibition of protein 
biosynthesis and local tissue damage96,97. Exoenzyme S causes direct tissue destruction through its 
action on the actin cytoskeleton of the host’s cells98. The secretion of phospholipase C and rhamnolipid 
promotes a synergetic break down of the host’s lipids forming the surfactant and eventually aid the 
scavenging of nutrients for the bacteria’s good99. This is particularly clear in the CF airways in which 
the surfactant is cleaved, transported and metabolised by P. aeruginosa. This provides a sustainable 
environment for the colonisation of the bacteria and the worsening of the patient’s condition. The 
package of secreted proteases includes LasB, LasA, and alkaline protease. The ability of P. aeruginosa 
to destroy the protein elastin promotes loss of the epithelial barrier of the infected tissues and opens 
a wider door to invasive infections100. 
P. aeruginosa possesses four dedicated secretion systems that are involved in the secretion of 
virulence factors, they are Type I, II, III and VI. There are two Type I secretion systems (T1SS), four 
Type II (T2SS), only one Type III system (T3SS) and three Type VI secretion systems (T6SS) that 
have been identified and located on the chromosome101,102. The Apr T1SS is known to secrete AprA, 
the alkaline protease along with AprX of unknown function103,104. The second, Has T1SS secretes haem 
scavenging proteins105. The two T2SS are the Xcp and Hxc systems. The Xcp system secretes a 
number of toxins and proteases that will eventually disrupt the host’s cells’ integrity (exotoxin A, 
lipases and elastases)106,107. The Hxc system on the other hand is dedicated to the secretion of the 
alkaline phosphatase LapA108. The T3SS in P. aeruginosa is of a more complex nature in terms of 
architecture with its needle like apparatus capable of injecting the products directly into the host’s 
cells. It secretes a number of enzymes known as ExoS, ExoT, ExoU and ExoY. These have a potent 
cytotoxic effect on the eukaryotic cells. Finally, the genome of P. aeruginosa contains 3 loci encoding 
T6SS components, called H1, H2 and H3. Also, much is now known about these effectors of this 
system. To date, they have been characterized to be either cell wall-degrading effectors (Tse1, Tae, 
VgrG these are amidase, glycosidase and muramidase respectively) or cell membrane-targeting (Tle, 
VasX are phopspholipase or pore forming respectively)109,110. The regulation of the T3SS and T6SS is 
under the control of the two-component system RetS/LadS as well as cyclic-di-GMP (c-di-GMP). 
These two systems thus coordinate the two secretion systems to further establish Pseudomonas 
pathogenesis111. 
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The motility of Pseudomonas aeruginosa can be an important factor in allowing first 
establishment then colonization of new niches. The microorganism can swim, swarm or twitch. 
Swimming is aided by the rotation of a single polar flagellum. It has been demonstrated that it also 
triggers phagocytosis by neutrophils, the first line of defence in human infections112. Swarming motility 
defines a multicellular phenomenon involving the coordinated and rapid movement of a bacterial 
population across semi-solid surfaces. This is usually linked to increased antibiotic resistance113. The 
twitching motility involves the extension and retraction of type IV pili and therefore plays a vital 
role in bacterial attachment and initial colonisation, particularly on mucosal cell surfaces114. These 
factors highlight the complexity of Pseudomonas aeruginosa pathogenesis, and it is particularly well 
equipped to take over a niche and lead to acute infections, and depending on the scenario, also a 
chronic infection.  
1.2. A metabolic choice: 2C or not 2C? 
1.2.1. TCA cycle 
1.2.1.1. Context and generalities 
Historically, the tricarboxylic acid cycle was identified in 1937 by Hans Krebs in animal 
tissues. Until about the late forties little was known about the cycle in microorganisms. The first 
steps of understanding of this cycle in unicellular organisms were in yeast although work slowly drifted 
to bacteria in the early fifties with the research conducted by Krebs, Kornberg and Monod among 
others115,116. The tricarboxylic acid (TCA) cycle was characterized in Pseudomonas in 1951117. 
The TCA cycle is part of the 
wider metabolic network, and 
especially glucose oxidation. The 
complete assimilation of a molecule of 
glucose eventually produces 38 
molecules of ATP. In bacteria, the 
complete oxidation of glucose involves 
three fundamental pathways. The first 
is the glycolytic or Embden-Meyerhof-
Parnas (EMP) pathway, the second is 
the Krebs cycle (also called the citric 
acid cycle or TCA), and the third is the 
series of membrane-bound electron 
transport complexes coupled to 
oxidative phosphorylation. Respiration 
is the metabolic process by which 
pyruvate or acetyl-CoA is completely 
Figure 2: TCA cycle schematic. The eight enzymatic reactions 
permit the production of intermediates metabolites rerouted for 
further synthesis of amino acids, fatty acids and gluconeogenesis. 
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oxidised to carbon dioxide118. This means that the TCA cycle plays a major role in the catabolism of 
organic fuel molecules, including glucose and other sugars, fatty acids, and some amino acids. In case 
of access to glucose in the environment, the glycolytic or EMP pathway first cleaves it into two 
molecules of pyruvate. However, there are two other glucose-catabolizing pathways found in bacteria: 
the oxidative pentose phosphate pathway and the Entner-Doudoroff pathway (EDP), which is almost 
exclusively found in obligate aerobic bacteria. Most Pseudomonas species (aeruginosa included) do 
not perform glycolysis via the EMP pathway because of the absence of key enzymes. As a result, 
sugars are metabolized in P. aeruginosa primarily by the EDP which yields two molecules of pyruvate 
out of one molecule of glucose119– 121. 
Before any of these molecules can enter the TCA cycle they first have to be broken down into 
acetyl-CoA by pyruvate dehydrogenase. Once fed into the cycle, acetyl-CoA is eventually converted 
into carbon dioxide and in doing so, yields reducing equivalents for electron transport. So, the TCA 
cycle consists of eight steps catalysed by eight different enzymes. The cycle is initiated (1) when 
acetyl-CoA reacts with the compound oxaloacetate to form citrate and to release coenzyme A. Then, 
in a succession of reactions, (2) citrate is rearranged to form isocitrate; (3) isocitrate loses a molecule 
of carbon dioxide and then undergoes oxidation to form a-ketoglutarate; (4) a-ketoglutarate loses a 
molecule of carbon dioxide again and is oxidized to form succinyl-CoA; (5) succinyl-CoA is 
enzymatically converted to succinate; (6) succinate is oxidized to fumarate; (7) fumarate is hydrated 
to produce malate; and, to end the cycle, (8) malate is oxidized to oxaloacetate. Each complete turn 
of the cycle results in the regeneration of oxaloacetate and the formation of two molecules of carbon 
dioxide (see figure 2). One advantage of the TCA cycle is the production of energy. In step 5, one 
molecule of ATP is regenerated directly after dephosphorylation of GTP by a nucleoside diphosphate 
kinase. The production of molecules of NAD+, NADP+ and FAD indirectly lead to the formation of 
ATP during the final step of respiration which includes electron transport and oxidative 
phosphorylation122. The TCA cycle also has an important anabolic role in the cell. It works as the 
central metabolic “hub” of the cell for the biosynthesis of key cellular intermediates for anabolic 
reactions. For example, many amino acids are synthesized starting with the transamination of α-
ketoglutarate and oxaloacetate. Porphyrins and heme are synthetized from succinyl-CoA while citrate 
initiates the synthesis of fatty acids and sterols123. 
1.2.1.2. Regulation 
The expression of the TCA cycle enzymes is regulated at the transcriptional level. In 
Escherichia coli, three regulatory systems interact to balance the levels of these enzymes. Firstly, the 
substrate uptake relies on an intracellular sensor (usually a transcription factor) that will trigger a 
positive feedback loop. The accumulation of an intermediate signals nutrient availability, the 
information is transferred via a transcription factor to amplify the flux. A typical example of this 
system is the Lac operon and the output of the presence or absence of lactose as an inducer124,125. 
Secondly, the carbon catabolite repression (CCR) integrates several regulatory circuits which can 
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prioritize one substrate over another by sensing the presence of preferred carbon sources126– 128. It 
consequently reduces the uptake of alternative carbon sources. This system centres around the 
transcription factor Crp in E. coli, or alternatively Crc in P. aeruginosa. Crc (Catabolite Repression 
Control)129,130 is a post-transcriptional global regulator of carbon metabolism. Crc binds an A-rich 
region located close to the ribosomal binding site of the target mRNAs and inhibits translation 
initiation131. The mechanism of action is similar to that of RsmA, which means that the actual 
regulation of Crc itself is dependent on a small RNA (CrcZ) that binds the protein preventing it from 
binding to its target132. Finally, the CbrAB two-component system was discovered in P. aeruginosa 
as important regulatory elements for the expression of several catabolic pathways. cbrAB mutants 
are unable to utilize a variety of organic compounds as sole carbon source133,134. Such a two-component 
system consists of a sensor protein kinase (or transmitter) paired with a cognate response regulator. 
The environmental signals (carbon source available) trigger autophosphorylation of the transmitter 
that will subsequently transfer its phosphate to the acceptor domain of the regulator resulting in its 
activation135,136. 
1.2.2. The glyoxylate shunt 
1.2.2.1. Generalities 
The glyoxylate shunt is present in a wide range of plants, yeasts and bacteria. It allows the 
net conversion of acetyl-CoA to malate and is thus defined as an anaplerotic or replenishing pathway. 
Acetyl-CoA plays a pivotal role in 
metabolism for being the end product 
of multiple catabolic routes (glycolysis, 
fatty acid β-oxidation, amino acid 
degradation). Moreover, in case of 
access to poor nutrient source such as 
acetate during infection scenarios, 
acetyl-CoA is the end product of the 
conversion catalysed by acetyl-CoA 
synthetase. This will feed into the first 
steps of the TCA cycle as seen 
previously. However, synthesis of sugar 
compounds from acetyl-CoA molecules 
alone is impossible, unless the organism 
develops a pathway termed the 
glyoxylate cycle, which is usually 
regarded as a bypass or shunt of the 
more generally occurring TCA cycle137. 
Two enzymes are specific to this cycle, 
Figure 3: Glyoxylate shunt schematic. The six enzymatic steps that 
make the glyoxylate cycle by-pass the two CO2-forming reaction 
catalysed by isocitrate dehydrogenase and a-ketoglutarate 
dehydrogenase. By doing so, two atoms of carbons are saved giving 
a substantial advantage when the cells grow on limited carbon 
source such as acetate. 
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isocitrate lyase (ICL) and malate synthase (MS). So, the glyoxylate cycle consists of six of the eight 
reactions of the TCA cycle but by-passes the two steps generating carbon dioxide (see figure 3). 
Thus, instead of oxidative decarboxylation in the TCA cycle, isocitrate is enzymatically cleaved to 
yield glyoxylate and succinate in a reaction catalysed by isocitrate lyase. This reaction is then followed 
by a condensation of glyoxylate and acetyl-CoA leading to the formation of malate by malate 
synthase138,139. By saving two atoms of carbon, the glyoxylate shunt allows microorganisms to produce 
precursors necessary for gluconeogenesis and other biosynthetic processes while growing on limited 
metabolic inputs with a C2 backbone such as acetate.  
Interestingly, the glyoxylate shunt was first discovered by Kornberg and Krebs in 1957 in 
Pseudomonas KB1140. The understanding of the implications of producing metabolic intermediates 
from C2 sources opened the door to the study of bacteria capable of surviving on poor nutrient 
sources141. Glucose, as the preferred carbon source, is not systematically present in the environment 
and that is particularly the case during infections69,142. Despite the fact that the shunt was first 
discovered in a pseudomonal species, most of the knowledge about it is based on E. coli. In this 
bacterial species, the two enzymes (ICL and MS) that form the bypass are induced when the bacteria 
grow on substrates such as acetate and ethanol as sole carbon source. On the other hand, they are 
completely repressed when carbohydrates or succinate are present in the growth medium143,144. In E. 
coli, the structural genes of isocitrate lyase and malate synthase (aceA and aceB, respectively) 
constitute an operon and they are expressed on a polycistronic mRNA145. A third enzyme accompanies 
the glyoxylate operon, this is isocitrate dehydrogenase kinase/phosphatase (AceK). It plays a major 
role in the regulation or partitioning of carbon flux between the TCA cycle and the glyoxylate shunt 
and this will be discussed in the next section. In terms of transcriptional regulation, in E. coli, the 
aceBAK operon is expressed from a single promoter after acetate induction and it is regulated by a 
repressor protein encoded by iclR146,147. IclR binds to a site which overlaps the -35 region of the 
aceBAK promoter148. Release of this repression upon adaptation to growth on acetate, fatty acids, or 
limiting glucose is presumably responsible for induction of the operon expression. The expression of 
the operon seems to respond to the general metabolic state of the cell, not necessarily to acetate only 
since growth on fatty acids triggers the expression without free acetate production148. Another 
regulator, encoded by fadR, participates in the negative transcriptional control of the operon along 
the regulation of fatty acid metabolism. FadR was initially identified for repressing the genes encoding 
the enzymes for fatty acid degradation149. However, it is now known that it also activates the 
expression of iclR by binding to its promoter region150.  
In Pseudomonas aeruginosa however, the genes encoding the glyoxylate shunt enzymes do 
not follow that same organisation; aceA, aceK and glcB, encoding ICL, AceK and MS respectively, 
are not in an operon and are separated on the genome. This highlights already the differences and 
the unique trait of P. aeruginosa compared with the well-studied bacterial model. In terms of genetic 
regulation of the bypass, a study attempted to investigate the effect of IclR on aceA151. The disruption 
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of the ORF predicted to encode IclR did not affect aceA expression in PAO1. The same study, 
however, found that RpoN negatively regulates aceA expression in PAO1. 
1.2.2.2. Branchpoint effect 
The branchpoint effect is the partitioning between the TCA cycle and the glyoxylate shunt; 
here, isocitrate plays a pivotal role. It is the substrate for isocitrate lyase on one hand, and isocitrate 
dehydrogenase on the other. Thus, there is a competition between these two enzymes for the 
substrate. In E. coli and S. enterica serovar Typhimurium, isocitrate dehydrogenase is regulated by 
phosphorylation. The function of this reversible phosphorylation is to regulate the branchpoint 
between the glyoxylate bypass and the TCA cycle during steady-state growth on acetate or fatty 
acids. Phosphorylation of isocitrate dehydrogenase diverts some of the flux from the TCA cycle to 
the glyoxylate shunt. The immediate effect of phosphorylation is to render isocitrate dehydrogenase 
inactive, forcing isocitrate through the glyoxylate shunt. So, inhibition of isocitrate dehydrogenase 
decreases flux through the TCA cycle and thus forces isocitrate through the bypass152,153. The resulting 
increase in the level of isocitrate further increases the velocity of isocitrate lyase, the first enzyme of 
the shunt. Partitioning of the flux can therefore be achieved through control of isocitrate 
dehydrogenase activity153. The single increase of isocitrate levels which occurs during growth on 
acetate does not trigger isocitrate lyase activity154. It has been demonstrated that mutant strains 
which are deficient in isocitrate dehydrogenase kinase activity failed to grow on acetate, suggesting 
the importance of the branchpoint regulation at that stage155. It is known that during growth on 
acetate, about 75% of the dehydrogenase enzyme is converted to its inactive phosphorylated form156. 
The phosphorylation cycle also controls the shunt during transition between carbon sources. 
For example, addition of a preferred carbon source such as glucose to a culture growing on acetate 
renders the bypass unnecessary. Under these conditions, the cells eventually shut down the bypass 
by dephosphorylating isocitrate dehydrogenase. Inhibition of the bypass occurs because the 
reactivation of isocitrate 
dehydrogenase draws isocitrate back 
to the TCA cycle. And because the 
Michaelis-Menten constant Km of 
isocitrate dehydrogenase (Km = 8 
µM) for isocitrate is significantly 
higher that of isocitrate lyase (Km = 
600 µM), isocitrate is naturally 
redirected through the TCA cycle157. 
This is also called the branchpoint 
effect. Because of the striking 
difference in the affinity of the two 
enzymes for the substrate, there is a 
Figure 4: Branchpoint model in E. coli. The affinity of ICD (Km = 8 
µM) for isocitrate outcompetes ICL (Km = 600 µM) and isocitrate goes 
through the TCA cycle. Flux through the glyoxylate shunt is 
redirected when ICD is phosphorylated, thus inactive, by AceK. 
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need to rewire the metabolism to push isocitrate through the bypass when necessary. The regulation 
of the glyoxylate bypass appears to be exquisitely sensitive to the metabolic state of the cell. Access 
to poor vs. rich carbon source and transition between the two if any, triggers a sensitive control at 
the branchpoint before partitioning of the carbon flux. For example, during growth on acetate, it 
appears that isocitrate and 3-phosphoglycerate (second last intermediate in the glycolysis before the 
production of PEP) participate in the control of the phosphorylation cycle. These intermediates 
probably act as indicators of the metabolic state of the cell and thus of the need to redirect isocitrate 
through the glyoxylate shunt. In case of depletion of these metabolites, phosphorylation of isocitrate 
dehydrogenase would increase, forcing isocitrate through the bypass. However, in case of transition 
to a preferred carbon source such as glucose, the levels of these two metabolites become normal but 
they do not prompt dephosphorylation of ICD. Dephosphorylation is more likely to be promoted by 
pyruvate as the levels of this metabolite rise significantly upon addition of glucose145,154,158,159. The 
effect of metabolite levels, the sensitivity of the phosphorylation cycle and the branchpoint effect are 
combined to produce a system in which very subtle changes in metabolic signals have the potential 
for producing profound changes in the flux between the TCA cycle and the glyoxylate shunt. This 
knowledge of the branchpoint has been gathered after extensive study on E. coli drawing the known 
model as seen in figure 4. 
Studies on other prokaryotes, such as Mycobacterium tuberculosis and Salmonella enterica, 
have confirmed the importance of the glyoxylate shunt. The bypass becomes functional when the 
bacterium has access to C2 substrate as the main carbon source160– 162. A study conducted on a DaceA 
mutant strain S. enterica serovar Typhimurium demonstrated that the bacteria were enabled to grow 
on acetate as sole carbon source160. Alternatively, a similar approach in M. tuberculosis concluded 
that a Dicl1 Dicl2 double mutation eliminated growth on fatty acids162. This establishes the importance 
of the glyoxylate shunt and more particularly the first enzyme of the bypass in scenarios of growth 
on limited carbon sources including acetate and fatty acids. Considering the abundance of these 
pathogens in human infections, the question of infection attenuation and link between metabolism 
and virulence ensues. 
1.2.3. Metabolism and virulence are linked 
Work performed in M. tuberculosis and P. aeruginosa demonstrated that isocitrate lyase 
activity influences virulence163. The main studies performed on M. tuberculosis looked at the severity 
of mice’s lungs infection, primarily infected with M. tuberculosis wild-type. The infective strain was 
either a single mutant of isocitrate lyase (∆icl1 or ∆icl2) or a double mutant (∆icl1 ∆icl2). 
Mycobacterium tuberculosis is equipped with two isocitrate lyases. The loss of either one of the 
isocitrate lyase had no dramatic effect on the growth of M. tuberculosis during the first two weeks of 
infection. Modest reduction of the bacterial loads in infected lungs was seen during the time course 
of the infection between the second and sixteenth week. The double mutant however did not show 
any lung pathology and the mice remained healthy until the experiment was terminated. By contrast, 
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mice infected with the wild-type strain showed all signs of acute infection including splenomegaly 
along lung inflammatory lesions and lung enlargement161,162. 
A similar study was conducted in Pseudomonas aeruginosa with a ∆aceA mutant of PAO1 
in a rat chronic lung infection model. Disruption of aceA in PAO1 led to a four-fold reduction in 
histopathology in rat lungs. This is a clear indication that isocitrate lyase is indeed required for 
optimal virulence164. More studies investigated the glyoxylate shunt as a novel drug-target. One study 
performed on P. aeruginosa investigated new antimicrobial therapeutics that would target the 
glyoxylate shunt only. By cutting down the possibility for the bacteria to use the bypass, they would 
no longer survive on acetate and/or fatty acids and eventually be cleared of the infection site. A 
screening of nearly 150,000 molecules identified compounds that were able to inhibit the growth of 
P. aeruginosa in minimal media supplemented with acetate. Eight compounds eventually showed 
significant inhibition of both isocitrate lyase and malate synthase opening a door to further 
characterization of drugs targeting this pathway165. 
1.3. The enzymology at the branchpoint 
1.3.1. The isocitrate dehydrogenases 
In the TCA cycle, isocitrate dehydrogenase catalyzes the decarboxylation of isocitrate into ⍺-ketoglutarate. This enzyme has been extensively studied in E. coli and isocitrate dehydrogenase 
activity has been reported in multiple microorganisms : Corynebacterium glutamicum166, 
Mycobacterium tuberculosis167, Vibrio 
parahaemolyticus168, Rhodomicrobium 
vannielii169, Azotobacter vinelandii170, 
Colwellia psychrerythraea171 and 
another species of Pseudomonas172. 
Some of these species exhibit only one 
form of the enzyme (ICD), whereas 
others seem to possess a different 
isozyme (IDH). Some species contain 
both ICD and IDH such as P. 
aeruginosa, Colwellia maris, Vibrio sp. 
and M. tuberculosis. 
The ICD enzyme is dimeric, 
consisting of two subunits with an 
average molecular mass of 40-45 kDa 
each. In contrast, all IDH enzymes 
characterized to date are monomeric, 
with a molecular mass of 80-100 kDa. 
Figure 5: Schematic representation of the monomeric and dimeric 
isocitrate dehydrogenases (A) IDH from A. vinelandii (B) ICD from 
E. coli (Figure adapted from Yasutake et al., 2002183) 
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In both C. psychrerythraea and C. maris, optimum temperature for activity and thermostability of 
ICD indicate that it is a suitable enzyme in mesophilic organisms. IDH seems extremely labile above 
25°C, with an optimum temperature for activity of 20°C, revealing that it is cold-adapted in C. 
maris171. However, both isozymes present in Pseudomonas psychrophila have been studied and are 
adapted for a mesophilic organism172. Furthermore, the two encoding genes in Colwellia (previously 
described as Vibrio sp. strain ABE-1) are located in tandem, with the IDH gene followed by the ICD 
gene, although the expression of those two genes is independently regulated171,173. Interestingly, in P. 
psychrophila, the two genes are divergently transcribed172, and the P. aeruginosa icd and idh genes 
are similarly organized (PA2623 and PA2624 respectively). Nevertheless, the bacterial monomeric 
and dimeric enzymes catalyse the same reaction, despite having little homology in amino acid 
sequence174,175. 
ICD and IDH belong to a large, ubiquitous, and very ancient protein family whose members 
play central roles in energy metabolism176, amino acid biosynthesis177,178 and vitamin production179– 181. 
Both are NADP+-dependent enzymes which catalyse the oxidative decarboxylation of D-isocitrate to 
form α-ketoglutarate, CO2 and NADPH. In C. glutamicum, the Km values allow to conclude that the 
monomeric IDH displays an about 3-fold lower Km for both substrate and co-factor, and its overall 
catalytic efficiency at 21°C, calculated is 10-fold lower than the dimeric enzyme182.  
The crystal structures of ICD from E. coli183 and M. tuberculosis184 have been solved (PDB 
entries 4AJA and 4HCX respectively) as has that of IDH from A. vinelandii185,186 (PDB entry 1J1W). 
ICD consists of three domains: a large domain (domain A), a clasp-like domain (domain B) and a 
small domain (domain C)183. Although the amino acid sequences of both isozymes are different, the 
folding topology of IDH is related to that of ICD. Indeed, the monomeric IDH is created by fusing 
one subunit of ICD with the smaller domain of the second subunit, albeit with some differences. The 
structure essentially consists of all three domains from the first subunit of ICD and domains B’-C’ 
from the second subunit (see figure 5). As stated above, phosphorylation of ICD inactivates the 
enzyme. This occurs on Ser113 of the E. coli enzyme183 but nothing has been concluded concerning 
the M. tuberculosis version as there is no AceK in this microorganism. Amino acid sequences 
demonstrate that Ser115 from P. aeruginosa aligns with Ser113 from E. coli. This is of particular 
interest for further investigation. 
1.3.2. The isocitrate dehydrogenase kinase/phosphatase 
In E. coli, isocitrate dehydrogenase (ICD) is regulated by a bifunctional protein, ICD 
kinase/phosphatase (also named AceK). Interestingly, it possesses the two opposing activities within 
one protein, and specifically recognizes only intact ICD158,187. The transfer of the phosphate from ATP 
to Ser113 causes complete inhibition of ICD activity by blocking isocitrate from binding through a 
combination of electrostatic and steric effects. Interestingly, NADP+ and NADPH bind to both the 
phosphorylated and dephosphorylated forms of ICD188. The phosphatase activity has an absolute 
requirement for ATP or ADP; and this protein has an intrinsic ATPase activity as well189. 
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From structural and computational data, isocitrate dehydrogenase kinase/phosphatase 
appears to be a monomer of about 65-68 kDa. AceK structure has been extensively studied in E. coli 
and a regulatory mechanism has been proposed based on those data. The protein structure contains 
two functional domains. The C-terminal domain resembles eukaryotic protein kinase and represents 
the kinase/phosphatase domain. The N-terminal or regulatory domain has allosteric binding pockets 
involved in the regulation of the function of the catalytic domain190. ATP is found in a pocket between 
the two domains. AceK displays highly specific binding to ICD. However, considering that the 
phosphorylation site lies buried deep inside the ICD structure (see figure 5), Zheng et Jia190 have 
proposed that ICD forms a tight homodimer with the two active sites on opposite sides. In the open 
conformation, the phosphorylation loop undergoes a significant conformational change with the 
residue Ser113 moving and rotating. As a result, the serine changes from a buried, inwards-facing 
orientation to an exposed, outwards-facing position, rendering Ser113 accessible to ICD 
kinase/phosphatase. The ICD phosphorylation cycle is controlled by a variety of metabolites; AMP, 
pyruvate and 3-phosphoglycerate activate ICD phosphatase but inhibit ICD kinase. Other compounds 
such as NADPH inhibit both activities. Isocitrate seems to inhibit ICD kinase but its effect on ICD 
phosphatase remains controversial191,192. 
1.3.3. The isocitrate lyase 
In E. coli, isocitrate lyase has a much lower affinity for isocitrate than ICD. Under growth 
conditions supplemented with glucose, ICL cannot compete with isocitrate dehydrogenase. However, 
flux regulation can be simply achieved by changing the activity of either one of the two enzymes, ICL 
or ICD. In E. coli, aceA gene expression is increased when the bacterium grows on acetate as a sole 
carbon source. In that case, AceK inactivates ICD by phosphorylation, and so pushes isocitrate 
through the glyoxylate shunt. However, when glucose is added to the medium, ICD is reversibly 
dephosphorylated resulting in the restoration of its activity139,155. After the branchpoint, ICL 
represents the first enzyme that catalyses the cleavage of isocitrate into succinate and glyoxylate. 
The enzyme simply binds the substrate, there is no co-factor; however magnesium seems indispensable 
to coordinate the binding of the substrate and for optimal activity193,194. 
The protein structure of ICL from two species of prokaryote has been resolved: E. coli (PDB 
entry 1IGW) and M. tuberculosis (PDB entry 1F61) and one species of eukaryote, Aspergillus nidulans 
(PDB entry 1DQU). Those studies have established that the quaternary structure of ICL is a 
tetramer195– 197. However, analysis of the amino acid sequences reveals that the subunit molecular mass 
varies between 48 kDa for the prokaryotic enzymes and 67 kDa for the eukaryotic version. The P. 
aeruginosa enzyme has an intermediate mass of 59 kDa and 97 extra residues compared with the E. 
coli enzyme. As noted by Britton et al.195, in the eukaryotic enzyme, the extra 104 residues form an 
additional head domain, so this could also be the case in the P. aeruginosa ICL. In P. aeruginosa, 
there is a single copy of ICL-encoding gene (PA2634, aceA) and the protein sequence shares just 30% 
similarity with the species presented above aka. E. coli. 
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Isocitrate lyase became of major interest in Mycobacterium tuberculosis as a potential drug 
target; and is well-studied in E. coli. The link between virulence and metabolism established in mice 
models with lungs infection attracted research in targeting the glyoxylate shunt to “starve” the 
mycobacteria198– 200. In Pseudomonas aeruginosa, isocitrate lyase mediates survival on poor nutrient 
sources (as described above) and is linked with T3SS expression. Indeed, a study conducted on PAO1 
under oxygen-limited conditions, concluded that in a DaceA mutant the expression of PcrV (T3SS 
core component), PopN (T3SS translocation regulator), ExoS (T3SS effector protein) and ExsD 
(T3SS regulator) was greatly reduced201. However, very little is known about the enzymology and 
structure of ICL in Pseudomonas aeruginosa. This work attempts to investigate for the first time this 
glyoxylate bypass that was first discovered in the Pseudomonas genus. 
1.4. Aims of this PhD project 
The TCA-glyoxylate branchpoint has been well-characterized in E. coli, the architecture 
remains simple. There are only two competitors for isocitrate, ICD in the TCA cycle and ICL in the 
glyoxylate shunt. Upon growth in poor nutrient sources, isocitrate is redirected towards ICL after 
ICD has been phosphorylated thus inactived. ICL and ICD compete for the same substrate, but the 
phosphorylation-mediated inhibition of ICD rewires the carbon flux through the glyoxylate shunt. So, 
there are two branches, TCA cycle and glyoxylate shunt, represented by two competitors ICD and 
ICL; and depending on the growth conditions, one branch is “on” while the other is “off”. However, 
in P. aeruginosa, that architecture is different. Three enzymes have to compete for the same substrate, 
ICD, IDH and ICL. The rerouting of carbon flux between the TCA cycle and the glyoxylate shunt is 
certainly different and more importantly flux control must be exerted differently. Furthermore, 
despite the fact that the glyoxylate shunt has first been discovered in a Pseudomonas KB1, very little 
is known about the multiple enzymes found at the branchpoint. The aim of this project was to 
determine the crystal structure, the function and the regulation of the TCA-glyoxylate branchpoint 
enzymes from P. aeruginosa in considerable detail. To investigate this further, I pursued the following 
objectives: 
• To resolve the X-ray crystal structure of ICD, IDH and ICL. The first three have been 
successful and have been deposited in the PDB. 
• To study the oligomeric status of the enzymes and capture the differences with other known 
enzymes in bacterial species. 
• To characterize the kinetic properties of the enzymes.  
• To examine the impact of potential regulatory metabolites on the activity of each enzyme.
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2. Materials and methods 
2.1. General microbiological procedures 
2.1.1. Strains 
The strains used in this study are listed in table 1. For long-term storage, cells were kept in 
25% glycerol solution at -80°C. For short-term storage, E. coli colonies on agar plates were stored at 
4°C, while P. aeruginosa colonies were kept on the bench at room temperature. 
Table 1: Bacterial strains 
2.1.2. Media components and supplements 
For standard bacterial growth, Luria Bertani broth (LB) was used. The LB broth preparation 
was sterilised by autoclaving for 20 min at 121°C. For growth study, MOPS minimal medium was 
used. The non-sterilisable elements of the MOPS medium were sterilised using 0.22 µm filter. 
For growth curves, MOPS minimal medium supplemented with carbon sources was used. See 
tables 2-5 for further details of media components and supplements. 
Table 2: Growth media 
Growth media Components per Litre pH 
Luria broth (LB) 
Tryptone 10 g 
7 NaCl 10 g 
Yeast extract 5 g 
 Genotype/Phenotype Source/Reference 
Escherichia coli   
   DH5⍺ Overexpression strain NEB 
   [DH5⍺]:His:icd N-terminally His6-tagged ICD protein Previous work (PartII student) 
   [DH5⍺]:His:idh N-terminally His6-tagged IDH protein Previous work (PartII student) 
   [DH5⍺]:His:aceA N-terminally His6-tagged ICL protein Previous work (PartII student) 
   [DH5⍺]:His:aceK N-terminally His6-tagged AceK protein Previous work (PartII student) 
   [DH5⍺]:His-MBP:icd N-terminally His6-MBP-tagged ICD Part of this study 
   [DH5⍺]:His-MBP:idh N-terminally His6-MBP-tagged IDH Part of this study 
   [DH5⍺]:His-MBP:aceA N-terminally His6-MBP-tagged ICL Part of this study 
   [DH5⍺]:His-MBP:aceK N-terminally His6-MBP-tagged AceK Part of this study 
Pseudomonas aeruginosa   
   PAO1 Wild type B. Iglewski, Rochester, USA 
   PAO1::Picd Plasmid pLP170 containing icd::lacZ fusion Part of this study 
   PAO1::Pidh Plasmid pLP170 containing idh::lacZ fusion Part of this study 
   PAO1::Pacea Plasmid pLP170 containing aceA::lacZ fusion Part of this study 
   PAO1::Pacek Plasmid pLP170 containing aceK::lacZ fusion Part of this study 
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Solid agar 1.5% w/v 
LB liquid media 1 l 
7 
Agar (Formedium) 15 g 
Phosphate buffered Saline (PBS) (Oxoid: 
purchased as premixed 10X) 
NaCl 8 g 
7.4 
KCl 0.2 g 
Na2HPO4 1.44 g 
KH2PO4 0.24 g 
Table 3: 1X MOPS medium 
Table 4: 10X MOPS medium 
Table 5: 100X micronutrient stock 
Components mg/100ml Stock concentration 
Ammonium molybdate tetrahydrate 0.3 3 μM 
Boric acid 2.4 400 μM 
Cobalt chloride 0.7 30 μM 
Cupric sulfate 0.3 10 μM 
Manganese sulfate 1.6 80 μM 
Zinc sulfate 0.3 10 μM 
2.1.3. Growth conditions 
All growth experiments were conducted at 37°C. For growth on solid media, 1.5 % w/v agar 
was added to the appropriate liquid medium. The plates were usually incubated for 18-24 h before 
any further experiment. For small-scale liquid culture or overnight culture, a single colony was 
inoculated in 10 mL LB into a 30 mL screw-cap plastic tube. The E. coli or PAO1 strain was 
incubated at 37°C on a rotary drum at 120 rpm for 18-24 h. 
Components per Litre Final concentration 
10X MOPS medium 1 M 40 mL 40 mM 
Carbon source   
     Acetate 1 M 40 mL 40 mM 
     Glucose 1 M 20 mL 20 mM 
K2SO4 27.5 mM 10.5 mL 0.29 mM 
K2HPO4 172.8 mM 7.6 mL 1.32 mM 
Components per Litre Final concentration 
MOPS pH 7.5 1M 400 mL 400 mM 
Tricine pH 7.5 1M 40 mL 40 mM 
FeSO4 18.4 mM 9.7 mL 0.18 mM 
NH4Cl 1.9 M 50 mL 95 mM 
CaCl2 53 mM 100 mL 5.3 μM 
MgCl2, 6 H2O 512 mM 10 mL 5.1 mM 
NaCl 5 M 100 mL 500 mM 
Micronutrient stock 100 X 10 mL 1X 
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2.1.4. Growing and harvesting bacterial samples 
For medium-scale liquid culture (growth curve), a small aliquot of overnight culture was used 
to inoculate 50 mL of liquid media in a baffled 250 mL Erlenmeyer flask to adjust to a starting OD600 
= 0.05. Antibiotics and other supplements, if required, were added at the start. The flasks were 
shaken at 250 rpm and 37°C in a water bath for the course of the experiments. Growth was monitored 
by optical density (OD) measurement at 600 nm wavelength using an Eppendorf BioSpectrometer. 
For large-scale liquid culture (protein overexpression), 9.6×108 cells/mL of overnight E. coli 
culture was used to inoculate 2 to 6 L of LB media supplemented with carbenicillin in baffled 2 L 
Erlenmeyer flasks. The flasks were incubated in an orbital shaker at 250 rpm and 37°C. After reaching 
OD600 ~ 0.5/0.6, 1 mM (His6-tagged protein) or 0.3 mM (His6-MBP-tagged protein) of isopropyl b-D-
1-thiogalactopyranoside (IPTG) was added to the bacterial culture to induce protein expression. 
Harvesting of bacterial cells was carried out by centrifugation of liquid culture using a 
Beckman Coulter Avanti J26-XP1 centrifuge (7,455 g, 20 min, 4°C). For smaller-scale samples (i.e. 
10 or 50 ml), sedimentation was achieved in 30 ml screw-cap plastic tubes or 50 ml Falcon tubes in 
an Eppendorf 5810R centrifuge (3,214 g, 20 min, 4°C). 
2.2. DNA manipulation 
2.2.1. DNA extraction, purification, sequencing and storage 
Genomic DNA was extracted from bacterial cells using a GeneJET genomic DNA purification 
kit (Thermo Fisher) following the manufacturer’s guidelines. The concentration of DNA samples was 
measured using a Nanodrop (ND-1000, Thermo Scientific) to measure absorbance at A260/A280. PCR 
products were purified using a GeneJET PCR purification kit (Thermo Fisher), and when necessary, 
migrated DNA fragments were purified after agarose gel electrophoresis with a GeneJET gel 
extraction kit. All DNA samples were stored at -20°C for further analysis.  
DNA sequencing was performed by the GATC Biotech company after preparing the samples 
according to their guidelines. The data were analysed using either ApE or SnapGene software. 
2.2.2. Polymerase Chain Reaction (PCR) 
PCR reaction mix components were usually combined in final concentrations specified by 
each manufacturer’s guidelines. In general, the reaction mix (50 µL) contained 1 µL of template DNA, 
1 µL of each forward and reverse primers (stock 100 µM, Sigma-Aldrich), 1 µL of dNTP mix (stock 
10 µM, Bioline), 5 µL of dimethyl sulfoxide (DMSO, Sigma-Aldrich), 10 µL of Phusion buffer HF and 
0.5 µL of Phusion polymerase enzyme (either NEB or produced in the laboratory). 
DMSO acts as a polar aprotic solvent; it inhibits secondary structure formation in DNA and 
decreases the melting temperature of complementary DNA. DMSO was usually added at a final 
concentration of 5-10% v/v in all PCRs due to the overall GC-rich content of the DNA templates 
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and primers. The template DNA used was either PAO1 genomic DNA, plasmid DNA, or DNA directly 
from a bacterial colony in “colony PCR”. Colony PCR followed the same program as classic Phusion 
PCR; it simply required an additional step of 5 min at 95°C in order to lyse the cells and release the 
DNA. 
PCR primer design was done manually, based on the available sequence of the four genes 
(icd, idh, aceA and aceK), and using NEB Tm calculator to anticipate the melting temperature. 
Table 6 below lists the PCR primers and their characteristics. The restriction enzymes sequences 
(bold) were incorporated within the primers for cloning purposes. 
Table 6: PCR primers 
Gene Oligo name Sequence (5’-3’) Use 
icd 
ICD-fw CCCCGGATCCATGGGATACCAAAAGATCCA 
Cloning for 
protein 
overexpression 
from pMAL-c2x 
ICD-rv CCCCAAGCTTCTACATCTTGGCAATCATCG 
idh 
IDH-fw CCCCGGATCCTCCATCCGCTCGAAGATCAC 
IDH-rv CCCCAAGCTTGTTTCTGCTTCGTCAGCGTGA 
aceA 
ICL-fw CCCCGGATCCATGTCCGCATATCAGAACGA 
ICL-rv CCCCAAGCTTTTAGTGGAACTGGTTCATGG 
aceK 
AceK-fw CCCCGGATCCATGGTCCAGAGCGCCCCAGC 
AceK-rv CCCCAAGCTTCTACCCGAGCAACTGCTCGG 
Picd 
Picd-fw GATCGAATTCTGTCGCTGGTCTCGACGTCG 
Cloning for gene 
expression study 
with LacZ fusion 
Picd-rv GATCGGATCCCCGTGTTGTGGTTAAAACCC 
Pidh 
Pidh-fw CCCCGAATTCTCATGACCGGGCTGATATCG 
Pidh-rv CCCCGGATCCCTACGGTAACTCTCTTTTTT 
Pacea 
Pacea-fw CCCCGAATTCCTCGACCAGACAAGACCATC 
Pacea-rv CCCCGGATCCGGTCAATCCTTCAAGAAATG 
Pacek 
Pacek-fw CCCCGAATTCCGGCGCAGGTTCATCCAGTT 
Pacek-rv CCCCGGATCCGCTGGCGTCCTTTCGTTGTT 
PCR cycle conditions varied depending on the length of the fragment being amplifid, the 
melting temperature (Tm) of the primers and the type of template DNA. A Veriti 96-well 
thermocycler was used for all reactions. Table 7 below shows the program used for most reactions. 
Table 7: Typical PCR program for Taq/Phusion polymerase 
1 cycle Denaturation 95°C, 10min 
30 cycles 
Denaturation 95°C, 1 min 
Annealing 62°C, 30 sec 
Elongation 72°C, 1 min 
1 cycle Elongation 72°C, 8 min 
1 cycle Hold 4°C, indefinitely 
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2.2.3. Agarose gel electrophoresis 
Linear DNA was separated by electrophoresis through agarose gels. DNA samples were mixed 
with BioLine loading dye and loaded onto a 1 % agarose gel (1 % w/v agarose dissolved in 1X Tris-
Acetate-EDTA (TAE) buffer). Before casting, ethidium bromide was added to the molten agarose at 
a final concentration of 0.4 µg/mL. 
Migration was performed using a Mini-Sub® Cell GT Cell (Bio-Rad) at 80 V for about one 
hour in 1X TAE buffer. Then, the DNA fragments stained with ethidium bromide were visualised 
using a UV transilluminator at 365 nm. HyperLadder I (200 –  10,000 bp, BioLine) was used as a size 
indicator. 
2.3. Strains preparation 
2.3.1. Plasmid construction 
The plasmids used in this study are summarized in the Table 8 below. The fidelity of the 
cloned PCR-amplified products was confirmed by sequencing. All the His6-tagged protein encoding 
genes (icd, idh, aceA and aceK) were the results of the work of a PartII student in the laboratory. 
He cloned the four subsequent genes into pQE80. The same icd, idh, aceA and aceK genes were later 
cloned into a modified version of pMAL-c2x. Vector pMAL-c2x encodes an MBP-tag, the modified 
version of it produced in the laboratory encodes a His6-tag located at the N-terminus of the MBP-
tag. The modification work of the pMAL-c2x vector, renamed His-pMAL-c2x, was performed by Dr. 
Martin Welch who added the corresponding genetic element into the original vector using PCR 
amplification. After modification of the vector, icd, idh, aceA and aceK genes were cloned into His-
pMAL-c2x. The purpose of this new construct was to allow the production of a native protein, with 
no tag attached to it as His-pMAL-c2x carries a Factor Xa cleavage site. 
Finally, the promoter regions of all genes were cloned into pLP170 vector (non-commercial 
vector, first developed by the Iglewski group) to study the gene expression in different carbon sources 
(glucose and acetate supplemented minimal medium). 
Table 8: Plasmids used in this study 
2.3.2. Cloning 
His6-MBP-tagged constructs were cloned into His-pMAL-c2x vector. After PCR amplification 
of genomic DNA, the icd, idh, aceA and aceK amplicons and the plasmid were individually purified 
Plasmid Description Source/Reference 
pQE80 Bacterial expression, CbR Qiagen 
His-pMAL-c2x Bacterial expression, CbR This study (originally from NEB) 
pLP170 lacZ transcriptional fusion, CbR Preston et al., 199732 
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and digested by BamHI and HindIII for 2h at 37°C. Both insert and vector were then incubated with 
T4 DNA ligase (NEB) for 1h on ice then 1h at room temperature. Promoter regions of all four genes 
were cloned into the pLP170 vector after amplification and digestion with EcoRI and BamHI for 2h 
at 37°C. 
2.3.3. Competent cells 
E. coli DH5α electrocompetent cells were used to incorporate the four His-pMAL-c2x 
constructs (icd, idh, aceA and aceK) into the cells. After overnight growth and subculture, the cells 
were pelleted, washed three times with ice-cold water and suspended in 10% v/v ice-cold glycerol for 
electroporation.  
Similarly, electrocompetent cells of P. aeruginosa PAO1, provided by Dr. Stephen Dolan, 
were used to introduce into the cells the four pLP170 constructs carrying the promoter regions of 
either icd, idh, aceA and aceK. Prior to transformation, the cells were grown overnight and 
subcultured into 10 mL of LB. After growth, the cells were pelleted, washed three times with PBS 
and resuspended in 10% v/v glycerol before electroporation. 
2.3.4. Transformation by electroporation 
Introduction of plasmid DNA into E. coli DH5α or P. aeruginosa PAO1 was performed by 
electroporation. A volume of 100 µL of competent cells was electroporated at 2.5 kV with 2 µL of 
ligated product. Four E. coli DH5α samples were transformed with the four His-pMAL-c2x constructs carrying either icd, idh, aceA or aceK  genes. Alternatively, four P. aeruginosa PAO1 
samples were transformed with the four pLP170 constructs, Picd, Pidh, PaceA or PaceK respectively. 
Immediately after electroporation, 900 µL of LB were added to the cells, which were then incubated 
at 20°C for 1h on a rotating drum. Finally, 100 µL were plated on carbenicillin-supplemented LBA 
for overnight growth and selection. 
2.4. Gene expression analysis 
Four gene promoter lacZ fusions were generated using the promoter-less lacZ plasmid pLP170, 
as described in Table 6. The transcriptional activity of the promoters that were fused to a lacZ gene 
can be measured by b-galactosidase activity. 
2.4.1. Growth curves 
The four P. aeruginosa wild-type PAO1 strains were transformed as described in section 2.3.2. 
with pLP170 constructs carrying the promoter of each gene upstream of lacZ. Ahead of the 
experiment, overnight cultures of each strain were prepared to reach stationary phase in order to 
inoculate 50 mL flasks starting with a normalised OD600 of 0.05. 
The cells were grown in MOPS medium supplemented with either acetate or glucose as single 
carbon source. Every hour (up to 10 h), 1 mL of culture was harvested for growth analysis. The 
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growth rate was monitored by optical density of each sample was measured at 600 nm using an 
Eppendorf BioSpectrometer. Finally, 100 µL of each sample was saved in a 96-well plate to carry on 
the β-galactosidase analysis. All experiments were performed in triplicate. 
2.4.2. β-Galactosidase assay 
The β-galactosidase assay (MUG) measures the cleavage by β-galactosidase of 4-
methylumbelliferyl-β-D-galactopyranoside (4-MUG) into fluorescent 4-methylumbelliferone. The 
harvested cells previously put aside were diluted by a factor of 1/100, following which 10 µL were 
then distributed into another 96-well plate. To that, 100 µL of lysozyme and 4-MUG mixture (see 
Table 9) was added immediately before measuring the production of 4-methylumbelliferone. 
Table 9: Solutions for β-galactosidase assay 
Components Final concentration 
4-Mu-β-D-galactoside 1X 
Lysozyme in PBS buffer 18.1 mg/mL 
Monitoring of the release of 4-methylumbelliferone (4-MU) by β-galactosidase was done using 
a Gemini XPS microplate reader operated by the SoftMax Pro software. The plate was incubated at 
37°C for the duration of the measurements. The excitation wavelength is 360 nm while the emission 
wavelength is 450 nm, eight readings were performed per well for the same duration of the 
measurements. Analysis of the results and plotting were performed using Graphpad Prism 6 software. 
2.5. Protein overexpression 
2.5.1. His6-tagged proteins 
The transformed strains were grown at 37°C in 1 L LB broth containing carbenicillin (50 
µg/mL). After having reached an OD600 ~ 0.5/0.6, the protein expression was induced by addition of 
IPTG, to 1 mM final concentration. After 2 h of induction, the cells were pelleted in a Sigma® 4-16K 
centrifuge at 5,170 g for 10 min. The pellets were resuspended on ice in 60 mL of lysis buffer (Table 
10) containing an EDTA-free protease inhibitor cocktail from Roche®. From there, the samples were 
sonicated 8 rounds 30 sec on, 30 sec off, on full power. The cell debris was sedimented by 
centrifugation using a Beckman Coulter Avanti J26-XP1 centrifuge (14,636 g, 20 min, 4°C). 
Supernatants were applied to an Ni-NTA column (Qiagen)	 (2-ml packed resin bed volume), 
equilibrated with lysis buffer. After passing the supernatant at a 1 mL/min pace through the column, 
the column was washed with 500 mL of lysis buffer to eliminate contaminants. The sample was 
eventually eluted in 10 mL of elution buffer. Following that, the sample was dialyzed with at least 
four batches of dialysis buffer (see Table 10 for buffer composition). Finally, the samples were 
concentrated using Vivaspin columns, MWCO 10,000 Da (Sartorius) in an Eppendorf 5810R 
centrifuge (3,220 g, 20 min, 4°C). 
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Table 10: Buffers for His6-tagged proteins expression 
Buffer Components per Litre Final concentration 
Lysis 
NaCl 5 M 60 mL 300 mM 
TRIS-HCl, pH 7.5 1 M 50 mL 50 mM 
Imidazole 3 M 3.3 mL 10 mM 
Glycerol 100% 50 mL 5% v/v 
b-Mercaptoethanol 350 µL 5 mM 
Elution 
NaCl 5 M 60 mL 300 mM 
TRIS-HCl, pH 7.5 1 M 50 mL 50 mM 
Imidazole 3 M 100 mL 300 mM 
Glycerol 100% 50 mL 5% v/v 
Dialysis 
NaCl 5 M 60 mL 100 mM 
TRIS-HCl, pH 7.5 1 M 50 mL 25 mM 
Glycerol 100% 100 mL 10% v/v 
EDTA 0.5 M 2 mL 1 mM 
DTT 154 mg 1 mM 
2.5.2. His6-MBP-tagged proteins 
The strains containing the plasmids for the expression of ICD, IDH, ICL and AceK were 
grown at 37°C in glucose-supplemented LB broth (0.2% w/v glucose) and selected with carbenicillin 
(50 µg/mL). When an OD600 ~ 0.5/0.6 was reached, the protein expression was induced with IPTG, 
to 0.3 mM final concentration (manufacturer’s guidelines suggest a lower concentration of IPTG for 
better results). After another 2 h of induction, the cells were harvested in a Beckman Coulter Avanti 
J26-XP1 centrifuge (7,741 g, 15 min, 4°C). The pellets were resuspended on ice in 60 mL of column 
buffer containing an EDTA-free protease inhibitor cocktail. The samples were then sonicated for 8 
rounds of 30 sec on, 30 sec off, on full power and the cell debris was sedimented by centrifugation 
using the same Beckman Coulter Avanti J26-XP1 centrifuge (14,636 g, 20 min, 4°C). 
The supernatants were then applied to an amylose resin column (NEB) (2-ml packed resin 
bed volume) equilibrated with 200 mL of column buffer (Table 11). After passing the supernatants 
at a 1 mL/min pace to allow binding of the MBP-tag, the column was washed using 500 mL of column 
buffer. Finally, the samples were eluted in 10 mL of elution buffer 1. A first dialysis is necessary to 
lower the salt concentration in the sample prior to Factor Xa protease cleavage. The sample was 
treated with four batches of dialysis buffer 1, two batches with 100 mM of NaCl then another two 
batches with 50 mM. The samples were subsequently concentrated to reduce the volume to 2 mL 
using Vivaspin columns, MWCO 10,000 Da in an Eppendorf 5810R centrifuge (3,220 g, 20 min, 4°C). 
The concentration of the sample was estimated by measuring its absorbance at 280 nm using an 
Eppendorf BioSpectrometer. The estimation of the protein solution concentration permits to calculate 
the correct amount of Factor Xa protease to add in the next step.  
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All four proteins ICD, IDH, ICL and AceK were cleaved in order to remove the His6-MBP 
tag using Factor Xa protease applying a ratio 1:100 (1 µg of Factor Xa cleaves 100 µg of fusion 
protein).The cleavage was conducted for 24 h at 6°C with rotation. To stop the cleavage, 200 µL of 
p-aminobenzamidine agarose was poured in a new tube and washed several times with Factor Xa 
cleavage buffer before the sample was applied. The sample was mixed, then centrifuged 1 min at 
16,873 g in a benchtop centrifuge in order to save the supernatant containing the His6-MBP tag and 
the native protein. 
Table 11: Buffers for His6-MBP-tagged proteins expression 
Buffer Component per Litre Final concentration 
Column 
NaCl 5 M 40 mL 200 mM 
TRIS-HCl, pH 7.4 1 M 20 mL 20 mM 
EDTA 0.5 M 2 mL 1 mM 
DTT 154 mg 1 mM 
Elution 1 
NaCl 5 M 40 mL 200 mM 
TRIS-HCl, pH 7.4 1 M 20 mL 20 mM 
EDTA 0.5 M 2 mL 1 mM 
Maltose 500 mM 20 mL 10 mM 
Dialysis 1 
NaCl 5 M 20 mL then 10 mL 100 then 50 mM 
TRIS-HCl, pH 7.5 1 M 25 mL 25 mM 
Glycerol 100% 100 mL 10% 
Factor Xa cleavage 
NaCl 5 M 10 mL 50 mM 
TRIS-HCl, pH 6.5 1 M 20 mL 20 mM 
CaCl2 500 mM 2 mL 1 mM 
Lysis 2 
NaCl 5 M 60 mL 300 mM 
TRIS-HCl, pH 7.5 1 M 50 mL 50 mM 
Glycerol 100% 50 mL 5% β-Mercaptoethanol 350 µL 5 mM 
Dialysis 2 
NaCl 5 M 20 mL 100 mM 
TRIS-HCl, pH 7.5 1 M 25 mL 25 mM 
Glycerol 100% 100 mL 10% 
EDTA 0.5 M 2 mL 1 mM 
DTT 154 mg 1 mM 
The supernatants were then applied to an Ni-NTA column, previously equilibrated with 500 
mL of lysis buffer 2. A loop was created by connecting the top and bottom of the column for an hour 
to optimize the binding of the His part of the tag, leaving the native (cleaved) protein in the 
flowthrough. The flowthrough was then collected in 15 mL of lysis buffer 2. A second dialysis was 
performed with dialysis buffer 2 (see Table 11 for buffer composition) followed by concentration of 
the samples in Vivaspin columns, MWCO 10,000 Da in an Eppendorf 5810R centrifuge (3,220 g, 20 
min, 4°C) to reduce the volume to 2 mL. Finally, all samples were aliquoted in 50 µL and snap frozen 
in liquid nitrogen. 
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2.5.3. Protein concentration determination 
2.5.3.1. Direct determination 
Using an Eppendorf BioSpectrometer, the absorbance of the samples was measured at 280 
nm and the concentration was determined after computing the extinction coefficient ε in Expasy 
ProtParam tools. The concentration of the samples could be determined based on the extinction 
coefficient and molecular weight of the proteins. See below the Table 12 compiling the relevant 
parameters. 
Table 12: Extinction coefficient and predicted weight of all proteins 
Protein Extinction coefficient (M-1.cm-1) Molecular weight (g.mol-1) 
ICD 57870 45577.40 
His6-ICD 57870 46400.25 
His6-MBP-ICD 124220 92779.88 
IDH 82280 81634.12 
His6-IDH 82280 82594.11 
His6-MBP-IDH 148630 128973.74 
ICL 54320 58886.70 
His6-ICL 54320 59709.55 
His6-MBP-ICL 120670 106089.18 
AceK 79760 66760.82 
His6-AceK 79760 67583.67 
His6-MBP-AceK 146110 113963.30 
2.5.3.2. Bradford assay 
Alternatively, the Bradford assay was used in order to determine the concentration of protein 
samples. Following the method from Olson et al.202, the preparation of the standard curve included γ-globulin, NaOH and Bradford reagent (BioRad). The preparation of the samples to determine the 
concentration followed a similar procedure by adding NaOH and Bradford reagent to the solution. 
All measurements were performed using an Eppendorf BioSpectrometer at a wavelength of 595 nm. 
2.6. SDS-PAGE analysis 
After having conducted purification with MBP or Ni-NTA resins, 5 µL of each sample was 
saved at each step for SDS-PAGE analysis. Protein samples were prepared in 4X sample buffer and 
boiled at 95°C for 5 min. Finally, they were loaded onto a 12 % acrylamide gel and electrophoresed 
in running buffer for 15 min at 120 V, then 1 h at 150V. Precision Plus Protein marker (BioRad) was 
used as an indicator of molecular mass. Table 13 shows the buffers used for the preparation of the 
gels. 
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Table 13: Buffers used for preparation and running gels 
2.7. Gel filtration 
Analytical gel filtration with multi-angle light scattering was performed at a flow rate of 0.5 
mL/ min through a 300 × 7.8 mm TSK-Gel G3000 SWXL column (Toso Haas) equilibrated with 20 
mM Tris-HCl pH 8.0, 150 mM NaCl. The column eluate was monitored in line with a Mini-DAWN 
light scattering detector at 690 nm, Quasi-elastic light scattering detector, differential refractometry 
and absorption detector at 280 nm. Molecular masses were calculated using Astra Software (Wyatt 
Technologies) and the Debye fit method203. A gel Filtration Marker Kit for Protein Molecular Weights 
29,000-700,000 Da from Sigma-Aldrich® was used to calibrate the column. 
2.8. Analytical Ultra Centrifugation (AUC) 
The technique used to determine the oligomeric assembly of the enzymes in this study was 
sedimentation velocity. This technique is a classical method for the characterization of interactions 
of purified proteins in dilute solutions. Conceptually, it consists simply of the application of a 
centrifugal force, the observation of the macromolecular redistribution through the chamber, and the 
eventual quantitative analysis of the data. Sedimentation techniques provide information on self-
association properties of a protein, enabling to distinguish higher-order quaternary structure (dimer, 
trimer, tetramer for example). The starting point in most situations is calculating the sedimentation 
coefficient distributions c(s), which extracts information on purity, number of species, their relative 
abundance and low-resolution shapes. So, sedimentation velocity permits the observation of the 
separation of proteins due to their different rates of migration in the centrifugal field204. 
Sedimentation velocity analysis was conducted on ICD and IDH. The samples were first 
dialysed with 100 mM NaCl and 25 mM TRIS to remove all traces of glycerol and DTT that could 
affect the readings. AUC was performed using a Beckman Optima XL-I with absorbance and 
interference optical detection system and an An60Ti rotor. Each protein was tested at three different 
concentrations: 0.1, 0.5 and 1 mg/mL. Epon double-sector centrepieces were filled with 400 µL of 
sample solution or PBS (control), respectively. All four samples were centrifuged at a rotor speed of 
11,648 g and at a rotor temperature of 20°C. Absorbance data were acquired at a wavelength of 280 
nm, and in time intervals of 2 min; interference scans were taken at time intervals of 1 min.  
Buffer Components per Litre Final concentration 
5X upper pH 6.8 
TRIS 60.55 g 0.5 M 
10% SDS w/v 50 mL 0.5% w/v 
5X lower pH 8.8 
TRIS 151.42 g 1.25 M w/v 
10% SDS w/v 50 mL 0.5% 
10X running pH 8.3 
Glycine 144 g 1.92 M 
TRIS 30 g 0.25 M 
SDS 10g 35 mM 
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Firstly, buffer viscosity, protein partial specific volumes and frictional ratios were calculated 
using the software SEDNTERP205. Secondly, data were analysed using SEDFIT206 based on the 
parameters determined by SEDNTERP. 
2.9. Enzyme kinetic measurements 
2.9.1. Isocitrate dehydrogenase assay 
2.9.1.1. Basic kinetics and regulator screening 
All enzyme kinetics were performed by incubating the purified enzyme in 50 mM TRIS pH 
7.5 and 5 mM MgCl2 at 37°C. The initial rates were measured across a range of substrate (+)-
potassium Ds-threo-isocitrate monobasic (0 to 600 µM) at a set concentration of 200 µM NADP+, 
then across a range of NADP+ (0 to 600 µM) at a set concentration of 200 µM of substrate. 
Absorbance measurements of NADPH formation were recorded at 340 nm. The values were converted 
to millimolar per minute assuming a molar extinction of 6,220 M-1.cm-1 for NADPH. The allosteric 
regulator assays were carried out in the same conditions (50 mM TRIS pH 7.5, 5 mM MgCl2, 200 µM 
NADP+ and 200 µM Ds-threo-isocitrate) screening 33 potential regulators at a fixed concentration of 
1 mM (see table 14 for a full list). All assays were conducted in triplicate. 
Table 14: List of regulators tested 
acetate itaconic acid 
acetyl-CoA L-glutamic acid 
ADP α-ketoglutarate 
AMP L-malic acid 
ATP maleic acid 
citrate malonic acid 
coenzyme A methylglyoxal 
3-deoxy-2-keto-6-phosphogluconate (KDPG) 3-nitropropionic acid 
D-glucose-6-P oxaloacetate 
D-glyceraldehyde phospho-enol-pyruvate 
fructose-1,6-biphosphate 6-phospho-gluconate 
fumarate pyruvate 
GDP succinate 
glycolic acid glyoxylate+oxaloacetate 
glyoxylate malate+oxaloacetate 
GTP succinate+glyoxylate 
2.9.1.2. Competitive kinetics 
Following the screening of regulators, more kinetic assays against isocitrate were performed 
to characterize the activity of the regulators to determine activators, inhibitors and the competitive, 
uncompetitive or non-competitive effect of these molecules. To do so, the enzyme was incubated in 
50 mM TRIS pH 7.5 and 5 mM MgCl2 at 37°C with 200 µM NADP+ and 1 mM of the regulator. This 
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was tested against a range of concentrations of isocitrate from 0 to 600 µM. All measurements were 
performed in triplicate and monitored at 340 nm. 
2.9.1.3. Effect of nucleotides 
From previous work done in the lab, ATP seemed to have an effect on ICD activity. Further 
investigation was then performed to define with greater details how ATP affects ICD activity. 
2.9.1.3.1. Simple study of the effect of nucleotides 
As described above in section 2.9.1.2, the effect of ATP and other nucleotides was studied by 
incubating ICDPa in 50 mM TRIS pH 7.5, 5 mM MgCl2, 200 µM of substrate, 200 µM of NADP+ and 
1 mM of ATP. The samples were incubated at 37°C and analysed at t0min and t30min. Similar conditions 
were used to study the effect of other nucleotides (AMP, ADP, GDP and GTP) and all measurements 
were recorded at 340 nm. 
2.9.1.3.2. Study of several concentrations of ATP 
The effect of ATP was further investigated by looking at the effect of several concentrations 
of ATP. The assay was designed to incubate ICDPa in 50 mM TRIS pH 7.5, 5 mM MgCl2, 200 µM of 
substrate, 200 µM of NADP+ and increasing concentrations of ATP (0.025, 0.05, 0.1, 0.5, 1, 5, 10, 15, 
25 and 50 mM). Again, the experiment was done in triplicate. 
2.9.1.3.3. Time-dependent effect of ATP 
Refined analysis of the effect of ATP over time was done in order to see the effect of a longer 
incubation time on the rate of inhibition by ATP. Samples of 200 µL containing 50 mM TRIS pH 
7.5, 5 mM MgCl2, 5 mM of substrate, 5 mM of NADP+ and ATP (either 0.025, 0.05, 0.1, 0.5, 1, 5, 
10, 15, 25 or 50 mM) were incubated at 37°C. From these samples, 5 µL were taken out at 0, 5 min, 
10 min, 20 min, 30 min, 45 min and dispensed in a reaction mixture with 50 mM TRIS pH 7.5, 5 mM 
MgCl2, 200 µM of substrate, 200 µM of NADP+ and the corresponding concentration of ATP. The 
formation of NADPH was monitored at 340 nm.  
2.9.1.3.4. Competitive kinetics against ATP 
Finally, the competitive kinetics against isocitrate or NADP+ were performed using the same 
design as for the competitive kinetics against a regulator. The enzyme was incubated at 37°C in 50 
mM TRIS pH 7.5, 5 mM MgCl2 with a 200 µM fixed concentration of Ds-threo-isocitrate and another 
fixed concentration of ATP (either 0.1, 0.5, 1, 5, 10 mM), following which a range of NADP+ 
concentration was tested from 0 to 600 µM. The reverse experiment was also done, incubating the 
enzyme in the same conditions with a 200 µM fixed concentration of NADP+ and tested across a 
range of concentration of isocitrate from 0 to 600 µM. The formation of NADPH was monitored at 
340 nm. 
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2.9.1.4. Investigation of AceK on ICD and IDH 
Isocitrate dehydrogenase kinase/phosphatase was incubated with either ICD or IDH in order 
to investigate a potential effect on the activity of each enzyme. This is an indirect assay monitoring 
the loss of activity with a decrease in the formation of NADPH at 340 nm. The assay was conducted 
by mixing in a 1 mL total volume 50 mM TRIS pH 7.5, 5 mM MgCl2, 200 µM NADP+, 200 µM Ds-
isocitrate, 1 mM ATP, 2.19 nM ICD or 0.612 nM IDH protein and 10 nM of AceK protein. The 
control samples consisted of the same reaction mixture minus ATP and AceK; this was to assess the 
stability of the enzyme over time. Control tubes were prepared then incubated, and ICD or IDH 
enzyme was added immediately before measurement. The samples tubes were prepared with all the 
reagents except the substrate. Isocitrate was added at the moment of the measurement at t0min and 
t30min. Incubation at 37°C was done in a heat block over the course of the experiment. 
2.9.2. Isocitrate lyase assay 
2.9.2.1. Direct assay 
Basic kinetics were performed using a modified direct assay145. The enzyme was incubated in 
25 mM imidazole pH 6.8, 5 mM MgCl2, 1 mM EDTA, 4 mM phenylhydrazine and across a range of 
substrate concentrations (0 to 600 µM). All samples were incubated at 37°C before and during the 
assay, monitoring the formation of phenylhydrazine-glyoxylate complex at 324 nm.  
The majority of the regulators were tested using this method with a fixed concentration of 80 
µM of substrate observing the effect of 1 mM of regulator. All the values were converted to millimolar 
per minute assuming a molar extinction of 16,800 M-1.cm-1 for the phenylhydrazine-glyoxylate complex 
formed during the reaction. 
2.9.2.2. Coupled assay 
The coupled assay employed lactate dehydrogenase (LDH) from porcine heart207. The 
necessity for the coupled assay is due to the fact that phenylhydrazine reacts with the aldehyde group 
of glyoxylate forming the phenylhydrazine-glyoxylate complex. Conceptually, phenylhydrazine reacts 
with any ketone or aldehyde. However, the chemicals shown in table 15 below already possess either 
one of these, making the direct assay unsuitable. The coupled assay overcomes this issue by using a 
secondary reaction with LDH that mirrors the response of ICL to the presence of the regulator.  
Thus, the ICL was incubated with 50 mM MOPS-NaOH pH 7.3, 15 mM MgCl2, 5 mM DTT, 
1 mM EDTA, 400 µM NAD+ and 60 U of LDH. The assay was first used to screen a few regulators 
that could not be assayed with the direct assay (see Table 15) in the presence of a fixed concentration 
of substrate at 200 µM challenged by 1 mM of regulator. From there, competitive kinetics at a fixed 
concentration of regulator against a range of substrate concentration (0 to 400 µM) was performed 
to study the type of response. The values were converted to milli-micromoles of NADH per minute 
assuming a molar extinction of 6,220 M-1.cm-1 for NADH. 
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Table 15: Regulators showing an impaired response in the direct assay 
succinate+glyoxylate α-ketoglutarate 
glyoxylate+oxaloacetate glyoxylate 
malate+oxaloacetate D-glyceraldehyde 
pyruvate D-glucose-6-phosphate 
3-deoxy-2-keto-6-phosphogluconate 6-phospho-gluconate 
oxaloacetate fructose-1,6-bisphosphate 
methylglyoxal  
2.9.2.3. Competitive kinetics 
The screening of regulators resulted in showing the potency of a few molecules, but these 
molecules do not have any ketone or aldehyde group. The competitive kinetics were conducted using 
the direct assay with phenylhydrazine. In that case the enzyme was incubated with 25 mM imidazole 
pH 6.8, 5 mM MgCl2, 1 mM EDTA, 4 mM phenylhydrazine, 1 mM of the regulator and tested across 
a range of substrate concentrations (0 to 200 µM). Similar to kinetic experiments conducted to 
determine Km and Vmax, the samples were incubated at 37°C during the experiment and monitored at 
324 nm for the formation of phenylhydrazine-glyoxylate complex. 
2.9.3. Kinetics plots and calculations 
All data generated by the kinetics experiments were plotted and analysed using Graphpad 
Prism 6. The parameters such as 퐾푚 and 푉푚푎푥 were calculated according to the Michaelis-Menten 
equation:  푌 = 푉푚푎푥 × 푋퐾푚 +푋 
in which 푉푚푎푥 is the maximum enzyme velocity, and 퐾푚 is the Michaelis-Menten constant. 푋 is the variable concentration of substrate or co-factor tested. 퐾1 2⁄  was calculated following a sigmoidal fitting equation:  푌 = 푉푚푎푥 × 푋ℎ퐾1 2⁄ℎ +푋ℎ 
where h is the Hill slope. The curve is sigmoidal due to positive cooperativity. 퐾1 2⁄  is the 
concentration of substrate that produces a half-maximal enzyme velocity. 푉푚푎푥 and 푋 are the same 
as described above. 
Finally, 푘푐푎푡 was derived from either:  푌 = 퐸푡 × 푘푐푎푡 × 푋퐾푚 +푋 푘푐푎푡 = 푉푚푎푥퐸푡  
where 퐸푡 is the concentration of enzyme used in the experiments. 
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Calculations carried out using known concentrations of enzyme for each assay (퐸푡). The 
optimal enzyme concentrations were found to be: 
• ICD: 2.19 nM 
• IDH: 0.612 nM 
• ICL: 42.4 nM 
Regarding competitive kinetics, a Lineweaver-Burk plot was used to characterize the type of 
competitive, non-competitive or uncompetitive profile of the different regulators tested. It is a simple 
double-reciprocal of the data where  푋 = 1[푆] 
  and 푌 = 1푉푚푎푥 × (1 +퐾푚[푆]) 
in which [푆] is the range of concentration of substrate tested against the regulators that 
displayed a statistically significant response over the screening assay. 
Statistical significance of the response regarding the effect of regulators was determined using 
a one-way ANOVA test with p-value < 0.05 (*) unless otherwise stated. 
2.10. Thermal shift assay 
Thermal shift was performed on IDH and ICL as both enzymes responded to a selection of 
regulators. The assay allows to quantify the change in thermal denaturation of the protein under 
varying conditions. In this case, the binding of low molecular weight ligands can increase the thermal 
stability of the protein as described by Koshland208. This assay was conducted to confirm some 
findings from the kinetic assays of IDH and ICL, the binding of some regulators would help determine 
the affinity of the regulators with the protein. 
To monitor protein unfolding, the fluorescent dye Sypro orange was used. Sypro orange is a 
highly sensitive dye, commonly used for thermal shift assay as its fluorescence properties (λex 470 nm 
/ λem 570 nm) are compatible with filter sets found on real-time PCR instruments. The unfolding 
process following the raising of the temperature during the assay exposes the hydrophobic regions of 
proteins and results in an increase in fluorescence. The dye is released from the hydrophobic cavities 
of the protein and is eventually used to monitor the protein-unfolding transition209– 212. 
2.10.1. Testing regulators 
All experiments were done in Hard-Shell® 96-Well PCR Plates (Biorad) at a 25 µL total 
reaction volume in each well. Regarding ICL, the analysis was carried out in the presence of 50 mM 
MOPS, 15 mM MgCl2, 400 µM of regulator and 5 µM of protein pre-mixed with Sypro orange dye at 
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a 1:250 ratio of protein:Sypro orange. IDH analysis was similar: the reaction mixture included 50 mM 
TRIS pH 7.5, 5 mM MgCl2, 400 µM of regulator and 5 µM of pre-dyed protein. 
2.10.2. Equipment settings 
The thermal shift assay was conducted in a Biorad CFX-Connect Real Time Detection 
System, originally designed for PCR. The system contains a heating/cooling device for accurate 
temperature control and a charge-coupled device (CCD) detector for simultaneous imaging of the 
fluorescence changes in the wells of the microplate. The plate was heated from 25 to 95°C with a 
heating rate of 0.5°C/min. The Bio-Rad CFX Manager software was used to operate the equipment.  
2.10.3. Analysis of thermal shift data 
The fluorescence imaging data were fitted to the sigmoidal Boltzmann equation which 
assumes a two-state model (before and after transition). It analyses the Relative Fluorescence Unit 
(RFU) as a unit of the readings for the assay:  퐹푥 = 퐹퐴 + (퐹퐵 −퐹퐴)1 + 푒푇푚−푥푘1  
as a function of temperature, supported by Graphpad Prism 6 software. The equation includes 
the following parameters: 퐹퐴 is the initial or pre-transition reading (the protein is correctly folded at 
low temperatures). 퐹퐵 is the late or post-transition reading (after passing a certain threshold, the 
stability of the protein breaks down and it unfolds, liberating the fluorescent dye and thus a higher 
reading). 푇푚 represents the actual melting or transition temperature: it is the x-value equivalent to 
half of 퐹퐵. Finally, 푘1 is the slope greater than one of the derived curve during the transition phase. 
The thermal shift itself is simply derived from the difference between the values obtained for 
the samples with regulators vs. the protein alone as a control: ∆푇푚 = 푇푚푟푒푔푢푙푎푡표푟 −푇푚푐표푛푡푟표푙 
Usually, adding a low molecular weight molecule enhances the stability of the protein, since 
the transition temperature is higher than the control temperature. 
2.11. Crystallisation and X-ray experiments 
2.11.1. Approach to crystallisation 
2.11.1.1. Crystallisation screening and optimization 
Crystallization trials were performed using the vapor diffusion sitting-drop technique in 96- 
well MRC 2-drop plates (Molecular Dimensions). Screening and viewing of all proteins were performed 
using a Rock Imager 1000 (Formulatrix) operated by Rock Maker software. The plates were stored 
at 19°C for the duration of the experiment and imaging was automatically set to take pictures of the 
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crystal growth after 1, 2, 3, 5, 8 (+ UV image to characterize protein crystal vs. salt crystal), 13, 21 
and 34 days of incubation. 
Screening plates tested were as follow: 
• From Molecular Dimensions: JCSG+, Midas, PACT suite, Wizard I and II 
• From Qiagen: Classics suite, PEGs I suite, PH Clear I suite 
In cases where the screening was successful, but the crystals were too small, optimization was 
pursued to refine the conditions of the screening. Optimization plates were usually prepared using the 
Dragonfly® crystal robot (TTP Labtech Ltd) which dispensed microliters of solution in a horizontal 
or vertical gradient and added the substrate or the co-factor to some rows of the plate. Protein and 
mother solution dispensing was performed by the Mosquito® crystal robot (TTP Labtech Ltd) mixing 
200 nL of each solution. 
2.11.1.2. Crystallisation conditions for ICD 
The first isocitrate dehydrogenase crystallised in the presence of sodium acetate 0.1 M pH 4.6 
with 30% v/v PEG 300. The protein concentration was 10 mg/mL. These conditions were successful 
from the PEGs suite screening plate. 
2.11.1.3. Crystallisation conditions for IDH 
The second isocitrate dehydrogenase crystallised after optimization in the presence of 21.5% 
w/v PEG 3350, NaH2PO4 0.2 M, glycerol 5% and NADP+ 150 µM at a protein concentration of 17.5 
mg/mL. 
2.11.1.4. Crystallisation conditions for ICL 
The last enzyme crystallised after optimization with HEPES 0.1 M pH 5, CaCl2 0.1 M, 20% 
w/v PEG 6000, glycerol 5%, glyoxylate 1 mM and 2% thymol as additive. The protein concentration 
of 18 mg/mL permitted crystallisation. 
2.11.2. Crystal “fishing” and storage of the samples 
Fully grown crystals were “fished” using CrystalCap™ SPINE HT (Hampton Research) 
mounted loops and vials. The crystals were cryo-protected after immersion in a drop containing the 
crystallization condition solution supplemented with 26% v/v ethylene glycol and then snap-frozen 
in liquid nitrogen. All crystals were stored in their vials and kept in liquid nitrogen before being sent 
to the synchrotron. 
2.11.3. Sending samples and Synchrotron “shooting” 
The X-ray diffraction data collection was performed at Diamond Light Source, beamline I04-
1 or I02 (Oxford, UK). The crystallographic data collection statistics are summarised in table 16 for 
all three proteins.
2. Materials and methods 
36 
Table 16: Data collection and refinement statistics 
 ICD IDH ICL 
Data collection statistics 
Radiation source Diamond (UK), I04-1 Diamond (UK), I04-1 Diamond (UK), I02 
Wavelength (Å) 0.9282 0.9282 0.9795 
Space group P1211 C2221 I222 
Cell dimensions 
     a, b, c (Å) 88.88, 95.55, 104.01 126.46, 149.02, 201.13 80.94, 116.02, 128.53 
     ⍺, β, γ (°) 90, 99, 90 90, 90, 90 90, 90, 90 
Resolution range (Å) 2.70-47.78 (2.70-2.79) 2.71-29.62 (2.71-2.78) 1.88-29.49 (1.88-1.93) 
Total reflections 304691 (17419) 940727 (66819) 614357 (27689) 
Unique reflections 44233 (2978) 51799 (3682) 48986 (3287) 
Multiplicity 6.9 (5.8) 18.2 (18.1) 12.5 (8.4) 
Completeness (%) 98.0 (89.4) 99.6 (97.2) 99.4 (92.1) 
Mean I/sigma(I) 17.9 (2.0) 17.3 (3.7) 21.7 (3.0) 
R-merge 0.068 (0.826) 0.176 (0.891) 0.086 (0.656) 
R-pim 0.028 (0.348) 0.059 (0.304) 0.036 (0.340) 
CC-half 0.99 (0.79) 0.99 (0.92) 0.99 (0.78) 
Refinement 
Rwork (%) 24.56 20.80 18.32 
Rfree (%) 28.37 26.67 21.17 
No. of molecules per ASU 4 2 1 
No. of total atoms (no H) 12832 11551 3798 
     atoms for ligands n/a 58 6 
     atoms for waters 36 197 182 
Ramachandran plot analysis, number of residues in: 
Favoured regions (%)  92.19 93.91 96.90 
Allowed regions (%)  7.03 5.54 2.69 
Disallowed regions (%) 0.78 0.55 0.41 
B-factor (Å2) 
Average/Wilson 114.21/68.00 52.31/43.36 35.10/26.42 
Ligands n/a 28.88 52.86 
Solvent 38.04 35.87 32.55 
RMS deviations 
Bond lengths (Å)  0.003 0.01 0.01 
Bond angles (°)  0.602 1.52 1.43 
PDB entry 5M2E 6G3U 6G1O 
2.11.4. Crystal structure determination, model building and 
refinement 
All crystal structures were solved by molecular replacement (MR) using templates already 
deposited in the Protein Data Bank (PDB). ICD, IDH and ICL were solved using the templates 
1BL5213, 4ZDA (to be published) and 3I4E (to be published) from Escherichia coli, Mycobacterium 
smegmatis and Burkholderia pseudomallei respectively. The choice of these templates was guided after 
a BLAST analysis of each P. aeruginosa protein sequence against the PDB. The results with the 
highest identity scores were extracted for molecular replacement work. 
2. Materials and methods 
37 
All MR calculations were performed using PHASER214 as part of the PHENIX215 
crystallographic software package. The obtained models were alternatively subjected to manual 
rebuilding using the molecular graphic suite COOT216 and crystallographic refinement with PHENIX 
software or CCP4 package. 
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3. Isocitrate dehydrogenase (ICD) 
3.1. Introduction 
In this chapter, I will be discussing the first isocitrate dehydrogenase, ICD. I will start with 
the results of a bioinformatic analysis of the genomic context of icd gene and the analysis of ICD 
protein with respect to its evolution and conservation among pathogenic bacteria. Overall, 
phylogenetic analysis reveals that the use of nicotinamide adenine dinucleotide phosphate (NADP+) 
by prokaryotic ICD arose around the time eukaryotic mitochondria first appeared, about 3.5 billion 
years ago. The switch of the coenzyme specificity of prokaryotic ICD from nicotinamide adenine 
dinucleotide (NAD+) to NADP+ appears to be an ancient adaptation to anabolic demand for NADPH 
during growth on acetate181,217. This evolutionary aspect demonstrates how important ICD/IDH are 
in all prokaryotic and eukaryotic cells. ICD is particularly well conserved among bacteria as the 
enzyme of the TCA cycle that decarboxylates isocitrate. It is present in all bacteria studied here for 
the purpose of understanding the importance of the isocitrate branchpoint, and how carbon flux is 
rerouted depending on the carbon source available in the environment. ICD has been thoroughly 
studied in E. coli218 since the 1970s regarding its kinetics, expression profile and structure. However, 
little is known about it in Pseudomonas.  
In this chapter, I investigate the structure and kinetics of ICD in P. aeruginosa. Firstly, this 
study includes all the steps of the purification and analysis of the oligomeric status with gel filtration 
and analytical ultracentrifugation. I will then discuss the gene expression profile of icd gene when the 
cells are grown in different carbon sources. Most of the results I present here are related to the kinetics 
of the enzyme and its regulation via phosphorylation by isocitrate dehydrogenase kinase/phosphatase. 
I also solved the crystal structure of ICD and I will then complete the results with a thorough 
description of the structure. This investigation includes the protein-protein interface analysis, a 
comparison with the E. coli ICD structure and a detailed analysis of the active site. 
3.2. Bioinformatic analysis 
In the P. aeruginosa genome, the icd gene is positioned at 2.965 Mbp. This gene is composed 
of 1,257 base pairs (figure 6A). icd is located next to the idh gene (the second isocitrate 
dehydrogenase); both genes share the same 539 bp-long intergenic region and are divergently 
transcribed. Upstream of icd is cspD, which encodes a cold-shock protein member of the CspA cold 
shock stress adaptation family of proteins219. icd orthologues are also present in other Pseudomonas 
species (figure 6B). In other species of Pseudomonas, the icd sequence is conserved. P. fluorescens, 
P. putida and P. stutzeri have a gene that is the same size (1,257 bp), although the annotated icd 
gene in P. syringae is much longer at 2,223 bp. Further investigation showed that icd in P. syringae 
in fact corresponds to idh. In all species of Pseudomonas, the predicted sub-cellular location of the 
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translated protein is cytoplasmic. Furthermore, the overall genomic context in each species shows the 
same pattern: cold-shock protein (cspD) or ATP-binding protease component (clpA) adjacent to icd. 
Figure 6: Genetic context of the icd gene in P. aeruginosa PAO1 and other Pseudomonas 
species (A) The highlighted icd annotated gene is 1,257 bp encoding a 419 amino acid-long 
protein (stop codon included). idh gene is located immediately adjacent to the icd gene and 
shares a single intergenic region of 539 bp (B) icd orthologues in other Pseudomonas 
species display a similar genomic organisation, with idh nearby and cold shock protein or 
ATP-binding protease component upstream. 
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Amino acid sequence alignment of a few distant species shows that ICD is relatively well 
conserved among these bacteria (figure 7). The sequence alignment shows that the multiple residues 
involved in the binding of the substrate (highlighted in green) belong to conserved section of the 
Figure 7: ClustalOmega alignment of ICD amino acid sequence (yellow: phosphorylation site, green: substrate 
binding, blue: magnesium binding). ICD protein length is slightly variable from one species to another, the average 
length is around 420 amino acids. However, it is remarkable how well the enzyme is conserved. The later 
adaptation of ICD in species such as E. coli or P. aeruginosa does not seem to have affected the amino acid 
sequence. 
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sequences. The same is true when it comes to the residues that bind the magnesium ion (highlighted 
in blue) necessary for the catalytic reaction to take place. Finally, and most importantly with regard 
to regulation, the serine residue (highlighted in yellow) that is phosphorylated by the isocitrate 
dehydrogenase kinase-phosphatase seems to be conserved. 
3.3. Purification of ICD 
3.3.1. Preliminary results 
In order to study P. aeruginosa ICD (namely ICDPa in the rest of 
this dissertation), I first purified the enzyme. Firstly, the icd gene was PCR 
amplified from PAO1 gDNA and cloned into either pQE80 or a modified 
version of pMAL-c2x. The pQE80 vector that carries icd was introduced into 
E. coli DH5α for overexpression. The cloning was done by a previous member 
of the laboratory. Initially, I purified ICDPa with a His6-tag attached to the 
N-terminus of the protein (encoded in the pQE80 vector) using an Ni-NTA 
column. However, tagged proteins can be experimental hurdles in 
crystallisation, I thus decided to produce a new un-tagged protein to 
circumvent these hurdles. I started using a modified version of the pMAL-
c2x vector. A His6-tag was added to the N-terminus of the already present 
MBP-tag in the vector (work performed by Dr. Martin Welch). The vector 
was then renamed His-pMAL-c2x. A Factor Xa cleavage site located between 
the C-terminus of the MBP and N-terminus of the encoded protein was 
already part of the initial vector, allowing the eventual purification of an un-
tagged protein following Factor Xa digestion. I then cloned the ICD encoding 
gene into His-pMAL-c2x, transformed the construct into the same E. coli 
DH5α to overexpress and purify the product. Before cleavage, the construct 
would be a His6-MBP-ICD protein. Briefly, the purification workflow follows 
three steps. The first step uses an amylose resin to purify the construct via 
affinity of the MBP tag for the resin. The second step uses Factor Xa to 
cleave the His6-MBP-tag from the N-terminus of ICDPa. Finally, the third 
step uses a Ni-NTA resin to retain the His6-MBP-tag while the cleaved, native 
ICDPa in solution flows through and is collected.  
The figure 8 presented above shows that the molecular mass of the 
purified ICD is between 37 and 50 kDa. This corresponds nicely to the molecular mass predicted from 
the ICD amino acid sequence, which is 45,577 Da. This step demonstrates that the purification of the 
protein is complete, the molecular mass of the product is consistent with the predicted mass. The 
product of the purification after overexpression from E. coli DH5α containing the icd pQE80 construct 
was similarly successful, the molecular mass of the concentrated solution of protein was consistent 
Figure 8: Coomassie 
stained SDS-PAGE 
analysis after purification 
of ICDPa. This gel shows 
the un-tagged protein 
after purification from 
the icd His-pMAL-c2x 
expressing system and 
cleavage by Factor Xa. A 
clear single band is 
visible with a molecular 
mass of around 45 kDa 
compared with the 
molecular mass ladder 
displayed on the left-
hand side of the figure. 
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with its prediction. The SDS-PAGE analysis results after migration of the His6-tagged ICD showed 
the presence of additional bands (see appendix 2), probably degradation products that did not affect 
the continuation of the work. It is noticeable that the downstream treatment of the sample with 
Factor Xa resulted in a single band instead but with a much lower yield than the simple purification 
conducted on the His6-tag version of ICD. 
3.3.2. Gel filtration analysis 
 Besides SDS-PAGE analysis, a 
complementary technique to estimate the 
oligomeric status of ICDPa is gel filtration. A sample 
of 40 µg of concentrated ICDPa solution were 
injected into a TSK-Gel G3000 SWXL column 
equilibrated following the guidelines described in 
chapter 2. The native molecular mass was 
determined to be approximately 90,800 Da (see the 
results header of figure 9). Furthermore, the 
narrow peak observed in the figure 9 graph 
demonstrates that the sample, which is the product 
of the purification from the icd pQE80 construct, 
eventually has very little contaminants (see 
appendix 3 for the full results). These results show 
that the native ICD from P. aeruginosa is a dimeric 
enzyme. This result is in accordance with ICD in E. 
coli, which is also a dimer183. It demonstrates how 
much both enzymes are similar, the high amino acid 
identity (79%), and the oligomeric status. 
3.3.3. AUC data 
Analytical ultracentrifugation with a set of sedimentation velocities (SV) was used to further 
examine the oligomeric status of ICDPa. SV is a complementary technique to gel filtration that 
provides an information-rich characterization of many aspects of protein behaviour in solution, 
including the protein mass and size, density, hydrodynamic shape, size-distribution and purity. In the 
case of ICD, two hundred boundary profiles were recorded at three different concentrations (0.1, 0.5 
and 1 mg/mL). The data were analysed as specified in chapter 2 using SEDNTERP and SEDFIT. 
The profiles recorded and presented in figure 10 show that the frictional ratio for ICD is 1.33. The 
frictional ratio (calculated as f/f0) is a parameter of AUC that changes depending on the shape of the 
protein. On one hand, f (for frictional coefficient) is a measure of the resistance to movement of a 
molecule; this resistance is a function of both the size and the shape of the molecule. It is measured 
Figure 9: Gel filtration of ICD. The graph shows a 
single peak at a volume of 8.6 mL which corresponds 
to a molar mass of around 90 kDa. The three 
moments Mn, Mw and Mz are defined as the number 
average molecular mass, the weight average 
molecular mass and the higher average molecular 
mass. They are statistical average molecular mass of 
all the polymer chains in the sample. 
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by its rate of sedimentation. On the other hand, f0 corresponds to the frictional coefficient of a 
spherical particle from the Stokes equation). This means that a frictional ratio closer to 1 suggests 
that the protein is more globular. With a frictional ratio of 1.33, the results for ICDPa support the 
formation of a dimer with a moderately extended shape220.  
Furthermore, the calculated molecular mass was 91,500 Da, which agrees nicely with the data 
from gel filtration. This leads to the conclusion that ICD is a stable dimer in solution, again 
comparable in P. aeruginosa with ICD from E. coli. 
3.4. Gene expression of icd 
Two carbon sources, acetate and glucose, were tested to compare the responses of the cells as 
an adaptation to their environment. In order to investigate the effect of carbon source on the 
expression of icd, the promoter of the gene was fused with a promoter-less LacZ in pLP170. 
Theoretically, in the case of access to acetate only, and because it has only two carbons, the use of 
the glyoxylate shunt instead of the TCA cycle would be the appropriate response to save these two 
atoms from the decarboxylating steps of the TCA cycle. By doing so, the cells are capable of producing 
Figure 10: SV-AUC data of ICD protein. The figure shows the plotting of 100 absorbance scans recorded at 280 
nm for a protein sample of 0.5 mg/mL. The rmsd of the scans is of 0.0095, higher than the noise rmsd. The most 
prominent almost single peak with a molecular mass of 91.5 kDa indicates that ICD is a dimer. The frictional ratio 
(1.33), which is a useful parameter to identify the shape of the assembly, suggests that the dimer has an extended 
form. 
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the intermediates for other biochemical pathways, gluconeogenesis and to grow biomass. On the other 
hand, glucose is a rich carbon source. If the cells only have access to such a nutrient source, their 
metabolism should be rewired to promote the TCA cycle only. Glucose is a ring of six carbons, the 
loss of two molecules of CO2 does not affect the continuation of the TCA cycle. So, as a summary 
that means that acetate vs. glucose is in fact glyoxylate shunt vs. TCA cycle. The results of the 
growth of Pseudomonas in both media in figure 11 show that there is no impairment of the growth 
of the bacteria whether they have access to acetate or glucose. There even seems to be an overall 
better growth on single carbon sources for the strain containing the Picd::lacZ construct (blue line) 
compared with the wild type containing the empty vector (black line). I have no explanation for this 
since the two strains should differ only in the presence of Picd in the PAO1 strain transformed with 
Picd::lacZ construct. 
The measurements from the 
fluorescent β-galactosidase assay are plotted 
as a bar chart in both panels of the figure 
11. They show that there is a slight 
expression of the lacZ encoding gene present 
in the promoter-less vector, as seen between 
7 and 10h of experiment in the panel B 
(MOPS + glucose). This suggests that the 
supposedly promoter-less plasmid responds to 
induction and still produces a very small 
amount of β-galactosidase, although this is 
negligible compared with the Picd::lacZ 
construct.  
The response of the construct is of 
interest. When the cells are grown in acetate 
(panel A), the results from the β-
galactosidase assay highlight a strong 
increase of the signal over the exponential 
phase between 6 and 7h of experiment; 
followed by a decrease as the bacteria reach 
stationary phase (8-10h). The maximum 
value is around 3,000 nmol.min-1.A600-1. 
On the other hand, when the cells are 
grown in glucose, the β-galactosidase activity 
seems more consistent along the time course 
of the experiment. The results show a slightly steadier expression of lacZ when fused with the icd 
Figure 11: Gene expression results of Picd::lacZ fusion (A) 
MOPS + acetate (B) MOPS + glucose. The black line and 
columns indicate the WT strain, PAO1 transformed with the 
empty vector. The blue line and columns represent the Picd 
cloned into pLP170 and introduced into PAO1. The growth 
curve is plotted against the left-hand side y-axis (OD600). 
The values measured from the b-galactosidase assay are 
plotted as a bar chart against the right-hand side axis that is 
in nmol.min-1.A600-1 
ACETATE 
GLUCOSE 
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promoter. The maximum activity is lower with 1,250 nmol.min-1.A600-1; however the distribution on 
the graph demonstrates that the gene expression is ongoing during stationary phase with a new 
increase after 8h of growth. 
So, growth of PAO1 in a shorter carbon medium (acetate) seems to trigger the expression of 
icd more as the β-galactosidase activity values are higher; this trend seems consistent with a study 
performed on E. coli221. In this study on E. coli, the Picd::lacZ gene expression varied depending on 
whether glucose or acetate was used for cell growth, the β-galactosidase activity measured after the 
cells were grown in acetate was 2.3-fold higher than when the cells where grown on glucose in aerobic 
conditions. This is a similar pattern seen in P. aeruginosa; the β-galactosidase activity measured from 
the cells grown in acetate was 2.4-fold higher than in the cells grown in glucose. The fact that icd is 
still expressed in limited nutrient source demonstrates that the TCA cycle is still operational. The 
main hypothesis is that the production of α-ketoglutarate and co-production of NADPH is vital to 
combat oxidative stress. NADPH is the ultimate reductive force required to neutralize reactive oxygen 
species (ROS) as it maintains anti-oxidative systems in reduced/active states. ICD is the major 
NADPH-producing enzyme in ROS-exposed P. fluorescens when grown on simple carbon source222. 
3.5. Kinetic analyses 
3.5.1. Michaelis-Menten data 
ICD kinetic profile was determined following the established assay assessing the formation of 
NADPH at 340 nm by mixing a solution of purified untagged ICD with its substrate, co-factor and 
magnesium ion223. The design of the experiment is set to investigate the Km of the enzyme by varying 
its substrate concentration while maintaining the co-factor at a saturating concentration. Then, the 
affinity of the enzyme for the co-factor was investigated by varying NADP+ concentration while 
maintaining the substrate at a saturating concentration. This yielded Kisocitrate = 25 µM and KNADP+ 
= 32 µM (see figure 12A-B). The Vmax for isocitrate was 0.08 ΔmM.min-1 and 0.09 ΔmM.min-1 for 
NADP+. The Michaelis-Menten equation fits the data correctly. Despite the fact that ICDPa is a 
dimer, and as such is a potential allosteric enzyme consisting of multiple subunits and active sites, it 
is safe to infer that the enzyme follows a steady-state ordered mechanism. This has been extensively 
studied in Pseudomonas nautica224, Escherichia coli225, R. sphaeroides226. Finally, the first order rate 
constant kcat was calculated based on the enzyme concentration used in the assay (2.19 nM). The 
values of kcat for isocitrate and NADP+ were 36,529 min-1 (609 s-1) and 41,095 min-1 (684 s-1) 
respectively. These values are high; however they are not atypical for a central metabolism enzyme. 
It has been suggested that enzymes operating in central metabolism are under stronger selective 
pressures to increase their rates, hence their higher kcat227.  
ICD has not been studied in Pseudomonas aeruginosa before, but kinetic parameters have 
been reported for ICD from M. tuberculosis184 and E. coli228. For the Mycobacterium enzyme, Kisocitrate 
= 50 µM and KNADP+ = 15 µM, while for the Escherichia enzyme, Kisocitrate = 11 µM and KNADP+ = 17 
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µM. In my hands, purified ICDEc yielded Kisocitrate = 20 µM and KNADP+= 15 µM, i.e., values falling 
within the same range as the published ones. Furthermore, kcat was determined for the M. tb and E. 
coli enzymes at respectively, 33 s-1 and 80 s-1. This highlights a variability in the kinetics of this 
enzyme in different pathogenic species. ICD activity in Pseudomonas aeruginosa is similar, overall, 
when compared to the E. coli model. 
3.5.2. Screening of potential regulators 
I wanted to investigate the potential regulation of ICD activity by a subset of molecules that 
the protein might encounter in the cell. This includes a selection of 31 products from central 
metabolism including the TCA cycle and the Entner-Doudoroff pathway. The enzyme was incubated 
with saturating concentrations of isocitrate and NADP+ along with magnesium and a fixed 
concentration of each regulator. Similar to the kinetic studies discussed in the previous section, I 
monitored the formation of NADPH at 340 nm as the enzymatic reaction progresses in the presence 
of each regulatory candidate. The results were analysed with a one-way ANOVA (p < 0.05 and n = 
3) (see figure 13A), and statistically significant results are marked with an asterisk. 
Firstly, the product of the reaction (α-ketoglutarate) has a slight (23%) yet significant 
negative effect on the enzyme activity indicative of product inhibition. The literature reports another 
case of ICD product inhibition in Brevibacterium flavum in which the isocitrate dehydrogenase is 
inhibited to 36% of its activity229. This indicates that ICDPa is less sensitive to product inhibition 
than the B. flavum enzyme. However, further investigation about the effect of this product inhibition 
was performed to understand the type of inhibition and will be discussed later. 
Secondly, neither glyoxylate alone nor oxaloacetate alone affected the activity of ICD. 
However, there was a noticeable inhibitory effect when an equimolar (1 mM) mixture of both 
compounds was present, yielding 93% inhibition of ICDPa. As seen in figure 13A, the bar chart 
shows a large decrease in ICDPa activity when compared with the uninhibited control. Such an 
inhibition has already been reported in the literature for ICD from E. coli225, T. thermophilus230 and 
Figure 12: Kinetics results of ICD (A) Michaelis-Menten and Lineweaver-Burk plots with respect to isocitrate 
indicate that Km = 25 µM and Vmax = 0.08 ΔmM.min-1 (B) Michaelis-Menten and Lineweaver-Burk plots with 
respect to NADP+ conclude that Km = 32 µM and Vmax = 0.09 ΔmM.min-1 
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mammals cells231. The different investigating groups found that the mixture of both compounds caused 
25-75%, 42% and 40% inhibition respectively. In this context, ICDPa seems remarkably affected with 
only 7% of activity remaining. For the E. coli enzyme, the mechanism that has been proposed to 
explain this inhibition is the formation of a condensation product with a very strong affinity for ICD. 
Using HPLC analysis, Nimmo et al. demonstrated that mixtures of glyoxylate and oxaloacetate form, 
firstly oxalomalate and then 4-hydroxy-2-oxoglutarate. Oxalomalate is likely the active compound 
inhibiting the enzyme due to its similarity with isocitrate225.  
The inhibition of ICDPa by α-ketoglutarate was further investigated. A solution of purified 
enzyme was incubated across a range of isocitrate concentrations with a saturating concentration of 
NADP+ and a fixed concentration of α-ketoglutarate (1 mM) to monitor the activity of ICDPa. By 
doing so, I determined how α-ketoglutarate competes against isocitrate. Analysis of the resulting 
kinetic data using a Lineweaver-Burk plot (figure 13B) shows that the control and α-ketoglutarate 
lines intersect the y-axis (1/Vmax) at the same point but their x-intersection (-1/Km) is different. This 
indicates that α-ketoglutarate is a competitive inhibitor of isocitrate binding to ICD. The Km value 
in presence of α-ketoglutarate is higher than the control (64 µM) whereas Vmax is 0.09 ΔmM.min-1, so 
within the range of the Vmax of the control (see section 3.5.1). The scenario of a competitive inhibition 
supposes that the inhibitory compound(s) are capable of binding to a free active site of the enzyme, 
which then prevents binding of the substrate. 
The affinity of the inhibitor for the enzyme can be inferred from the Ki value. The Ki 
represents the concentration of inhibitor at which, under saturating substrate conditions, the reaction 
Figure 13: Kinetic impact of potential regulators of ICDPa (A) Screening of organic acids and metabolic 
intermediates, values marked with * are significantly different from control (p<0.05 and n=3). Out of 31 
compounds tested, only two yielded a significant response. A mixture of glyoxylate and oxaloacetate inhibits ICD 
activity. A lesser inhibition occurs in presence of a-ketoglutarate (B) Lineweaver-Burk plot of a-ketoglutarate vs. 
isocitrate. Both control and a-ketoglutarate lines intersect the y-axis at the same point, whereas the x-intersect is 
different. This indicates that the inhibition seen when the enzyme is in presence of a-ketoglutarate is of a 
competitive type. 
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rate is half of the maximum reaction rate (Vmax). The Ki value was determined from the modified 
Michaelis-Menten equation: 퐾푚(표푏푠) = 퐾푚 × (1 + [퐼]퐾푖) 
in this experiment, [I] = 1000 µM. The Ki obtained for α-ketoglutarate was 665 µM. This is 
a rather high value for Ki but it is consistent with another study conducted on Brevibacterium flavum 
ICD. For B. flavum ICD, the Ki is 1.1 mM229. A Ki in the high µM range is rather high, indicating 
that α-ketoglutarate is a weak inhibitor.  
3.5.3. Effect of nucleotides 
3.5.3.1. Effect of ATP 
 The regulation of ICD by central metabolism compounds did not reveal strong regulatory 
candidates. The results were significant for some molecules but overall, there is no obvious trend that 
would explain the rerouting of carbon at the TCA Glyoxylate Branchpoint (TGB). This indicates 
that there must be other regulatory mechanisms controlling ICDPa activity. One mechanism is the 
effect of AceK (isocitrate dehydrogenase kinase/phosphatase) to inactivate ICD. This is based on the 
extensive knowledge of ICD in E. coli for which we know that AceK is the major regulator. In E. 
coli, AceK phosphorylates ICD rendering it inactive, thus pushing isocitrate through the glyoxylate 
shunt. I investigated this mechanism in P. aeruginosa and this is discussed in the section 3.5.4. 
However, I also examined the effect of ATP (and other related nucleotides). In E. coli, AceK 
phosphorylates ICD in presence of ATP, so I decided to see if ATP alone has an intrinsic effect on 
ICDPa. The ubiquity of ATP and its association with AceK, makes the molecule a good regulatory 
candidate.  
A brief study of the effect of AceK on ICDPa has already been performed by a PartII student 
in 2014. She concluded that ICDPa is completely inhibited by ATP after 2 h of incubation. 
Interestingly, the effect of ATP on bacterial isocitrate dehydrogenase has not been widely studied. A 
few publications report such an effect in the Crithidia fasciculata enzyme232,233 and the Salmonella 
typhimurium enzyme234. To investigate this further, I incubated the enzyme with saturating 
concentrations of substrate and co-factor and a fixed concentration of 1 mM ATP. In the 
Pseudomonas aeruginosa enzyme, there as a significant inhibition of ICD activity in presence of 1 
mM of ATP (figure 14A). This effect is measurable after an incubation time of up to 30 min. The 
loss of activity in the P. aeruginosa enzyme (28%) C. fasciculata nor in S. typhimurium in which the 
inhibition accounted for 55% and 60% of activity loss respectively. However, in Pseudomonas, ICD 
is not the only enzyme affected by ATP. Another metabolic enzyme of the Entner-Doudoroff pathway 
exhibits inhibition by ATP: glucose-6-phosphate dehydrogenase (G6PD)235. In that case, ATP seems 
to inhibit G6PD activity. The enzyme performs at 15% of its capacity, the inhibition is significantly 
stronger than for ICD. The effect of a single concentration 1 mM ATP on ICDPa is significant, thus, 
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I decided to investigate further and studied the effect of 
lower and higher concentrations of the same nucleotide 
ATP.  
Other concentrations of ATP had a similar 
inhibitory effect on ICDPa as seen in figure 14B. Higher 
concentrations of ATP greatly affected ICD activity. 
From 25 mM and beyond, there was total loss of activity 
when ATP is incubated with the enzyme. Concentrations 
less than 1 mM or equal to 1 mM do not show inhibition. 
This corroborates the results from figure 14A, inhibition 
by 1 mM ATP was significant after 30 min of incubation. 
So, the length of incubation seems to be important in the 
case of low concentrations of ATP, I decided to investigate 
further. The purified enzyme was incubated in substrate 
and co-factor saturating concentrations and with low 
concentrations of ATP (0.025 to 1 mM) for up to 30 min. 
Higher concentrations of ATP (5 to 20 mM) were also 
tested. 
The results were plotted as a bar chart (figure 
14C), and all the values were first analysed with a two-
way ANOVA analysis (p < 0.05 and n = 3). Even the very 
low concentration of 0.025 mM ATP had a slight, yet 
significant, inhibitory effect. At higher concentrations i.e. 
from 0.05 to 5 mM, the pattern was similar. The initial 
rate of the enzyme is lowered by 0.02 mM.min-1 when 
incubated with 0.025 mM ATP; while the effect of 5 mM 
ATP inhibits ICDPa by 0.06 mM.min-1. Higher 
concentrations of ATP (10 mM and more) show an 
immediate inhibition of the enzyme when compared with 
control and nearly total inhibition after incubation. This 
indicates that ICDPa is affected by ATP in two ways. On 
the one hand, high concentrations of ATP immediately 
inhibit the enzyme; on the other hand, for low 
concentrations of ATP, inhibition is time-dependent. For 
the latter, a greater effect is seen after 30 min of 
incubation. The need of incubation to observe the effect of 
ATP may explain why no inhibition could be detected in figure 13A. 
Figure 14: Study of the effect of ATP on ICD 
activity (A) Incubation of 1 mM of ATP for 30 
min (B) ATP inhibition over a larger range of 
concentrations, passed 1 mM the inhibition is 
instantaneous (C) Lower concentrations of 
ATP require time to inhibit ICD 
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I have demonstrated that ATP inhibits ICD. The 
next step in this study is to understand what type of 
inhibition ATP yields. To analyse ATP inhibition profile, 
purified ICDPa was incubated with saturating 
concentration of NADP+ and fixed concentrations of ATP 
(either 0.1, 0.5, 1, 5 and 10 mM) across a range of 
isocitrate. Then vice versa, the enzyme was incubated 
with saturating concentration of isocitrate with fixed 
concentrations of ATP and across a range of NADP+. The 
concentration of ATP in the cell can reach up to 10 mM236, 
so the inhibition may be physiologically meaningful. Marr 
et al. studied the inhibitory activity of ATP and other 
nucleotides on ICD from Salmonella typhimurium234 and 
demonstrated a competitive inhibition by ATP with 
respect to isocitrate and NADP+. In Pseudomonas 
aeruginosa however, as indicated in figure 15A-B, 
inhibition by ATP with respect to both isocitrate and 
NADP+ is of a non-competitive type. The lines on both 
graphs intersect the x-axis (-1/Km) at the same point. 
Additionally, the lower concentrations of ATP (0.1, 0.5 
and 1 mM) do not show a large response as the plots are 
very similar to the control line. This is consistent with the 
previous results seen in figure 15B, low concentrations of 
ATP have little effect on ICDPa activity. However, at 
higher concentrations (5 and 10 mM) the effect is more 
obvious. 
Further studies of this inhibition in ICD from 
Vigna radiata237 (mung bean), suggests that as in S. typhimurium, ATP is a competitive inhibitor 
with respect to isocitrate. On the other hand, studies performed on ICD from another eukaryote 
(Crithidia fasciculata, a trypanosomatid species of mosquitoes) showed that ATP is a non-competitive 
inhibitor with respect to both the substrate and co-factor of the enzyme233. Additionally, there is one 
hypothesis that has been advanced to explain how ATP inhibits ICD. It is thought that the inhibition 
of ICD by ATP could be correlated with the decrease of free Mg2+ in the reaction mixture238 as the 
nucleotide might act as a chelator239,240. Nearly 90% of the magnesium in a bacterial cell is chelated 
with either ribosomes, DNA, RNA, membranes elements and nucleotide triphosphates241. Indeed, the 
Mg-ATP complex is the true substrate of numerous enzymes (mostly kinases)242,243. In Pseudomonas 
aeruginosa, since ATP is a non-competitive inhibitor it can bind to either the free enzyme or to the 
enzyme-substrate complex during the reaction. The magnesium depletion mechanism hypothesized 
Figure 15: Lineweaver-Burk plots of ATP 
inhibition (A) Effect of ATP with respect to 
isocitrate shows a non-competitive profile (B) 
The same non-competitive inhibition happens 
with respect to NADP+ 
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would explain the inhibition. If ATP chelates magnesium, the enzyme no longer has access to an 
essential catalytic element and the reaction is aborted. The time-dependent inhibition by lower 
concentrations of ATP might support this hypothesis. In the reaction mixture, it is possible to infer 
that the enzyme and ATP will compete for the free magnesium, eventually abolishing ICD activity. 
In this regard, the higher concentrations of ATP (10 mM and more) greatly exceed the concentration 
of magnesium in the reaction mixture (5 mM). To investigate this further, the nearby conserved 
tryptophan residue (Trp135) could be used as a fluorescent reporter to monitor metal ion binding in 
the active site. To do so any prebound Mg2+ should be removed from the purified protein. The 
demetallized protein can then be incubated with Mg2+ then Mg2+ and ATP. A change in the relative 
tryptophan fluorescence intensity will indicate that the environment around the tryptophan residue(s) 
changes upon binding of Mg2+ compared to the control (demetallized protein only) and further 
changes if ATP complexes free Mg2+. 
3.5.3.2. Effect of other nucleotides 
After seeing the inhibitory effect of ATP, I 
decided to see if this was transferable to other nucleotides. 
I therefore tested AMP, ADP, GDP and GTP at a single 
concentration (1 mM) after an incubation time of 30 min. 
All nucleotides demonstrate inhibition of ICD as shown in 
figure 16. AMP has less effect on the enzyme than ADP, 
GDP or GTP. AMP only inhibits ICD by 27% whereas 
ADP and GDP inhibit by 55% and 58% respectively. GTP 
falls in between with an inhibition of 38%. Overall, the 
results with P. aeruginosa ICD are similar to the results 
obtained with S. typhimurium ICD, in which ADP and 
GTP inhibited by 60% AMP by 10% only234. Once again, 
the inhibition by these nucleotides is significant after a 
period of incubation of 30 min which is why it was not 
detected during the screening of the regulators. 
Similar to the hypothesis previously discussed of 
ICD inhibition due to the formation of a Mg-ATP complex, Mg is also chelated by other nucleotides; 
AMP, ADP, ATP and GTP241,244. The time-dependent inhibition of ICD by these nucleotides under 
the conditions described for this experiment, may explain the results. As the nucleotide concentration 
is of 1 mM competing against isocitrate for Mg2+ at 5 mM, it is possible to attribute the delay 
observed to this primary competition for magnesium. The Mg-ATP complex formation and the Mg-
isocitrate complex245 formation is the foremost competition before binding to ICDPa. Further 
investigation would study the demetallized purified protein incubated with i.e. Mg2+, or Mg2+ and 
isocitrate, or Mg2+ and ATP, or Mg2+, isocitrate and ATP. The relative tryptophan fluorescence 
Figure 16: Effect of other nucleotides on ICD 
activity. Values marked with * are significantly 
different (p<0.05 and n=3). All nucleotides 
tested showed an inhibitory effect on ICD 
activity 
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intensity and fluorescence quenching (using Trp135 as a fluorescent reporter) would indicate the 
conformational changes of the active site upon binding of Mg2+ or Mg-isocitrate complex. 
3.5.4. Effect of AceK 
The third and last mechanism investigated for the 
regulation of ICD is isocitrate dehydrogenase 
kinase/phosphatase (AceK) in Pseudomonas aeruginosa. AceK 
is the most recognized regulator of ICD activity and helps to 
coordinate carbon flux through the glyoxylate shunt in E. coli 
by inhibiting isocitrate dehydrogenase. This has been thoroughly 
studied in E. coli, and AceK remains the first example of 
prokaryotic phosphorylation identified. It is known that in E. 
coli, AceK phosphorylates its substrate, ICD, on Ser113. In P. 
aeruginosa, Ser115 corresponds perfectly to the phosphorylation 
site as it matches the 3D structure conformation. This will be 
discussed in the next section regarding the ICDPa crystal 
structure. 
In order to test the effect of AceK on ICD from 
Pseudomonas aeruginosa, both enzymes were incubated with 
isocitrate and NADP+. Upon addition of ATP, AceK would 
phosphorylate ICD and the remaining ICD activity would be 
monitored by measuring the reduction of NADP+ to NADPH. 
The loss of ICD activity, if any, accounts for AceK phosphorylation. The incubation, up to 30 min, 
reflects previous work done in the laboratory showing that there might be a time-dependent factor 
acting for significant loss of activity of the enzyme. The results in figure 17 show that after addition 
of ATP, there is initially no significant decrease in ICD activity in the presence of AceK. However, 
after 30 min of incubation, ICD activity is decreased by 71%. Note that the inhibition is not total, as 
ICD remains up to 29% active. This could suggest that even though flux through the glyoxylate shunt 
is promoted upon inactivation of ICD, the TCA cycle is not completely shut down. This suggests 
that even in vivo, when the cells are growing on a limited nutrient source (aka. acetate) and rewire 
their carbon flux through the glyoxylate shunt, there is still a substantial flux through the TCA cycle. 
Saving two atoms of carbon is essential for the bacteria by rerouting carbon flux through the 
glyoxylate shunt. However, the cells sustain the production of NADPH by ICD and NADH by α-
ketoglutarate dehydrogenase. The NADPH/NADH-generating reactions coupled to central carbon 
metabolism ensure that the cellular redox balance is maintained246– 248. 
Overall, these results highlight the apparent similarities between ICDPa and the other 
isocitrate dehydrogenases, particularly that from E. coli. In P. aeruginosa, ICD is sensitive to 
competitive product inhibition. It is greatly inhibited by a mixture of glyoxylate and oxaloacetate. 
Figure 17: Effect of AceK on ICD. The 
experiment was performed with three 
samples allowing a one-way ANOVA 
analysis with p-value<0.01. After 30 
min of incubation, ICD is significantly 
inhibited by AceK 
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But more importantly, the principle means of controlling the activity of ICD is by AceK-dependent 
phosphorylation.  
3.6. Crystal structure of ICD 
3.6.1. Structure description and interface analysis 
The three-dimensional structure of ICDPa was solved by molecular replacement using ICDEc 
(PDB 1BL5) as a template. The structure was refined to 2.7 Å. The analysed crystal contains two 
dimeric ICD molecules in the asymmetric unit. Each dimer is composed of 836 amino acid residues 
each, along with 36 water molecules (see figure 18C). The structure presented is an apo structure 
as it has been crystallised without any specific ligand. Overall, the electron density map allowed 
largely unambiguous tracing of all molecules in the unit cell. The structure is available in the PDB 
under the accession code 5M2E and the appendix 5 compiles a few of the validation elements 
including Ramachandran plot and Polygon analysis. 
The ICD dimeric molecule is roughly kidney shaped, with an intricate clasp domain between 
the two subunits as shown in figure 18A-B. A PISA249 analysis indicates that with 26 interfaces 
calculated, the assembly is indeed a dimer. The binding between the two subunits is made of a close 
Figure 18: ICD crystal structure (A) Frontal view of the dimer with the clasp domain on top (B) Bottom view of 
the dimer after a 90° rotation on the x-axis (C) There are four molecules in the asymmetric unit, showcasing two 
dimers facing each other (D) Residues making the interface between the two subunits mainly belong to the clasp 
and the four central a-helices 
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interaction of two α-helices located on top of the structure as in figure 18A. Underneath are two β-
strands criss-crossing each other. Additional loops and helices strengthen the interaction along the 
inner side of the structure, where four α-helices create a channel-like sub-structure inside the dimer. 
Such a conformation might explain a potential clasp-like effect when the substrate and co-factor are 
bound. The whole structure is comprised of 14 α-helices and 20 β-strands per monomer. In addition, 
92.2% of residues are in the most preferred regions of the Ramachandran plot. 
The residues comprising the interface between the two subunits of ICD were defined using 
MacPyMOL with the InterfaceResidues script. This script finds interface residues between two 
proteins or chains, using the following concept. It evaluates interface residues based on the difference 
between the complex-based areas and the chain-only-based areas. Such a difference isolates the 
residues that are overlapping and in contact to form the dimer. The cut-off used to identify the 
residues was of 0.5 Å2, which is the difference in area over the residues considered as interface residues. 
Residues whose ∆ASA250 (difference in accessible surface area) from the complex to a single chain is 
greater than this cut-off are kept. In addition to the size and shape of the interface, the ∆ASA remains 
a powerful method that may eventually provide a measure of the binding strength through the 
correlation between the hydrophobic free energy of transfer from polar to a hydrophobic environment 
and the solvent ASA251. 
A more thorough analysis by COCOMAPS252 indicates that most of the residues of each chain 
involved in the interface are between positions 150 and 210 and then again a few more residues around 
position 300. Both tools concluded that there are in total 75 residues from chain A and 74 residues 
from chain B that form the interface. The charts in figure 19 show the distribution of the residues 
forming the interface, and the distance range with a lower cut-off of 7 Å is shown in red. Both charts 
overlap showing that there are more residues around position 200 which corresponds to the top part 
Figure 19: Analysis of the interface of ICD (A) Space-filling representation of the residues from both chains 
forming the interface (B) Intermolecular contact map, a black dot is present at the cross-over of residues i and j, 
belonging to molecule 1 and molecule 2, respectively, if any pair of atoms belonging to the two residues is closer 
than the cut-off distance (default value is 8 Å) (C) Distance range map reporting inter-molecular contacts at 
increasing distances, as coloured dots. Red, yellow, green and blue indicate contacts within 7 Å, 10 Å, 13 Å and 16 
Å, respectively 
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of the interface. This correlates with the inner contact of the two α-helices and the β-strands that 
form the clasp on top of the structure. The remaining residues scatter along the four α-helices making 
the core of the dimer. With regard to the ∆ASA in homodimers generally, it varies widely from 368 
Å2 to 4,746 Å2, and the results for ICD fall into that category with an average of 3,136.7 Å2 253. This 
also means that 16% of the overall surface of the protein is buried upon the complex formation. The 
polar vs. non-polar surfaces between the two subunits show that the mean polar interface area is 
2,224.8 Å2 whereas the non-polar is 911.9 Å2. Finally, deeply buried atoms in the core of the protein 
and interfacial residues in protein binding complexes tend to have lower B-factors in comparison to 
the rest of the protein254,255. This is the case for most of the 149 residues making the interface of ICD. 
There is indeed a trend of reduced B-factors, in comparison to the outer edge of the protein. The 
trend is even more obvious when comparing to the loops that tend to show more disorder and 
flexibility.  
3.6.2. Structural comparison with E. coli 
Dimeric ICD of P. aeruginosa and E. coli share 
79% of amino acid identity. There is a slight difference 
between the two, as E. coli is two-residues shorter, but 
the overall structure is extremely similar. The residues 
involved in the substrate, co-factor and cation binding 
are all conserved but with a shift of two residues. The 
superimposition of two apo structures of ICD from both 
species (E. coli PDB 3ICD) demonstrates a tenuous 
difference in the bending of the structure indicated by 
a rmsd of 1.98 Å (figure 20). There are also a few 
differences in the organisation of the structure. The 
large β9-strand present in P. aeruginosa (black arrow) 
from Cys196 to Ser204 is absent in E. coli. However, 
three small β-strands are missing in P. aeruginosa (β1, β2 and β11 E. coli numbering) (see appendix 4 for a 
detailed alignment of the amino acid sequence and 
secondary structure elements). Overall, the secondary 
structure is comparable; most of the α-helices overlap while the loops are more variable. The 12 β-
sheets forming the core of the enzyme are persistent in both structures. When looking at the dimer, 
the E. coli structure seems to be marginally more closed whereas the P. aeruginosa structure has a 
slightly “wider” conformation. 
The E. coli model used for residue comparison (PDB 4AJB) is a complex of ICDEc (a K100M 
mutant) crystallised with isocitrate, Mg2+ and thio-NADP+ (a non-hydrolysable analogue of 
NADP+)256. The rmsd value after overlaying the two proteins was 1.94 Å. Overall, the secondary 
Figure 20: Superposition of ICDPa and ICDEc apo 
monomers. Both proteins are very similar, a few 
secondary elements are dispersed between the 
two but overall the monomers and then dimers 
are equivalent on all aspects. 
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structure elements of the cleft around the isocitrate binding site are tighter in the ICDEc structure, 
consistent with the presence of an activated form of the enzyme that closes its active site upon binding 
of the substrates. The binding of the substrate and co-factor clearly affects the overall bending of the 
active site and the dimer. The superposition of the two structures in figure 21A demonstrates how 
deep isocitrate is embedded into the active cleft. It sits at the very back of the cleft surrounded by α4 on the right, β6-7 at the back and α9 (from chain A) and α8 (from chain B) on the left. Refer to 
appendix 4 for a sequence and secondary structure alignment. Crystallographic analyses of the 
superposition of both structures yield considerable insight into the molecular basis of catalysis. When 
overlaid with the E. coli model, the residues binding the substrate in P. aeruginosa (Ser115, Asn117, 
Arg121, Arg131, Arg155, Tyr162 and Lys232*) (residues marked with * belong to the opposite chain) 
exhibit a different conformation (figure 21B): they all point outward from the active site. The 
residue Tyr162 shows a difference of 2.83 Å in the placement of the side chain away from Tyr160 in 
E. coli bound to the substrate. Additionally, the most remarkable shift is Arg121 which is displaced 
by about 7.41 Å outside the active site in comparison with Arg119 bound to isocitrate in E. coli. This 
displacement is further increased by the shift of 2.63 Å at the Ca of Arg121. Another strongly affected 
residue is Ser115, the distance between the two Ca between ICDPa and ICDEc is 3.58 Å. The hydroxyl 
group of this side chain points nearly 180° in the opposite direction when the substrate is not bound. 
This suggests isocitrate binding changes the conformation of the catalytic site. Finally, the binding 
of magnesium and its coordination with isocitrate is promoted by Asp285* and Asp309. However, the 
conformation of these residues is unaffected by Mg2+. 
Following up the substrate, NADP+ binds more on the rim of the cleft as seen in figure 21C-
E. It engages with a much more flexible section of the enzyme. Most of the residues are located on a 
loop running between β6 and α10; a few more are part of α12 from chain A. More residues belong to 
the same α8 in chain B. This establishes a domain closure by a hinge motion of the loop from chain 
A that comes capping the active site cleft during catalysis256. The binding of the co-factor can be 
divided into two categories: the binding of the adenosine moiety on one hand and the nicotinamide 
moiety on the other. Similar to the substrate binding, residues from both chains participate in the 
binding of NADP+. Generally, the number of residues required to bind NADP+ is greater than for 
the substrate as the molecule is much bigger and is part of a complex network with water molecules 
and isocitrate. Previous work185,245,257– 262 highlighted different residues for co-factor binding, and shed 
some light understanding the multiples stages of activation of the enzyme and the consequences on 
the flexibility of the active cleft. The template used to study NADP+ binding is 4AJ3, a wild type 
ICDEc crystallised with isocitrate, Ca2+ and NADP+. The adenosine moiety is directly or indirectly 
bound to ten residues from both chains, creating a complex network with water molecules. As seen 
in figure 21D, the main ones are His341, Gly342, Thr343, Asn354, Tyr347, Tyr393, Gln289*, and 
Arg294* accompanied by Gln290* interacting with water. In P. aeruginosa, all these residues are 
conserved. The superposition of the two active sites reveals a large shift of the β6/α10 loop between 
ICDPa in yellow which is in an open conformation and ICDEc after closure of the cleft initiated by 
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NADP+ binding. The top part of the loop shifts by 4.40 Å calculated between the two Ca of ICDEc 
His339 and ICDPa His341. The bottom part of the loop displaced even more (by 7.33 Å) between 
ICDEc Tyr345 and ICDPa Tyr437. The α12 helix that carries Tyr393 and Arg397 in P. aeruginosa is 
displaced by 4.20 Å on average away from the active site cleft. The residues from chain B are better 
conserved in their orientation. The Ca are closer between the two species, however the side chains 
are dissimilar. For example, the side chain of Arg294* is 4.74 Å away from its equivalent Arg292* 
bound to the phosphate group. The nicotinamide moiety interacts mainly with the short loop located 
Figure 21: Active site of ICDPa superposed with ICDEc (A) View from the top reveals isocitrate embedded deep into 
the active site cleft, interacting with both chains (B) All the residues binding isocitrate are highly conserved (C) Top 
view in presence of NADP+ demonstrates that the binding occurs at the rim of the subunit and displays a shift of 
the loop to bind the ADP moiety (D) Superposition of the residues involved in binding the ADP moiety indicates 
high conservation but significant shift due to substrate binding (E) Top view of chain A bound to NADP+ detailing 
the nicotinamide moiety. There is an evident shift of the small a4-b5 loop upon binding (F) Residues binding the 
nicotinamide ring, both chains participate in binding to the co-factor in the active cleft, the main Lys100-Thr107 
loops works as an anchor 
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between α4 and β5, in particular Lys100-Thr107. This forms an anchor for the nicotinamide ring 
binding. Two additional residues, Asn234* and Glu338, promote the interaction with isocitrate and 
water molecules. The superposition of those residues in figure 21F shows that the loop in P. 
aeruginosa increasingly shifts from 4.06 Å (Pro102 vs. Pro104) to 7.55 Å (Thr107 vs. Thr105). The 
increasing shift of the loop corresponds to closing motion promoted by NADP+ binding, the “front” 
of the loop (see figure 18A for a frontal view of the dimer) must cover more distance to interact 
with the co-factor. Overall, the binding residues are conserved, but their conformation is dictated by 
the binding of the ligands, this also promotes the hinge motion that operates after binding isocitrate 
and NADP+. 
3.7. Discussion 
The most common isocitrate dehydrogenase among bacterial species is a remarkable example 
of conservation across evolution. The alignment and phylogenetic tree discussed in section 3.2.2 
proved that ICD is particularly well conserved among Gram-negative bacteria but also between Gram-
negative and Gram-positive bacteria. Based on the work performed to investigate the evolutionary 
distinction of eubacterial NADP-dependent isocitrate dehydrogenase it was concluded that the 
enzyme is monophyletic, and it diverges near the branchpoints of the eukaryotic NAD+- and NADP+-
dependent isocitrate dehydrogenases. This seems to indicate that NADP+ dependence evolved very 
early, concomitant with the appearance of eukaryotes estimated around 2-3.5 billion years ago263. Due 
to its major role in carbon metabolism, ICD shows strong similarity across a wide range of species as 
seen in the previous sections. The length of the enzyme is as conserved across most bacterial species.  
The overexpression and purification of ICD in Pseudomonas aeruginosa yielded a 
concentrated solution of protein. Further investigation of the oligomeric status of the enzyme in this 
microorganism confirmed that it has an homodimeric quaternary structure which is consistent with 
other species harbouring the same enzyme. The gel filtration and sedimentation velocity experiments 
both yielded nearly the same calculated molecular mass (90 kDa). These findings corroborate the 
conservation status of ICD in Pseudomonas aeruginosa compared with the well-studied ICD from E. 
coli. Despite the fact that the glyoxylate shunt was first discovered in Pseudomonas strain KB1, little 
is known about the TGB in this microorganism nor any characteristics of ICD.  
Here, I present the crystal structure and kinetics of ICD from Pseudomonas aeruginosa. A 
crucial objective of the work was to characterize this enzyme and establish differences in behaviour 
that may account for understanding how P. aeruginosa partitions carbon flux in central metabolism. 
Structural analyses and sequence alignments conducted with CCP4MG264, PyMol265 and Jalview266 
highlighted the similarity of ICDPa with ICDEc, especially in the residues that are thought to be in 
contact with either the substrate or the co-factor. In this study, ICDPa is an apo structure with no 
ligand or co-factor in the electron density map. The superposition of ICDPa and ICDEc structures 
shows conformational displacements of the residues lining the substrate and co-factor binding sites in 
ICDPa. Further structural analyses and alignments have revealed that the catalytic site and the overall 
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shape are highly conserved, including the positioning of the residues that participate in the substrate, 
ion and co-factor binding (figure 21). The alteration in the overall bending of the active site cleft in 
P. aeruginosa could be attributed to the fact that the model used for comparison includes the 
substrate, co-factor and metal, thus triggering a more “closed” conformation of the enzyme.  
From a general point of view, the catalytic site in ICDPa lies in the same configuration as in 
ICDEc, displaying a pocket at the front of each subunit divergently oriented from each other. The 
phosphorylation site (Ser115) is on the helix α14 at the front of the pocket, the residue overlays with 
Ser113 in E. coli which indicates that it is capable of binding the substrate and probably involved in 
AceK-mediated phosphorylation. In the case of inactivation by phosphorylation, the negative charge 
of the phosphate leads to complete inactivation of the enzyme in E. coli as the serine can no longer 
bind to the substrate188. However, when binding the substrate, there is a conformational change, the 
side-chain is reoriented inward as seen in figure 21B. Finer-Moore et al.267 have already suggested a 
conformational change of ICDEc in presence of AceK. AceK promotes a cascade of conformational 
changes making Ser113 (in E. 
coli) available for 
phosphorylation. This has been 
confirmed by the study of a S113 
mutant188,268– 270. All substitutions 
for that serine resulted in 
lowered activity when compared 
to the wild type enzyme. Further 
investigation on ICD from P. 
aeruginosa exploring the effect 
of S115 directed mutagenesis. 
Such experiments help 
understanding how enzymes 
discriminate between ligands 
such as substrates and inhibitors 
for the development of rationally 
designed drugs for example. 
These experiments would also 
focus on AceK phosphorylation 
capacity on ICD and how other 
residues replacing Ser115 could 
implement or diminish the 
phosphorylation-mediated 
inactivation.  
Figure 22: Proposed catalytic mechanism of isocitrate dehydrogenase. ICD 
mechanism follows a general acid-base chemistry supplemented by two 
main catalytic residues Lys232 (chain B) and Asp307 (chain A). Figure 
adapted from Aktas and Cook270 
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The active site is well defined: seven residues bind to isocitrate but interestingly three residues 
in particular explain the catalytic mechanism of ICD. Aktas and Cook proposed a catalytic mechanism 
based on a general acid-base chemistry involving the lysine-tyrosine pair271 (figure 22). The similarity 
of the active site with other bacterial species such as E. coli256 and M. tuberculosis184 supports 
evidences for this mechanism. This is a two-step mechanism with deprotonation followed by 
decarboxylation. Firstly, Lys232* would initiate dehydrogenation by uncoupling the proton from the 
hydroxyl on C(2) of isocitrate. This is permitted after Asp309 (metal binding residue) aids the lysine 
to act as a base by deprotonating it. NADP+ is then reprotonated and eventually forms NADPH. On 
the other hand, oxalosuccinate, an enol intermediate, is the intermediate reaction product. From 
there, electron rearrangement occurs leading to decarboxylation at C(3) of isocitrate. In the 
meantime, Tyr162 approaches C(3) for protonation concomitant with Lys232* second deprotonation 
at C(2) hydroxyl to yield the α-ketoglutarate product. Further down the line, the triad Asp309-
Lys232*-Tyr162 might work the same in the second isocitrate dehydrogenase IDH. The remarkable 
similarity between the two active sites helps to anticipate a comparable mechanism.  
The Km of ICD for both isocitrate and NADP+ is comparable to other bacterial species. The 
affinity of ICDPa for isocitrate and NADP+ is half of the affinity observed for Mycobacterium ICD. 
Furthermore, the affinity for NADP+ is 2-fold greater than ICDMt or ICDEc. The overall conclusion is 
that ICDPa is similar to that from E. coli or M. tuberculosis regarding substrate and co-factor affinity. 
Additionally, the results presented in this work suggest that the product of the reaction, α-
ketoglutarate, has a negative feedback on the enzyme. However, the effect on ICDPa does not seem to 
be a strong inhibition. The competitive inhibition profile indicates that α-ketoglutarate binds to the 
active site, probably due to its similarity with the substrate. This is a typical non-allosteric or non-
regulatory enzyme. The weak inhibitory activity (23%) from α-ketoglutarate does not support carbon 
re-routing through the glyoxylate shunt instead of the TCA cycle. The competition of ICD with IDH 
and ICL for isocitrate supposes another regulatory mechanism capable of adjusting ICD activity 
based on metabolic cues. Furthermore, the presence of AceK in P. aeruginosa and Ser115 in ICD 
suggests that there is indeed such a mechanism. On the other hand, oxalomalate demonstrated a very 
significant inhibition of the enzyme. This has been extensively studied in the past, and it is now 
explicit that oxalomalate interacts with the isocitrate-binding site.  
Table 17: Kinetic parameters of ICD 
 Km (µM) Vmax (ΔmM/s) kcat (s-1) kcat/Km (s-1/µM) Ki (µM) Effect 
isocitrate 25.58 0.0013 608.83 23.80 n/a n/a 
     α-ketoglutarate 63.99 0.0016 745.81 11.66 665 competitive 
NADP+ 32.26 0.0015 684.93 21.23 n/a n/a 
The large loss of activity of ICD observed after incubation with AceK however, means that 
the phosphorylation-mediated inhibition is the main switch to decrease carbon flux through the TCA 
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cycle. Work performed by a Part II student in the laboratory demonstrated the inhibition of ICD in 
presence of AceK. AceK-mediated phosphorylation of ICD is presumed to be the regulatory 
mechanism by which P. aeruginosa is capable of inactivating ICD to partially divert carbon flux 
through ICL and malate synthase. However, ICD is not totally inactivated by AceK; this means that 
flux through the TCA cycle is biologically relevant when the cells grow on limited carbon source and 
oxidative stress conditions (accumulation of ROS upon cell growth). Keeping a small percentage of 
the flux through the Kreb’s cycle allows the bacteria to keep the NADPH-generating steps active and 
sustain an essential reducing agent as it plays an important role in various biological processes and 
is the driving force behind numerous biosynthetic reactions272. In order to be active, AceK requires 
ATP and it has been demonstrated in this study that ATP alone has a significant inhibition on 
isocitrate dehydrogenase. It is suggested that, after incubation, ATP interacts with the enzyme-
substrate complex in a non-competitive way by altering the Vmax. This appears to be a new aspect 
about isocitrate dehydrogenase that has not been shown before. The literature previously described 
a non-competitive inhibition in different species. The uncommon behaviour of ICDPa towards ATP is 
of interest regarding the regulation by AceK and the potential effect on the whole isocitrate 
branchpoint. Additionally, considering the concentrations of ATP in the cytoplasm of the cell, this 
inhibition could play a role in vivo but we do not know about it. This is a question to address in 
further research. 
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4. Isocitrate dehydrogenase (IDH) 
4.1. Introduction 
In bacteria, there are two isocitrate dehydrogenases. The most commonly found is the dimeric 
ICD discussed in the previous chapter. Some bacteria encode a second isocitrate dehydrogenase 
isozyme, IDH. In microorganisms in which IDH has been identified, it is described as a monomer (i.e. 
Azotobacter vinelandii, Corynebacterium glutamicum, Mycobacterium tuberculosis). IDH catalyses the 
same reaction as ICD, using the same substrate and co-factor. Interestingly, Pseudomonas aeruginosa 
is one of the few species that has the two isocitrate dehydrogenases. In this chapter, I will explore 
the structure and kinetics of the P. aeruginosa IDH. 
I will start with the bioinformatic analysis of idh gene and its encoded product, IDH. IDH 
was successfully overexpressed and purified, gel filtration analysis and AUC with sedimentation 
velocity indicate its oligomeric status. The effect of carbon substrates on the idh gene expression 
profile was investigated. I will then review the enzymology of IDH. The kinetics parameters (Km, 
Vmax, kcat) and regulation of IDH have been characterised, it is worth noting here that AceK is 
ineffective in regulating this enzyme. Finally, I will present the first P. aeruginosa crystal structure 
of IDH. The investigation includes a comparison with multiple structures from other species, a 
detailed analysis of the clasp domain and the active site, and an investigation to understand why 
AceK is ineffective. 
4.2. Bioinformatic analysis 
The idh gene is located beside the icd gene and is positioned at 2.967 Mbp in the PAO1 
genome. Both genes share an intergenic region of 539 bp and are divergently transcribed. idh is 
composed of 2,226 bp and encodes a 741-residue long protein (figure 23A). Downstream of idh is 
PA2625, encoding a conserved hypothetical protein. The next gene (trmU) encodes a tRNA 
methyltransferase. trmU is predicted to be included in an operon with the other PA2625, PA2627 
and PA2628 upstream and downstream of it, which likely play a role in transcription, RNA processing 
and degradation273. These metabolic genes (icd and idh) are not operonic but scattered within the 
genome, flanked by a group of genetic information processing related genes and nucleotide 
metabolism.  
Other species of Pseudomonas also encode an idh gene in their genome. P. fluorescens, P. 
putida, P. stutzeri and P. syringae show a similar size of idh and cytoplasmic location of IDH (the 
corresponding genes are coloured in red). As shown in figure 23B shows that P. aeruginosa, P. 
fluorescens, P. putida and P. stutzeri possess both isocitrate dehydrogenases in the same organization 
(opposite strands of DNA and direction of transcription). However, P. syringae only has one isocitrate 
dehydrogenase. The downstream genomic context of idh is similar in P. aeruginosa and P. syringae 
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as both species exhibit an operon of tRNA processing with trmU. The other three species (P. 
fluorescens, P. putida and P. stutzeri) show another operonic organisation with a tRNA processing 
centralised around mnmA, a tRNA-specific 2-thiouridylase. 
Figure 23: Genetic context of the idh gene in P. aeruginosa PAO1 and other Pseudomonas 
species (A) The highlighted idh annotated gene is 2,226 bp encoding a 742 amino acid-long 
protein (stop codon included). icd is located immediately adjacent to the idh gene sharing a 
single intergenic region of 539 bp (B) idh orthologues in other Pseudomonas species display 
a similar genomic organisation with icd nearby and cold shock protein or ATP-binding 
protease component. The coloured legend indicates the subcellular localization of the 
encoded gene. 
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The continuation of the bioinformatic study includes the study of the IDH protein sequence 
by BLAST analysis. This analysis excluded the Pseudomonas genus to focus only on all other bacteria 
that have been identified with an IDH protein. Here again, the results show a remarkably high 
sequence conservation ranging from 99 to 70%. The average length of the enzyme in all bacteria 
extracted from the BLAST analysis is similar; there is at most a shift of two or three residues with 
very little divergence in IDH. More interestingly, IDH has been characterized in two psychrophilic 
bacteria: Colwellia psychrerythraea and C. maris171 (Colwellia maris was previously described as 
Vibrio sp. strain ABE-1274). The enzyme in these microorganisms is well adapted to low temperatures. 
Additionally, these bacterial species exhibit both isocitrate dehydrogenases; in this case, it could be 
reasonable to assume that IDH is selected to continue the TCA cycle reaction at low temperature 
since ICD is not functional below 25°C. Further investigation showed that a genetic element is 
responsible for low-temperature-inducible expression of IDH in marine bacteria. A 35 bp 
transcriptional silencer was identified in the idh promoter region as 5’-
GTTATACCATACGGAGCTTAATTCTTTACGTAACA-3’275,276. A Clustal Omega alignment of 
the silencer region with the idh promoter region in P. aeruginosa, as seen in figure 24 shows that 
the silencer is reasonably conserved. However, it 
is split into two and thus does not appear to be 
functional as IDH activity is significantly 
reduced at low temperatures in P. aeruginosa. 
Indeed, previous work done by a PartII student 
in the laboratory indicated that IDH activity is 
2-fold decreased at temperatures below 27°C.  
The amino acid sequence alignment 
generated with Clustal Omega in figure 25 
shows that the IDH sequence is well conserved 
among diverse bacteria. All bacteria aligned 
exhibit consistent length of the protein around 
740 residues. Furthermore, the residues involved 
in the binding of the substrate (highlighted in green) and magnesium cation (highlighted in blue) are 
the same and consistently belong to well-conserved regions of the amino acid sequence. Moreover, it 
is interesting to note that all the binding residues are an exact copy of the ones found in ICD. The 
evolution of IDH from ICD supposes the conservation of the active site features in IDH. 
Figure 24: Alignment of idh promoter and transcriptional 
silencer. The alignment proves that it is conserved in P. 
aeruginosa in terms of sequence but it cannot be 
functional due to its separation. 
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Figure 25: ClustalOmega alignment of IDH amino acid sequence (highlighted residues in green: substrate binding, 
or blue: magnesium binding). IDH protein sequence is highly conserved between these four examples of divergent 
species. All substrate binding residues are similar to the ones found in ICD. 
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4.3. Purification of IDH 
4.3.1. Preliminary results 
The investigation of IDH in P. aeruginosa (IDHPa) started with the 
purification of the enzyme. Similar to ICD, the idh gene was first PCR 
amplified from PAO1 genome then cloned into either pQE80 (yielding His6-
tagged protein) or His-pMAL-c2x (yielding native protein after Factor Xa 
cleavage). The vector was then introduced into E. coli DH5α for 
overexpression. The extraction and purification of the protein followed the 
same steps as already discussed in the previous chapter (section 3.3.1). I then 
worked with two types of protein, on the one hand is a His6-tagged IDH and 
on the other hand cleaved, native IDH. 
The SDS-PAGE analysis after the purification using the idh His-
pMAL-c2x system is shown in the figure 26. The sample was initially 
denatured by boiling in 4X SDS-PAGE loading buffer supplemented with 200 
mM of DTT for 5 min. From there, the sample was loaded into the gel before 
migration (see chapter 2 for migrating conditions). As shown in the figure 
26, there is a clear single band for the purified IDH sample with a molecular 
mass slightly greater than the 75,000 Da ladder band. Alternatively, the 
Expasy toolbox predicted, from the amino acid sequence, a molecular mass 
of 81,634 Da. Given the margin between the 75,000 Da and 100,000 Da ladder 
bands, I concluded that the molecular mass of the concentrated solution of 
protein was consistent with its prediction. This means that the overexpression 
and purification processes are successful in producing the correct IDH enzyme 
from P. aeruginosa. Furthermore, the initial denaturation of the sample 
before SDS-PAGE analysis results in a single band corresponding to a 
monomeric-state of IDH. The oligomeric status of the enzyme is investigated 
in the next sections 4.3.2 and 4.3.3. Regarding the His6-tagged version of 
IDHPa, similar to ICD again, the SDS-PAGE analysis showed the presence of 
additional bands, probably degradation products (see appendix 2). The 
treatment of the IDH solution extracted from the idh His-pMAL-c2x 
expressing system with Factor Xa systematically delivered a product with a 
single band but a much lower yield. The simple purification conducted on the His6-tagged IDH 
however, yielded a more concentrated solution. 
4.3.2. Gel filtration analysis 
Besides SDS-PAGE analysis, another complementary technique to estimate the oligomeric 
status of IDHPa is gel filtration. A sample of 40 µg of concentrated IDHPa solution was injected into a 
Figure 26: Coomassie-
stained SDS-PAGE 
analysis after purification 
of IDHPa. This gel shows 
the un-tagged protein 
after purification from 
the idh His-pMAL-c2x 
expressing system and 
additional cleavage by 
Factor Xa. After 
denaturation of the 
DTT-treated sample, a 
single band and is visible 
with a molecular mass 
slightly higher than the 
75 kDa band. This figure 
is a “cut and paste” from 
the same gel, the IDH 
lane was pasted next to 
the ladder 
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TSK-Gel G3000 SWXL column previously 
equilibrated following the guidelines described in 
chapter 2. The molecular mass was estimated to be 
approximately 235,500 Da (see the molar mass 
moments values in figure 27). Furthermore, the 
narrow peak demonstrates that the sample, which 
was from the idh pQE80 expression construct, has 
few contaminants (see appendix 6 for the full 
results). These results show that IDHPa is assembled 
in a higher order oligomeric status. The molecular 
mass indicated from the gel filtration data would 
suggest that IDH is a trimer or an elongated dimer 
as gel filtration does not permit the detection of the 
shape of the protein. However, these results allow 
us to assert with confidence that in P. aeruginosa, 
IDH is not a monomer. IDH in other bacteria has 
usually been described as monomeric182,277– 279. Two other species have been defined with either a 
dimeric or tetrameric IDH in M. tuberculosis167 and T. maritima280 respectively. P. aeruginosa seems 
to join a small group of bacteria that has two isocitrate dehydrogenases, in which IDH is not 
monomeric. 
4.3.3. AUC data 
Analytical ultracentrifugation with a set of sedimentation velocities (SV) was used to further 
examine the oligomeric status of IDHPa. The results from gel filtration argued in favor of a non-
monomeric IDH, but further investigation was required to better understand IDH oligomeric status. 
To do so, two hundred boundary profiles were recorded at three different concentrations (0.1, 0.5 and 
1 mg/mL). The data were analysed as specified in chapters 2 and 3. The absorbance results obtained 
with the second concentration were computed, only thirty boundaries were used to fit the Stoke 
equation as seen in figure 28. 
The sedimentation coefficient graph in figure 28 shows a clear peak corresponding to a 
molecular mass of 273 kDa with a sedimentation coefficient of 11 Sv. This suggests that IDH is at 
least a trimer. However, the frictional ratio of 1.148 is particularly low. Indeed, a frictional ratio lower 
than 1.2 for a complex quaternary structure, for a metabolic enzyme is unusual. Further discussion 
argued that the value is underestimated. This could be the product of interference from glycerol, 
potentially present in the sample solution despite a thorough dialysis prior the experiment. So, how 
is the frictional ratio underestimated and what are the consequences? Firstly, AUC is defined as 
matrix-free, macromolecular separation method in which molecules are separated based on their size 
and shape using a strong centrifugal field. That means that larger molecules will sediment faster than 
Figure 27: Gel filtration of IDH. The graph shows a 
single peak at a volume of 7.2 mL which corresponds 
to a molar mass of around 235 kDa. All three 
statistical average molecular masses (Mn, Mw and Mz) 
of all the polymer chains in the sample are nearly the 
same value. 
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smaller molecules. Furthermore, hydrodynamic shapes, such as spheres or ellipses, will sediment faster 
than shapes with more friction, such as random coils or rods. In sedimentation velocity experiments,  
the sample is centrifuged at high speed to analyse the boundaries formed during sedimentation. In 
that case the sedimentation coefficient is defined Svedberg equation:		푠 = 푀(1−휈휌̅표)푁퐴푓  푠 is the sedimentation coefficient, in Svedberg (1 Svedberg = 10-13 s), 푀 is the molar mass, 휈 ̅ is the partial specific volume, 휌표 is the solvent density, (1−휈휌̅표) is the buoyancy term, 푁퐴 is 
Avogadro’s constant and 푓 is the friction coefficient. The Svedberg equation complements the Stokes-
Einstein equation (this equation details the diffusion coefficient of a particle undergoing motion in a 
fluid at uniform temperature) as such: 푠 = 푀(1−휈휌̅표)퐷푅푇  퐷 is the translational diffusion coefficient, 푅  is the gas constant and 푇  is the absolute 
temperature. So, this is the basis, it is evident that a higher molecular mass will result in a higher 
sedimentation coefficient meaning that the particle migrates faster through the solution column. 
Figure 28: SV-AUC data of IDH protein. The figure shows 30 absorbance scans recorded at 280 nm for a protein 
sample of 0.5 mg/mL. The rmsd of the scans is of 0.0082, within the noise rmsd. The most prominent, almost, 
single peak with a molecular mass of 273 kDa suggests that IDH protein is a trimer or potentially a tetramer. The 
frictional ratio in this experiment may have been underestimated due to the presence of glycerol. 
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Sedimentation coefficients of macromolecules are usually obtained in a buffered solution to aid their 
solubility. However, buffer salts affect the solvent viscosity and density, which therefore affect the 
rate at which the boundary sediments. That means that sedimentation coefficients are corrected for 
solvent conditions. The sedimentation velocity analyzed by SEDFIT relies on the algorithm called 
c(s)- continuous distribution of sedimentation coefficients. The diffusion is eventually corrected by 
finding the frictional ratio: 푓 푓0⁄ = 푀(1−휈휌̅표)푁퐴6휋휂0 (4휋푁퐴3휈푀̅ )13 1푠 
where 푓 푓0⁄  is the frictional ratio and 휂0 is solvent dynamic viscosity. The frictional ratio is 
the ratio of the drag of the macromolecule and the drag of a perfect sphere of equal molar mass and 
anhydrous volume. The relation between the frictional ratio and solvent dynamic viscosity supposes 
that in presence of glycerol, the viscosity increases. As a consequence, the frictional ratio decreases 
leading to an underestimated to a value of 1.148. However, despite these unsettling results, IDH 
certainly has a higher order quaternary structure more likely to be a tetramer or a dimer-tetramer 
equilibrium in solution. 
4.4. Gene expression of idh 
Similar to the work performed on ICD, the gene expression profile of idh was investigated 
after the cloning of the gene in pLP170 (a promoter-less lacZ fusion vector) and its introduction into 
PAO1. The cells were grown in minimal medium supplemented with either acetate or glucose. As 
detailed in section 3.4, the two carbon sources used should promote the partitioning of the carbon 
flux between either the glyoxylate shunt (acetate) or the TCA cycle (glucose). The study of the cell 
growth shows the effect of carbon source on PAO1 containing the Pidh::lacZ fusion compared with 
the control strain containing the promoter-less vector. 
As shown in figure 29 (green line), the growth rate of the cells in minimal media 
supplemented with either acetate or glucose, containing the Pidh::lacZ fusion is not affected when 
compared with the control (black line). The growth rate of the transformed PAO1 with the Pidh::lacZ 
fusion is even slightly better in single carbon source in comparison with the control line. I have no 
explanation for this since the two strains differ only in the presence of Pidh in the PAO1 containing 
Pidh::lacZ construct. Pidh-PAO1 and WT-PAO1 contain the metabolic machinery that is the TCA 
cycle and glyoxylate shunt, they are capable to utilize any carbon source available in the environment. 
As in the previous chapter, the values from the β-galactosidase assay are plotted as a bar 
chart in both panels of the figure. These values reflect the expression of Pidh::lacZ when the cells 
were grown in minimal medium supplemented with acetate (figure 29A) or glucose (figure 29B). 
The data show that the expression resulting from Pidh::lacZ construct (green) transformed into PAO1 
is systematically slightly lower than for the Picd::lacZ construct (blue). In the case of cell growth in 
acetate, the maximum is attained at 7-8h of experiment with a peak of 1,300 nmol.min-1.A600-1. After 
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this stage, there is a decrease of the 
signal detected until 10h of experiment. 
Overall, the profile is similar to what I 
have discussed with the Picd::lacZ 
construct, the signal obtained with the 
Pidh::lacZ remains lower. 
When the cells are grown in 
minimal medium supplemented with 
glucose, there is a sharp increase of the 
production of 4-methylumbelliferone 
from 5h of growth. The maximum is 
attained after 7h of growth when the 
signal peaks at 890 nmol.min-1.A600-1 
corresponding to the end of the 
exponential phase and before entering 
the stationary phase. The increase and 
decrease of the Pidh::lacZ construct 
expression is similar to the Picd::lacZ 
construct expression. Even when the 
cells are grown in acetate, icd and idh 
promoters initiate transcription, the 
TCA cycle is not completely 
suppressed. The subsequent synthesis 
of ICD and IDH supposes that there is 
permanent carbon flux through the 
TCA cycle. 
Suzuki et al. did a similar experiment to test the expression of icd and idh genes from Colwellia 
maris cloned into pIS102 or pIS202 respectively and introduced into E. coli DEK2004 (a mutant 
strain defective in icd). C. maris is another one of the few species that has both ICD and IDH. So, 
the expression profile of both encoding genes was investigated via Northern blot analysis, the chosen 
E. coli DEK2004 was grown in minimal medium supplemented with either acetate or glucose. The 
results obtained show similar expression of icd and idh. The monomeric isocitrate dehydrogenase 
(IDH equivalent) is consistently expressed at a lower level compared with the dimeric one (ICD 
equivalent) on rich (glucose) or limited (acetate) carbon sources after 2h of growth173. These results 
highlight the complexity of the competition at the TGB branchpoint. These observations in C. maris 
and P. aeruginosa indicate that the two isocitrate dehydrogenases are actively expressed even when 
the bacteria are grown on a short-chain carbon source. This suggests that in an effort to circumvent 
oxidative stress, prokaryotic cells upregulate NADP+-dependent ICD and IDH to produce NADPH, 
Figure 29: Gene expression results of Pidh::lacZ fusion (A) MOPS + 
acetate (B) MOPS + glucose. Similar to the plot shown in the 
previous chapter, black is the wild type PAO1 (empty vector), blue 
is the Picd::lacZ construct and green is the Pidh::lacZ construct both 
cloned into pLP170 and transformed into PAO1. The results from 
Pidh::lacZ construct show a similar trend than the Picd::lacZ 
construct over the time course of the experiment. 
ACETATE 
GLUCOSE 
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a reducing equivalent required to regenerate antioxidants, and α-ketoglutarate, a powerful 
antioxidant.  
4.5. Kinetic analyses 
4.5.1. Michaelis-Menten data 
Since the specificity for the 
substrate and co-enzyme is the same as 
for ICD, untagged IDH was studied 
using the same method by monitoring 
the formation rate of NADPH at 340 
nm. The kinetic studies at variable 
concentrations of NADP+ or isocitrate 
revealed that Kisocitrate = 18 µM and 
KNADP+ = 34 µM (figure 30A-B). The 
Vmax for isocitrate is 0.027 mM.min-1 
and 0.031 mM.min-1 for NADP+. 
Additionally, the oligomeric status of 
the protein described previously 
suggests that with multiple subunits 
and hence active sites, the enzyme is 
probably allosterically regulated. The 
first order rate kcat. for isocitrate, 
calculated as monomeric IDH, was 
11,020 min-1 (183 s-1). This is consistent 
with a metabolic enzyme performing at 
high rate226. 
The monomeric IDH has been 
studied in multiple species, although 
kinetic data have been reported for 
only a few species. In M. tuberculosis, IDH is known to have a Kisocitrate = 20 µM and KNADP+ = 19.6 
µM167. In C. glutamicum and Rhodomicrobium vannielii, IDH has a greater affinity with Kisocitrate = 5 
µM and KNADP+ = 4 µM182, and Kisocitrate = 3.3 µM and KNADP+ = 2.5 µM169 respectively for each 
microorganism. IDH in C. glutamicum is the only enzyme of the TCA cycle yielding α-ketoglutarate 
from isocitrate. The organisation of the TGB in Corynebacterium is similar to that in E. coli, IDH 
has a greater affinity (Km = 5 µM) for isocitrate than ICL (Km = 280 µM). The competition between 
ICD and ICL is limited, carbon flux is primarily directed through the TCA cycle. However, P. 
aeruginosa has ICD and IDH, the Km of the enzymes is similar with 25 µM and 18 µM respectively, 
Figure 30: Kinetic analysis of IDH activity (A) Michaelis-Menten and 
Lineweaver-Burk plots with respect to isocitrate (B) Michaelis-
Menten and Lineweaver-Burk plots with respect to NADP+ 
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and they compete with ICL for isocitrate. This means that the TGB in P. aeruginosa is more complex, 
the mechanisms that regulate the partitioning of metabolite fluxes at the bifurcation of the oxidative 
TCA cycle and the glyoxylate shunt have to balance anaplerotic fluxes (glyoxylate shunt) and fluxes 
generating energy and biosynthetic precursors (TCA cycle). 
4.5.2. Non-effect of AceK on IDH 
ICD is clearly regulated through phosphorylation by 
isocitrate dehydrogenase kinase/phosphatase. This has been 
thoroughly studied in E. coli158,281,282 and demonstrated in P. 
aeruginosa in the previous chapter. IDH is functionally similar 
to ICD, and the serine phosphorylated in ICD is also present 
in IDH. An important question to address is therefore whether 
IDH is also phosphorylated by AceK. In order to investigate 
the effect of AceK on IDH, I incubated the two enzymes in the 
conditions described in chapter 2. 
Figure 31 shows that after incubation, ICD is clearly 
inhibited by AceK. In comparison, IDH is not significantly 
inhibited by AceK even after 30 min. There was no statistical 
difference after analysing the data using a one-way ANOVA 
test based on a triplicate and p < 0.05. This means that the 
regulation of IDH is not phosphorylation-mediated. The 
regulation (if any) of IDH must be via another mechanism.  
4.5.3. Screening of potential regulators 
After confirmation of the lack of phosphorylation-driven regulation, I investigated the 
potential regulatory effect of organic acids and intermediates from the TCA cycle. This pursues the 
hypothesis of allosteric regulation of IDH (figure 32). I found that several compounds either activate 
or inhibit the activity of IDH. Like ICD, IDH is strongly inhibited by an equimolar mixture of 
glyoxylate and oxaloacetate. The mechanism of inhibition is through condensation of the two 
molecules to form oxalomalate. This has been reported in multiple organisms (E. coli231, 
C.glutamicum166, R. vannielii169, B. flavum283) in which the mixture affects the dimeric as well as the 
monomeric isocitrate dehydrogenase. It is speculated that oxalomalate could form under physiological 
conditions and that this could play an important role in regulation of the tricarboxylic acid cycle284.  
IDH was also strongly activated by several compounds. Oxaloacetate, pyruvate and 
glyoxylate activate IDH by 188%, 194% and 243% respectively. The activation by pyruvate has been 
reported in P. fluorescens IDH; however in this microorganism IDH activity is increased by 35% 
only285 even though P. aeruginosa and P. fluorescens IDH share 66% identity. In M. smegmatis, 
glyoxylate was recently reported to stimulate IDH activity in a dose-dependent manner, enabling 
Figure 31: AceK activity on IDH 
compared with ICD. Compared with 
ICD, it is evident that IDH activity is not 
inhibited after incubation with AceK, 
there is no phosphorylation. 
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“rheostatic” control of flux through 
the glyoxylate shunt. A mixture of 
malate and oxaloacetate also 
increases IDH activity by 158%. 
However, this could be the effect of 
oxaloacetate alone, as malate did not 
show any effect by itself. Finally, 
there is no product inhibition of IDH 
by α-ketoglutarate. Despite the 
similarities in both active sites, the 
two enzymes respond differently to 
the same compound. 
The effect of oxaloacetate, 
glyoxylate and pyruvate suggests 
that the regulatory mechanism of 
IDH involves a metabolite-mediated enzyme activation to achieve a balanced bifurcation of fluxes 
between the TCA cycle and the glyoxylate shunt. At that stage, in P. aeruginosa, I demonstrated 
that ICD is inhibited by AceK, but IDH is not. The latter is then activated by a subset of metabolites 
that act to maintain flux through the TCA cycle. Oxaloacetate and pyruvate emerge as potent 
activators of IDH, they signal to the cell that there are sufficient gluconeogenic precursors for biomass 
production. Overall, the effect of activators has not been reported for P. aeruginosa IDH before. 
These findings challenge the established regulatory paradigm in E. coli. This constant activation of 
IDH would ensure carbon flux through the TCA cycle to sustain secondary pathways related to 
oxidative stress and generate energy and biosynthetic precursors286,287. 
4.5.4. Activation profile kinetics 
The double-reciprocal plots for oxaloacetate and pyruvate in figure 33 show the activation 
effect of these molecules on IDH. As shown in figure 33B, oxaloacetate and pyruvate are 
uncompetitive activators, as the x-intersect and y-intersect are different from the control which also 
means that the regulator binds only to the complex formed between the enzyme and the substrate. 
So, these data indicate that both molecules bind to the enzyme-substrate complex and promote 
catalysis to produce α-ketoglutarate. Additionally, it is clear that in presence of the activators, the 
classical Michaelis-Menten curve has a sigmoidal profile (figure 33A). This demonstrates positive 
cooperative binding; the binding of the substrate or ligand at one binding site affects the affinity of 
other sites for their substrates. In that case, all three compounds had a pronounced effect on Vmax, 
and thus kcat with only a small impact on Km (alternatively Kh). The kinetic parameters in the 
presence of 1 mM oxaloacetate are Kh = 39 µM and Vmax = 0.178 mM.min-1, and in presence of 
pyruvate Kh = 42 µM and Vmax = 0.207 mM.min-1. There is a 7-fold increase of Vmax compared with 
Figure 32: Screening of potential regulators on IDH. Oxaloacetate, 
pyruvate and glyoxylate strongly activate IDH activity. Malate and 
oxaloacetate mixture activates IDH due to the oxaloacetate. IDH is 
also inhibited by glyoxylate and oxaloacetate forming oxalomalate. 
Values marked with * are significantly different (p<0.05 and n=3) 
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control. This means that kcat is similarly increased by 
a 6-fold factor (kcat = 1210 s-1 and 1408 s-1 in presence 
of oxaloacetate and pyruvate respectively whereas kcat 
=183 s-1 for isocitrate).  
Glyoxylate also displays a very strong 
sigmoidal response compared to control (figure 33A). 
The corresponding Lineweaver-Burk plot (figure 
33B) suggests that glyoxylate acts as a non-
competitive activator. The molecule can either bind to 
the free enzyme or the enzyme-substrate complex. The 
Vmax is significantly increased by a factor of 5 to 0.136 
mM.min-1 in presence of glyoxylate compared with 
0.027 mM.min-1 for isocitrate alone. Equally, kcat 
increases to 925 s-1 for glyoxylate. 
However, the double-reciprocal plot for the co-
factor shows a different profile (figure 33C). The y-
intersect shows that oxaloacetate and pyruvate were 
non-competitive activators with respect to NADP+. 
This indicates that oxaloacetate and pyruvate bind to 
the enzyme-substrate complex. The Km is not affected 
upon binding of the activator. Only the Vmax is 
changed by the binding oxaloacetate or pyruvate, and 
both show the exact same profile as both lines overlap. 
The Vmax is similarly increased in presence of 
oxaloacetate or pyruvate with values of 0.179 mM.min-
1 and 0.203 mM.min-1 respectively, compared with 
0.031 mM.min-1 for the control. Consequently, kcat is 
increased. There is a 6-fold increase of kcat upon 
addition of oxaloacetate or pyruvate (kcat = 1217 s-1 or 
1280 s-1 in presence of oxaloacetate and pyruvate 
respectively whereas kcat = 210 s-1 for NADP+). 
With respect to NADP+, glyoxylate is an 
uncompetitive activator as the x-intersect and y-
intersect differ from the control. This means that the 
kinetics in presence of glyoxylate exhibits a different 
trend. The Km and Vmax in presence of glyoxylate are 
significantly increased upon binding of the activator, 
Km = 160 µM and Vmax = 0.228 mM.min-1. This 
Figure 33: Activators of IDH (A) Isocitrate 
dependency of IDH kinetics changes from 
hyperbolic to sigmoidal in presence of glyoxylate, 
oxaloacetate and pyruvate B) Effect of the 
regulators with respect to isocitrate shows non-
competitive or uncompetitive activation (C) The 
same trend appears with respect to NADP+. 
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difference in the Vmax influences a 7-fold increase of the kcat up to 1544 s-1 in presence of glyoxylate 
whereas kcat = 210 s-1 for isocitrate alone. 
These results suggest that there is cooperativity in substrate binding, which is consistent with 
IDH adopting a higher-order structure in solution. Isocitrate and NADP+ bind in the active pocket, 
so glyoxylate or oxaloacetate or pyruvate can bind to another site and increase the activity of the 
enzyme. The in vitro activity of IDH is under the control of metabolic intermediates that activate 
the enzyme, potentially to push isocitrate through the TCA cycle to generate sufficient energy and 
biosynthetic precursors that remain essential during catabolism of C2-units nutrients source.  
4.5.5. Thermal shift assay 
I conducted a thermal shift assay 
(TSA) to study further the enzyme 
mechanism. Isocitrate and NADP+ bind to 
IDH active site, while the regulators bind to 
subsites. The assay helps estimating the 
correlation of protein stabilization and 
affinity of binding. The thermal shift assay 
allows an efficient and reliable study of such 
interactions between a protein and regulators. 
The principle is based on the binding of low 
molecular weight ligands that can increase 
the thermal stability of the protein. The 
method involves a small amount of protein 
mixed with some SYPRO Orange dye. The 
dye binds to hydrophobic patches/denatured 
protein and fluoresces. As the temperature 
increases and the protein unfolds, it is easy to 
monitor the increase in fluorescence and 
determine a melting temperature. The 
temperature and fluorescence monitoring are 
done using a qPCR machine. It is then 
straight forward to derive the difference in 
the melting temperatures, ∆Tm, between the control and the protein in presence of regulators288,289. 
The control (protein alone) serves as a baseline to determine if there is indeed a shift in the 
denaturation temperature of the complex by adding a ligand. From the figure 34, the only notable 
response is seen when the substrate is present with a positive shift of 6°C. So, the binding of the 
substrate strongly stabilizes the enzyme. However, a difficulty of fluorescence techniques in analysis 
Figure 34: Thermal shift assay of IDH in presence of all 
regulators. Only in presence of isocitrate, there is a 
significant difference in the denaturation temperature of 
IDH. The presence of other molecules did not affect IDH 
stability. 
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of protein– ligand interactions is to define an adequate threshold. It is common in compounds library 
screening to use a cut-off of 1-2°C212. 
As seen in the figure, the rest of the compounds tested did not affect protein stability: neither 
pyruvate nor oxaloacetate or even the mixture of glyoxylate and oxaloacetate. Only the substrate is 
significantly different compared to control. Isocitrate binds to the active site, but the activators are 
of a non-competitive or uncompetitive type, thus they bind to another site on the enzyme. The design 
of the experiment needs to be implemented, I tested each regulator alone, without the substrate in 
the mixture. Since oxaloacetate and pyruvate are non-competitive activators, they will not bind to 
IDH in the absence of isocitrate. The results showed that there is indeed no regulator binding without 
isocitrate present, meaning that the ∆Tm is barely affected. Further study of IDH stability and IDH 
mechanism supposes a TSA with the substrate and regulator in the reaction mixture. 
4.6. Crystal structure of IDH 
4.6.1. Structure description 
I solved the structure of IDH by molecular replacement using the structure of Mycobacterium 
smegmatis IDH (PDB 4ZDA) as well as an I-TASSER-generated model as templates. Pseudomonas 
and Mycobacterium IDH share 68% identity, making the M. smegmatis structure a suitable template. 
However, due to difficulties in treating the diffraction data (unit cell content), the I-TASSER model 
was also used to calculate the phasing. The structure was refined to 2.7 Å, with Rcryst 20.80% and 
Rfree 26.67%. The analysed crystal contains two non-symmetrical molecules of IDH (figure 35A); the 
chain B (light green) is tilted and showed regions of high flexibility due to static disorder. Comparison 
of the structure of the chains A and B reveal large conformational differences. As shown in the figure 
35B, the overall core of the enzyme is consistent between the two chains, but the smaller domain in 
chain B is shifted. This is especially noticeable on the helices and loops represented at the front, in 
particular α26-28. During model building of the two chains of figure 35A, this was particularly 
obvious as extended sections of these regions had to be redrawn and relocated within the electron 
density. Despite having two closely juxtaposed molecules present in the asymmetric unit, a PISA 
analysis indicated that there is no specific interaction that could result in the formation of a 
quaternary structure. 
A single molecule of IDH resembles the dimeric ICD (figure 35C). An extensive study of 
Azotobacter vinelandii IDH proved that the substrate binding residues are absolutely identical and 
that they share a common folding topology with ICDEc. Crystal structure analysis of ICDEc has shown 
that two identical subunits are related by a crystallographic 2-fold axis. A similar pseudo-2-fold axis 
exists in the larger domain of IDHAv and IDHPa. Indeed, the larger domain cannot be separated into 
two equivalent regions, because of the insertions of four α-helices (α10-α13 in P. aeruginosa). Crystal 
structure of ICDPa and IDHPa revealed that the tertiary structures is as conserved. Such a fusional 
structure suggests that IDH is the result of protein monomerization by a domain duplication from 
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ICD, IDH originated from the partial duplication of the shared ancestral gene, rather than the 
convergent evolution from different genes185.  
I crystallized P. aeruginosa IDH with NADP+ but only chain A showed electron density 
suitable to fit a molecule of the co-factor (figure 35D, ball and stick representation). Additionally, 
despite the fact that no other ligand was added in the crystallisation conditions, I was able to detect 
electron density for a molecule of α-ketoglutarate deeper in the active site pocket. The arrangement 
of the two ligands fits nicely with the structure solved for M. tuberculosis IDH (PDB 5KVU, data 
not published). In the M. tuberculosis structure, a small C4 molecule (malate or succinate) was 
modelled deep inside the pocket behind a molecule of NADP+. This supports the kinetic data for an 
ordered sequential mechanism in which isocitrate binds first. This process causes a conformational 
change required for binding the co-factor, NADP+, which caps the active site cleft.  
Finally, each chain can be divided into two domains displayed in orange and purple in the 
figure 35D. The smaller domain (orange) contains the N- and C-terminus; it is composed of fourteen α-helices (α1-6 and α21-28) along with four β-strands (β1-3 and β24). The larger domain (purple) 
Figure 35: IDH crystal structure (A) The asymmetric unit contains two molecules of IDH. Despite their close 
juxtaposition, these are not forming any quaternary structure (B) Superposition of the two chains demonstrates 
the displacement of a26-28 as pointed by the arrow (C) The superposition of the two dehydrogenases 
demonstrates the probable evolution of IDH from ICD as a monomerization step (D) IDH is organised in two 
domains, a small one in orange and a large one in purple, similar to ICD where the active site cleft fits between the 
two subunits, in IDH the active site fits between the two domains 
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comprises thirteen α-helices (α7-20) and nineteen β-strands (β4-23), including the eight β-strands 
forming the clasp-like domain (refer to appendix 7 for a sequence/secondary structure alignment). 
The NADP+-unbound chain B structure parameters reveal high-temperature factors, especially for 
the small domain, which suggests static disorder in the crystal in lower resolution of the diffraction 
data. This means that the polypeptide chain B was resolved for 737 of its 741 residues, the first four 
residues had no corresponding electron density to be modelled. Overall, this reinforces the importance 
of NADP+ to stabilise IDH during crystallisation and how the conformation of IDH is altered upon 
binding of the co-factor.  
4.6.2. Structural comparison and domain movement 
There are fewer crystal structures of IDH than that of ICD in the protein databank. Further 
study of P. aeruginosa IDH compares the crystal structure with IDH of A. vinelandii, C. glutamicum, 
M. smegmatis and M. tuberculosis. The superposition of them demonstrates that they have a very 
similar conformation. They overlay exactly the same secondary structure features despite a slight 
shift of some secondary structures. As seen in figure 36, the superposition of the ribbon 
representation of all structures demonstrates that despite the obvious differences in the length of the 
sequences, the overall shape of the protein is conserved in these microorganisms.  
The rmsd value after superposing the different structures ranges from 0.89 Å to 3.53 Å. The 
results of the superposition can be classified in three categories from three averages of rmsd of 1 Å, 2 
Å and over 3 Å. The superposition of the structures of P. aeruginosa with the other structures 
available crystallised with NADP+ shows the closest average rmsd (less than 1Å). The rmsd between 
IDHPa and IDHMt (PDB 5KVU, Mycobacterium tuberculosis) is of 0.89 Å while IDHPa and IDHAv1 
(PDB 1J1W, Azotobacter vinelandii) shows 0.97 Å of difference. This is demonstrated in figure 36A 
in which the tight superposition of the three structures is obvious. The outer α-helices overlay nicely, 
with some loops showing a little bit more flexibility. Both structures are in complex with NADP+; 
M. tuberculosis has additional molecules of either malate or succinate thus a lower rmsd. This might 
explain why it closes the active pocket and tightens the monomer in the presence of either one or 
both of the substrates. This is also consistent with the model in P. aeruginosa in which α-ketoglutarate 
is present. With the molecule of NADP+ sitting at the entrance of the active site pocket, it is 
reasonable to think that it closes the pocket more tightly. The second category with an average rmsd 
of 2 Å compiles two different species crystallised with the same ligands, isocitrate and an atom of 
manganese. These entries, IDHAv2 (PDB 1ITW, Azotobacter vinelandii) and IDHMs (PDB 4ZDA, 
Mycobacterium smegmatis) show a rmsd of 1.89 Å and 2.02 Å, respectively, when overlaid onto IDHPa. 
As seen in figure 36B, the difference remains subtle when comparing elements of the secondary 
structures in the core of the enzyme. However, the loops and α-helices on the left and bottom-right 
of the overlay show some more obvious deviation. The main difference is the obvious presence of the 
substrate in the active site pocket. The location of isocitrate is also very different: being more buried 
into the active site, isocitrate might not trigger the same closing effect on the two sub-domains of 
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IDH. Because there is no NADP+ on top of 
isocitrate that would pull together the 
monomer, the active site pocket remains 
semi-open leading to a greater difference 
when overlaying the models. Finally, the 
third category merges the two structures of 
Corynebacterium glutamicum IDH, IDHCg1 
and IDHCg2, respectively, (PDB 3MBC and 
2B0T) against Pseudomonas aeruginosa IDH. 
The rmsd of IDHPa vs. IDHCg1 and IDHCg2 is 
the most different with values of 3.42 Å and 
3.53 Å respectively. This deviation is 
especially noticeable in figure 36C where the 
arrow points out the shift of a major α-helix 
in the small domain of IDH. The 
crystallisation conditions for IDHCg1 and 
IDHCg2 were different. IDHCg1 co-crystallised 
with NADP+ and an atom of magnesium, 
whereas IDHCg2 co-crystallised with only 
magnesium. However, it is clear that the 
higher rmsd is probably due more to an 
intrinsic difference in the overall 
conformation of the protein than to an effect 
of the presence or absence of ligands. The 
molecule of NADP+ alone does not pull 
together the active pocket as seen previously. 
The comparison of bacterial IDH structures 
in the PDB and the new IDHPa proved that 
the crystallisation conditions play a major 
role in the conformation of the enzyme. This 
also suggests that the binding of the 
substrates is accompanied by structural 
rearrangements. 
4.6.3. The “clasp” domain 
The phenomenon of monomerization forming IDH from ICD has been extensively studied in 
Azotobacter vinelandii and there are many aspects to it. Firstly, with respect to the binding of the 
substrate, all the residues are very well conserved (this will be discussed in the next section). An 
Figure 36: Multiple overlays of IDH from different species. 
From A to C, there is an increase in the rmsd resulting from 
an increasing difference in the overall bending of the 
different monomers. (A) Co-crystallised IDH with NADP(H) 
or NADP(H) and malate/succinate (B) Co-crystallisation of 
IDH with isocitrate (C) Furthest relatives of IDHPa is 
Corynebacterium glutamicum 
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interesting feature of the monomerization of IDH from ICD is the evolution of the clasp domain in 
ICD to a Greek key motif in IDH. Initially, the clasp domain is the combination of an α-helix (α5) 
and two β-strands (β8-9) from each chain as seen in figure 37C. From the superposition of IDH and 
ICD, this clasp is replaced by eight β-strands (β6-9 and β16-20) linking the larger domain to the 
smaller domain in a similar way the clasp is linking the two protomers of ICD. Each domain of IDH 
has four β-strands that form a double Greek key motif (figure 37A-B). Such a stereotypic β-
sandwich consists of two pleated β-strands packed against each other; as a result, the cross-section 
has an elliptic shape290. The Greek key motif is an evolutionarily conserved super-secondary protein 
structural fold that offers structural compactness and high intrinsic stability against stress291. 
Structure-based sequence alignment in figures 37D-E shows the residues forming the two 
Greek key motifs. The β6-9 section, Glu186-Ser228 (figure 37D), represents either the purple or 
yellow ribbon in the panels A and B. Of the 42 amino acids that make the motif, the alignment shows 
seven conserved residues. The second β16-19 section, Asp424-Lys462 (figure 37E), is much more 
conserved with thirteen residues included in the four β-strands. 
4.6.4. The active pocket and the binding configuration 
The electron density corresponding to a molecule of NADP+ (present in the crystallisation 
conditions) was detectable. However, only one monomer showed density to fit such a molecule. The 
overall flexibility and disorganisation of chain B paired with poorer electron density could not support 
the modelling of a molecule of NADP+ per chain. Another surprise resulted from correcting the 
arrangement of NADP+, shifting the nicotinamide ring into an anti-configuration instead of a syn-
configuration liberated enough unmodeled matrix to fit a C5 molecule (probably α-ketoglutarate). 
Isocitrate would not fit as it has an extra carboxylic acid function on C(3), while α-ketoglutarate was 
accepted after rounds of refinement. NADP+ was located in the active cleft between the two domains, 
whereas α-ketoglutarate was located deeper in the cleft (closer to the β-sandwich). As shown in the 
Figure 37: Equivalent of the clasp-domain in IDH (A) IDHPa, the same chain goes back and forth from the large to 
the small domain creating two Greek key motifs sitting on top of the structure (B) IDHMs shows another Greek 
key motif (C) ICDPa, each chain supplies one a-helix and two b-strands to form the clasp domain (D) Clustal 
alignment of the first motif Glu186-Ser228 (E) Clustal alignment of the second motif Asp424-Lys462 
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figure 35D, both molecules are located in the active site as a ball and stick representation with the 
electron density grid. The ligands lie perfectly at the junction between the two domains. The molecule 
of NADP+ depicted in a beige grid shows through the electron density with a contouring of 1.7σ, and 
the same contouring was applied to the molecule of α-ketoglutarate in light blue. The electron density 
for NADP+ is very clear whereas the electron density proposed for α-ketoglutarate is more difficult 
to interpret. The decision to add this ligand was based on: 1) the length of the five-carbon long chain 
for the space given in the electron density, 2) the overall orientation in the active site pocket and 3) 
improved refinement statistics. 
 A more detailed exploration of the active site and the neighbourhood of NADP+ and α-
ketoglutarate gives insights into the molecular mechanisms employed by the enzyme. Similar to ICD, 
the residues for the binding of the substrate and co-factor are well characterized in IDH. There are 
seven residues involved in binding the substrate. The figure 38 shows an overlay of the following 
species: A. vinelandii IDHAv (PDB 1ITW or 1J1W), M. smegmatis IDHMs (PDB 4ZDA) and M. 
Figure 38: Active site analysis of IDH (A) Top view of the active site of IDH and localisation of a-ketoglutarate at 
the back of the cleft. The electron density for the ligand is contoured at 1.7σ (B) Superposition of the substrate 
binding residues in presence of a-ketoglutarate, the neighbourhood of the ligand calls for the same residues than 
for isocitrate, however no hydrogen bonds would be detected (C) Top view for the localisation of NADP+ in the 
cleft, similar to ICD, the co-factor sits at the rim of the pocket visible through a beige grid contoured at 1.7σ again 
(D) Analysis of the neighbourhood of the NADP+ ligand demonstrates high similarity in the binding residues with 
minor differences. This view is the product of my own investigation of all superposed structures, very little is 
known about the influence of the binding of the substrate and/or co-factor on the conformation of the active site 
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tuberculosis IDHMt (PDB 5KVU) with the same colour coding. IDHAv1 1ITW co-crystallised with Mn2+ 
and isocitrate, IDHAv2 1J1W co-crystallised with NADP+, IDHMs co-crystallised with Mn2+ and 
isocitrate and IDHMt co-crystallised with succinate or malate and NADP+. Crystal structure analysis 
of the active sites of IDH co-crystallised with isocitrate (IDHAv, IDHMs) or a C4 molecule (α-
ketoglutarate IDHPa or succinate/malate IDHMt) or NADP+ indicates that the residues involved in 
binding are very well conserved. The aspartate residues binding magnesium or manganese (when 
present in the crystallisation conditions) overlay with the same fidelity. 
As seen in figure 38A, α-ketoglutarate is embedded deep into the active site cleft. The active 
site comprises secondary structure elements such as α6, α20, β4 and flexible loops. The residues in 
IDHPa Ser133, Asn136, Arg140, Arg146, Lys255, Tyr420 and Arg547 are the equivalent of the residues 
Ser115, Asn117, Arg121, Arg131, Lys232*, Tyr162 and Arg155 in ICDPa (see figure 39B). Crystal 
structure comparison of IDHPa, IDHAv1, IDHMs and IDHMt in figure 38B shows that the residues 
involved in binding the substrate (alternatively α-ketoglutarate in IDHPa) are similar. The most 
distinct difference is between the serine residues of P. aeruginosa IDH and M. smegmatis IDH. The 
distance between the C⍺ of the residues is 2.28 Å. The rest of the residues barely show any difference 
in their orientation, angle or bond length. Overall, IDHAv1 and IDHMs superpose very tightly; apart 
from the distinct difference of the serine residue, the average discrepancy between residues is 1.3 Å. 
This applies to the following residues: Asn136, Arg140, Arg146, Tyr420 and their equivalent in the 
other structures. The underpinning element is the slightly more open conformation of the active site 
in IDHPa compared with IDHAv or IDHMs. The presence of α-ketoglutarate instead of isocitrate seems 
to have released some of the tension and the enzyme is ready to liberate the product. This could be 
further demonstrated by the different angle of Lys257 in Mycobacterium tuberculosis that is 5.42 Å 
away from Lys255 in Pseudomonas aeruginosa. The fact that IDHMt has been co-crystallised in 
presence of a C4 molecule supposes that the residue is too far away and cannot interact with the 
ligand. This also indicates that IDHPa active site is an intermediate state. Ser133 and Arg140 are 
displaced outward of the active site, as α-ketoglutarate is ready to exit the active site. The 
superposition of these similar models highlights the conformational intermediate states of the active 
site operating upon binding of isocitrate or α-ketoglutarate. 
Further investigation on the co-factor binding indicates that the residues binding NADP+ are 
similarly conserved (see figure 38D). Similar to the substrate binding, the active site pocket 
configuration is maintained across the species studied. The identification of the residues is based on 
the analysis of the neighbourhood of the NADP+ ligand using the dedicated CCP4mg tool with a 
threshold of 4 Å. The results were cross-checked with the few publications addressing NADP+ binding 
study in bacterial species186,277. Of all the structures available in PDB, only two of them had NADP+ 
embedded in their active sites, namely Azotobacter vinelandii (IDHAv2 PDB 1J1W) and 
Mycobacterium tuberculosis (IDHMt PDB 5KVU). Before investigating the binding residues, the ligand 
itself is first analysed. A superposition of the three molecules of NADP+ from the three structures 
show that the rmsd between IDHPa and IDHAv2 is 0.75 Å while it is only 0.29 Å between NADP+ in 
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IDHPa and IDHMt. In general, the known residues involved in binding the co-factor are Asn85, Ser87, 
the triad Gly584-Ser585-Ala586, His589, another triad Arg600-Trp601-Asp602 and finally Arg649. 
The majority of these residues are an almost perfect match in terms of superposition. There is barely 
any significant change in the orientation, and angle of the main or side chains. Similar to ICD, some 
residues are dedicated to binding the ADP moiety while others are binding the nicotinamide ring. It 
seems that the adenine moiety is close to the side chains of His589 and Trp601 and the main chain 
of Asp602, which means that hydrophobic interactions are primarily involved. Arg649 plays a major 
role in binding the phosphomonoester, even though the actual oxygen bound is different depending 
on the structure. On the other hand, the nicotinamide ring interacts with Asp87 and Ser89 even 
though there is no apparent hydrogen bond formation. The proximity analysis with a 4 Å threshold 
highlighted these residues and this is consistent with the study of IDHAv2186.  
4.6.5. Why is AceK inefficient on IDH? 
I have concluded that despite the fact that the serine phosphorylated in ICD is conserved in 
IDH, this alone is not sufficient to allow AceK-dependent inhibition of IDH. A structural study of 
ICDPa and IDHPa based on the knowledge extracted from a crystallised complex of ICD and AceK in 
Escherichia coli (PDB 3LCB) illustrates the protein-protein contact between ICD and AceK and why 
IDH is not phosphorylated by AceK. The remarkable conservation of the active site demonstrates 
that the secondary structure along the substrate binding residues is very well preserved. Figure 39A 
shows that the secondary structure elements making the cleft of ICD and IDH are identical. The 
multiple loops, α-helices and β-strands overlay nicely. Furthermore, all the binding residues are 
remarkably conserved in the active site pocket in a similar conformation, including the 
phosphorylation site (Ser115 in ICD vs. Ser133 in IDH) (figure 39B). The Cα displacement between 
ICD and IDH residues is the result of conformational changes upon binding of α-ketoglutarate in 
IDH. The active site in IDH is in a closed conformation, i.e. Arg140 (IDH) is displaced by 3.6 Å 
compared with Arg121 (ICD) that does not bind to a ligand. 
The recognition of ICD by AceK has been extensively studied190,292. AceK has a Substrate 
Recognition Loop (or SRL) (Glu484-Pro510) which extends deeply into the active site cleft of ICD. 
Further analysis of the contact between the two enzymes from E. coli shows that there are two 
recognizable motifs in ICD: the P-loop (phosphorylation loop, Leu103-Leu114) which carries Ser113 
and the ARS (AceK Recognition Segment, Gly254-Asn268). These two segments are present in P. 
aeruginosa ICD in a similar conformation advocating for the AceK-mediated phosphorylation (figure 
39C). The two loops have the same orientation in E. coli ICD and P. aeruginosa ICD and the 
phosphorylation site, Ser113 in E. coli, Ser115 in P. aeruginosa is conserved. The P-loop seems flexible 
depending on AceK presence. In the case of ICDPa, it remains disengaged and in a more open 
configuration. In ICDEc, the same motif is closer to the SRL; this seems to seal the active site cleft 
before phosphorylation. This flexibility might have a major role in the configuration of the active site 
depending on the presence or absence of substrates and clearly for phosphorylation/dephosphorylation 
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purposes. However, and despite the fact that IDH is structurally similar to ICD overall, inhibition by 
phosphorylation does not happen in IDH. A superimposition study of the two structures (ICDPa and 
IDHPa) shows that the ARS and the P-loop are missing in IDH. The P-loop is replaced by two sections 
that include four α-helices (α2-α3 and α4-α5), while the ARS is also replaced by a thread of five α-
helices (α10-14) (figure 39D). This change in the active site cleft makes it impossible for AceK, and 
in particular the SRL, to make close contact with its substrate. Additionally, there is a strong steric 
effect that prevents AceK from being able to engage into contact. IDH is by nature bulkier than ICD, 
making it impossible for AceK to approach the active site. Further, it has already been demonstrated 
that even a slight alteration of either the ARS or P-loop prevents AceK from recognizing ICD190. 
4.7. Discussion 
IDH remains poorly studied compared with ICD. The E. coli model used in microbiology 
allowed a thorough investigation of dimeric ICD. IDH however, has triggered more attention, in 
particular in Mycobacterium tuberculosis, studying the carbon fluxes between the TCA cycle and 
glyoxylate shunt during infections. Pseudomonas aeruginosa is one of the few micro-organisms that 
possess the two isocitrate dehydrogenases, and I studied both isozymes in this work. The distribution 
Figure 39: Structure of the active sites of ICD and IDH (A) The active site cleft in ICD and IDH is remarkably well 
conserved with secondary structure elements (B) ICD and IDH substrate binding residues are similar, binding of a-
ketoglutarate causes conformational changes as IDH residues are in a closed conformation (C) The recognition site 
of ICD for AceK includes an AceK recognition segment and a phosphorylation loop which carries the serine. In 
both species (P. aeruginosa and E. coli) these elements superpose (D) Superposition of the same elements between 
ICD and IDH demonstrates clearly that the two sets of a-helices prevent any attachment of AceK 
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of IDH within pathogenic bacterial species demonstrates that the enzyme is less prevalent than ICD. 
For example, out of the 43 species selected to construct all phylogenetic trees, only 13 of them encode 
IDH. In species that do encode IDH, the enzyme is particularly well conserved, with notably several 
psychrophilic species. IDH is known in psychrophilic bacteria to be well-adapted to cold, which gives 
the advantage of a functional TCA cycle in a cold environment. 
To start this work on IDH, I successfully cloned and overexpressed the enzyme either with a 
N-terminal His6-tag or in the native form (after Factor Xa digestion). However, the gel filtration and 
AUC data showed a discrepancy in the native molecular mass. The molecular mass obtained by gel 
filtration supported the presence of a trimer or elongated dimer. In contrast, the AUC data were 
consistent with a tetramer in solution. Overall, both approaches suggest that IDH has a higher-order 
quaternary structure. It is no longer possible to label it as a monomer, at least not in P. aeruginosa. 
The uncertainty in the oligomeric status requires further investigation. The addition of the substrate 
or a regulator did not refine the molecular mass. I recommend the production of another solution of 
IDH before any new AUC-SV experiment, furthermore the addition of the substrate and a non-
competitive regulator could improve the results. 
The gene expression of Pidh::lacZ alongside Picd::lacZ indicated the effect of carbon sources 
on the transcription of the genes and the equilibrium between the expression of idh and icd. I grew 
the cells in acetate to redirect carbon flux through the glyoxylate shunt, or in glucose to promote the 
TCA cycle. The two strains containing the isocitrate dehydrogenase promoter constructs showed 
better growth in minimal medium supplemented with single carbon source compared with the control. 
I have no explanation for this since these are not mutant strains, the control and lacZ reporter fusion 
strains should express a similar level of metabolic enzymes. The β-galactosidase assay indicated that 
the Picd::lacZ construct is consistently transcribed at a slightly higher level compared with the 
Pidh::lacZ construct when the cells are grown in acetate or glucose. This would suggest that ICD 
remains the preferred enzyme used in the TCA cycle to yield α-ketoglutarate. IDH appears to be less 
dominant as it is less transcribed during bacterial growth, but nonetheless, essential even during 
growth on limited carbon sources as ICD and IDH are consistently transcribed. This indicates that 
ICD and IDH are vital for fuelling the nutritional requirements of persistent P. aeruginosa, however 
these metabolic enzymes emerge as mediators of antioxidant defence. Hypothetically, ICD, IDH and α-ketoglutarate dehydrogenase, as part of a stratagem to combat oxidative stress, respond to an 
oxidative insult with an increased production of NADPH. The latter acts as a reductive force required 
to nullify the oxidative environment triggered by the oxidation of NADH, maintains anti-oxidative 
systems in reduced/active states; while the former produces ROS via the respiratory chain. A 
reductive environment promoted by NADPH is essential for normal cellular activity. So, the creation 
of a reductive environment mediated by the enhanced formation of NADPH is instrumental to the 
survival of P. aeruginosa in an oxidative environment and the manipulation of metabolic pathways 
and enzymes involved in NADH/NADPH metabolism is pivotal to ensure that ROS levels remain in 
the non-toxic range. Although ROS-detoxifying enzymes, such as catalase and SOD, are important 
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in nullifying oxidative stress, the efficacy of these enzymes depends on the reductive environment 
promoted by NADPH. To survive, high NADPH counters oxidative stress and low NADH limits ROS 
formation from the respiratory chain222,293. 
The kinetic parameters reveal a Km for isocitrate and NADP+ that are very similar to ICD. 
This means that ICD and IDH compete in the same range of affinity for the substrate and the co-
factor. In bacteria that have IDH or ICD only, the affinity for isocitrate is greater, ensuring carbon 
flux through the TCA cycle. However, in Pseudomonas aeruginosa, the similar affinity of ICD and 
IDH for isocitrate addresses the question of the regulation of IDH aside of the regulation of ICD. The 
mechanisms that regulate the partitioning of metabolite fluxes at the bifurcation of the oxidative 
TCA cycle and the glyoxylate shunt emerge. Strict regulation of fluxes at the TGB is essential during 
catabolism of C2-units derived from fatty acids in order to balance anaplerotic fluxes (glyoxylate 
shunt) and fluxes generating energy and biosynthetic precursors (TCA cycle). I demonstrated that 
ICD (like in other species, particularly E. coli) is regulated by the AceK-mediated phosphorylation. 
Inactivation of ICD by phosphorylation secures a rerouting of the carbon flux through the glyoxylate 
shunt instead of the TCA cycle. In the case of IDH, AceK does not have any effect on its activity. 
The incubation of the two enzymes with ATP did not result in any loss of activity of IDH over time. 
The screening of regulators became then of particular interest to investigate any allosteric effect of 
metabolic intermediates. 
Table 18: Kinetics parameters of IDH 
 Km (mM) Vmax (ΔmM/s) kcat (s-1) kcat/Km (s-1/µM) Ki (mM) Effect 
isocitrate 17.70 0.0005 183.67 10.38 n/a n/a 
     glyoxylate 20.67 0.0023 925.17 44.76 n/a non-competitive 
     oxaloacetate 39.16 0.0030 1210.88 30.92 n/a uncompetitive 
     pyruvate 41.95 0.0035 1408.16 33.57 n/a uncompetitive 
NADP+ 34.48 0.0005 210.88 6.12 n/a n/a 
     glyoxylate 160.40 0.0038 1544.22 9.63 n/a uncompetitive 
     oxaloacetate 29.00 0.0030 1217.69 41.99 n/a non-competitive 
     pyruvate 49.46 0.0034 1380.95 27.92 n/a non-competitive 
I demonstrate that IDH activity is mediated by metabolite-based regulation. The most 
intriguing result from the screening of regulators is the absence of identified physiological inhibitors 
(apart from oxalomalate). Interestingly though, three molecules have a potent activatory effect on 
IDH. Glyoxylate, oxaloacetate and pyruvate are very effective activators as they increase IDH activity 
by up to 2.4-fold. None of these molecules showed a competitive effect against either isocitrate or 
NADP+, instead they showed a non-competitive or uncompetitive effect indicating that the binding 
of the compound occurs in a site other than the active pocket. All three compounds changed the 
isocitrate dependency of IDH kinetics from hyperbolic to sigmoidal. These three compounds had a 
pronounced effect on kcat, so initially Vmax, but only a small impact on Km (even in the case of non-
competitive activators). However, most allosteric enzymes are K-type, which means that the Km is 
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altered. Only a small subset of enzymes are V-type, with a pronounced change of Vmax. In the case of 
IDH, the significant increase in kcat exemplified the V-type trend of IDH. The latter category 
represents only ∼ 1% of all studied enzymes294.	
Activation of IDH mediated by glyoxylate, is ideally suited because glyoxylate is a product 
of the ICL-catalyzed cleavage of isocitrate to glyoxylate and succinate. According to this scheme, if 
glyoxylate levels rise, the corresponding increase in IDH activity ensures that carbon flux will shift 
towards the TCA cycle, leading to a decrease in glyoxylate levels. If glyoxylate levels fall, the 
corresponding decrease in ICD activity ensures that carbon flux will shift back towards the glyoxylate 
shunt, leading to a recovery of glyoxylate levels. The glyoxylate-mediated activation of IDH functions 
as a molecular rheostat to maintain the proper balance of fluxes between the TCA cycle and the 
glyoxylate shunt295. Activation of IDH mediated by gluconeogenic substrates oxaloacetate and 
pyruvate is similarly suited. Oxaloacetate is the product of the oxidation of malate by malate 
dehydrogenase with reduction of NAD+ to NADH. According to this scheme, if oxaloacetate levels 
rise, so do NADH levels, the consequent increase of IDH activity ensures carbon flux through the 
TCA cycle, leading to increased levels of NADPH. This secures a NADH/NADPH homeostasis to 
circumvent oxidative stress. If oxaloacetate levels fall, NADH levels fall and NADPH production is 
no longer required to nullify oxidative stress. Pyruvate is the end product of glycolysis and the product 
of the dephosphorylation of PEP by pyruvate kinase. Increase in pyruvate levels is a metabolic cue 
suggesting growth on media with glucose, so catabolism of C6-units pushes flux through the TCA 
cycle as there is no risk in losing two carbons in the form of CO2. The corresponding increase in IDH 
activity fulfils the cataplerotic functions of the TCA cycle producing the gluconeogenic precursors to 
serve energy and to grow biomass. 
I solved the first X-ray structure of IDH from Pseudomonas aeruginosa. The structure 
presented shows two non-related protomers of IDH. The co-factor NADP+ crystallised in the IDH 
active site pocket, as did a molecule of α-ketoglutarate. Comparison of IDHPa with several bacterial 
and fungal IDH indicates that the structure of IDH is well conserved. Further investigation of the 
active site highlighted that the residues involved in substrate, co-factor and metal binding are 
conserved. The remarkable aspect of the work on IDHPa is the binding of only one molecule of NADP+ 
out of the two protomers represented. The bound protomer of IDHPa with NADP+ and α-ketoglutarate 
demonstrates that the active site is in an intermediate state of energy. The rmsd value from the 
superposition of IDHPa with IDH co-crystallised with isocitrate or IDHPa with IDH co-crystallised 
with NADP+ demonstrated that binding of the ligands triggers conformational changes. The hinge-
motion of the smaller domain of IDH closes the active site of the enzyme. The presence of NADP+ 
and α-ketoglutarate in IDHPa activates this hinge-motion, but only partially as the C5 compound 
disengages binding with several residues, leaving it ready to exit the active site. 
Work done on IDH from Azotobacter vinelandii investigating the evolutional pathway from 
ICD to IDH highlighted the similarity of the active site between the two enzymes. In P. aeruginosa, 
the substrate binding residues are identical between ICD and IDH, including the phosphorylation 
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site. I demonstrated that IDH is not inhibited by phosphorylation. The recognition motifs (ARS and 
P-loop) lining the ICD active site and recognised by AceK are not present in IDH. ICD and IDH 
have a similar affinity for isocitrate and are independently regulated via two mechanisms. The 
presence of these two isozymes remains unclear. The architecture of the regulatory circuit that 
controls bifurcation of fluxes at the branchpoint for the TCA cycle indicates that ICD and IDH are 
essential for growth on C2-units and C6-units. Phosphorylation-mediated inhibition of ICD but cross-
activation of IDH by glyoxylate, oxaloacetate and pyruvate suggests that metabolic cues maintain a 
molecular rheostat to balance fluxes between the TCA cycle and the glyoxylate shunt, in conjunction 
with NADPH-NADH homeostasis296. Further investigation with ∆icd, ∆idh or ∆icd-idh mutant 
strains of PAO1 (strains produced by Dr. Stephen Dolan in Dr. Martin Welch laboratory) would 
address the question if ICD and IDH are essential for growth of P. aeruginosa in an acetate 
supplemented growth medium. 
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5. Isocitrate lyase (ICL) 
5.1. Introduction 
Isocitrate lyase is the first enzyme of the glyoxylate shunt and is encoded by aceA. ICL 
catalyses the cleavage of isocitrate to yield glyoxylate and succinate. Then, the glyoxylate is 
condensed with an acetyl-CoA unit to yield malate in a reaction catalysed by malate synthase (MS). 
ICL therefore competes for the same substrate as ICD and IDH. During growth on fatty acids, carbon 
flux enters the central carbon metabolism as acetyl-CoA units. A fraction of the TCA cycle is diverted 
into the glyoxylate shunt to replenish biosynthetic intermediates by anaplerotic reactions. The 
glyoxylate shunt is vital for survival of P. aeruginosa during infection scenarios for reasons that are 
not yet clear. Furthermore, ICL plays an important role in ensuring optimal T3SS expression (PcrV, 
PopN, ExoS and ExsD expression are reduced in an aceA mutant) when P. aeruginosa is grown in 
oxygen-limited conditions201. This indicates that ICL impinges upon virulence of P. aeruginosa during 
infection scenarios such as the conditions encountered in the oxygen-limited environment of chronic 
CF lung infections297. 
In this chapter, I investigate the structure and kinetics of ICL from Pseudomonas aeruginosa. 
The SDS-PAGE analysis of ICL assesses the quality of the enzyme after purification; followed by the 
gel filtration and analytical ultracentrifugation studies indicating the oligomeric status of ICL in 
solution. I will continue by presenting the gene expression profile of aceA during growth of the cells 
in two different carbon sources (acetate and glucose). Most of the results presented refer to the 
kinetics of the enzyme and its allosteric regulation by a subset of metabolic intermediates. Lastly, I 
investigate the crystal structure of ICL. I will present a comparison of ICLPa to other bacterial and 
fungal ICL enzymes, a protein-protein interface analysis and a study of the active site cleft. 
5.2. Bioinformatic analysis 
The aceA gene, PA2634, is positioned at 2.977 Mbp in the PAO1 genome. Upstream of the 
gene is a 595-bp long denoted intergenic region that contains the promoter and gene regulatory 
elements. The Shine-Dalgarno sequence is located 10 bases upstream of the start codon to recruit the 
ribosome during translation. aceA is composed of 1,596 bp encoding a 531-amino acid long protein as 
seen in figure 40A.  
The upstream and downstream regions of aceA are uncharacterized. Upstream of aceA, the 
genes numbered PA2630 to PA2633 form an operon (computationally predicted) and are annotated 
as hypothetical proteins. PA2631 shows a high probability to be an acetyl transferase. Further studies 
on gene ontology indicate that PA2633 may be involved in protein secretion process. Downstream of 
aceA, PA2635 and PA2636, predicted to form another operon, are related to a probable arginine 
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translocation pathway. However, unlike in E. coli145, the glyoxylate shunt enzymes in P. aeruginosa 
do not comprise a single operon. 
 
Figure 40: Genetic context of the aceA gene P. aeruginosa PAO1 and other Pseudomonas 
species. (A) The highlighted aceA annotated gene is 1,596 bp encoding a 531 amino acid-
long protein. Two uncharacterized operons frame aceA, they are computationally 
predicted to be involved in protein secretion (upstream of aceA) and in arginine 
translocation (downstream of aceA) (B) aceA orthologues in other Pseudomonas species 
indicate that ICL is cytoplasmic (red box) 
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aceA orthologues are also present in other Pseudomonas species (figure 40B). In these other 
Pseudomonas species, the aceA sequence is conserved, however the length of the gene sequence is 
more variable. The examples in figure 40B indicate a predominant length of 1,326 bp, although the 
annotated aceA gene in P. aeruginosa is 1,596 bp-long and in P. stutzeri, aceA is composed of 1,644 
bp. The majority of other Pseudomonas species carry a shorter aceA gene, the longer aceA in P. 
aeruginosa is an exception encoding 100 additional residues that must give an advantage either in 
catalysis or assembly. These residues represent multiple gaps corresponding to Glu156-Ala169, 
Gln271-Phe288, Glu298-Lys311 and Ser407-Ala443 in P. aeruginosa. 
A BLAST analysis of the ICL amino acid sequence demonstrates the prevalence of ICL in 
most bacteria. ICL sequence identity within those species containing an ICL-encoding gene ranges 
from 91% (A. vinelandii) to 25% (B. pertussis) compared with the P. aeruginosa enzyme. However, 
some bacteria do not have a glyoxylate shunt. This is the case for the pathogens Campylobacter 
jejuni, Clostridium difficile, Legionella pneumophila, Listeria monocytogenes, Staphylococcus aureus 
for example. Absence of the shunt may relate to the specific growth conditions in which these species 
flourish. Indeed, common infections caused by C. jejuni, C. difficile, L. monocytogenes or S. aureus 
are associated with the blood-stream or gut. These two environments provide a high concentration of 
glucose ranging from 5 mM to 50 mM available for infective bacteria298,299. Intracellular bacteria, such 
as L. pneumophila, which reside within host-derived vacuoles find a potential rich source of carbon 
in cytosolic glycogen300,301. 
The alignment of five examples in the figure 41 shows the missing 100 residues in E. coli, 
C. glutamicum and M. tuberculosis in comparison with P. aeruginosa and B. cepacia. There are three 
prominent gaps between residues 144-163, 271-306 and 397-433 (Pseudomonas numbering). The boxes 
in figure 41 highlight in green the residues binding the substrate, in pink the catalytic triad and in 
blue the magnesium binding residues. 
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Figure 41: ClustalOmega alignment of ICL amino acid sequence (green: substrate binding, pink: catalyic triad, blue: 
magnesium binding). ICL protein is variable between a “short” (430 residues) and a “long” (530 residues) 
sequence. Very few regions are highly conserved, but the highlighted residues are systematically part of small 
clusters of fully conserved residues. 
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5.3. Purification of ICL protein 
5.3.1. Preliminary results 
Similar to ICD and IDH described in the previous chapters, I 
purified ICL. The aceA gene was PCR-amplified from the PAO1 genome 
and cloned into pQE80 (work carried out by a Part II student preliminary 
work done in 2014) or His-pMAL-c2x vector. The resulting construct was 
introduced into E. coli DH5α to overexpress the protein. The purification 
of His6-tagged ICL (aceA pQE80 cloned vector) and His6-MBP-tagged ICL 
(aceA His-pMAL-c2x cloned vector) used a Ni-NTA resin or a multi-step 
procedure with amylose resin (first His6-MBP-tagged ICL purification), 
Factor Xa digestion (His6-MBP-tag cleaved from the construct) and Ni-
NTA resin (His6-MBP-tag is retained, native ICL is collected).  
The SDS-PAGE analysis (figure 42) revealed that the purified 
ICL protein had a monomeric molecular mass of predicted by Expasy 
Protparam is 58,886 Da for untagged ICL. The band on the gel migrates 
with an apparent molecular mass of between 50 kDa and 75 kDa molecular. 
This means that the product of the purification from the E. coli DH5α 
aceA His-pMAL-c2x expressing system is correct. The SDS-PAGE analysis 
of the purified His6-tagged ICL (see appendix 2) indicated that the 
molecular mass was around 60 kDa, a larger band migrated with an 
apparent molecular mass of between 50 kDa and 75 kDa. ICL purified from 
E. coli DH5α aceA pQE80 and E. coli DH5α aceA His-pMAL-c2x 
expression systems were therefore successfully expressed and purified to 
homogeneity. 
5.3.2. Gel filtration analysis 
The molecular mass of ICL in solution, as 
determined by gel filtration through a TSK-Gel G3000 
SWXL column calibrated with the protein markers 
albumin (mol.mass. 66,000 Da), alcohol dehydrogenase 
(mol.mass. 150,000 Da), β-amylase (mol.mass. 200,000 
Da) and apoferritin (mol.mass. 443,000 Da), was 
around 232,000 Da (figure 43). This indicates that 
ICL is a tetramer in solution. This is consistent with 
the isocitrate lyase characterized from other 
microorganisms including E. coli302,303, Bacillus sp.304 
and M. tuberculosis305. 
Figure 42: Coomassie-
stained SDS-PAGE analysis 
after purification of ICL. 
The untagged protein after 
purification from the E. coli 
DH5α aceA His-pMAL-c2x 
expressing system is a 
single band visible with a 
molecular mass estimated 
around 60 kDa. This figure 
is a “cut and paste” from 
the same gel, the ICL lane 
was pasted next to the 
ladder. 
Figure 43: Gel filtration analysis of ICL. The graph 
shows a single peak with a corresponding 
molecular mass of 232 kDa. All three moments, 
Mn, Mw and Mz are consistent. 
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5.3.3. AUC data 
In addition to gel filtration, ICL was analysed using AUC with sedimentation velocity (SV-
AUC). This was carried out on samples containing three different concentrations of the protein (0.1, 
0.5 and 1 mg/mL). The results presented in figure 44 were obtained with the lowest concentration 
of 0.1 mg/mL. The fitting of the Stokes equation was successful for all dataset, with very little 
variability between the three samples. The data were analysed as specified in chapter 2 using 
SEDNTERP and SEDFIT. 
The profiles recorded and presented in figure 44 show a single protein peak with a 
sedimentation coefficient of 10.5 S. The calculations of the frictional ratio indicate that the isocitrate 
lyase molecule is more globular, with a frictional ratio of 1.17. Finally, the calculated molecular mass 
was 231,000 Da, which agrees well with the data from gel filtration. This leads to the conclusion that 
ICL is a stable tetramer in solution, consistent with other bacteria previously reported, such as E. 
coli, Bacillus sp. and M. tuberculosis. These parameters can be compared with those of the purified 
isocitrate lyase of Pseudomonas indigofera. The molecular mass of the P. indigofera enzyme is 222,000 
Da and its frictional ratio was calculated to be 1.39306. 
Figure 44: SV-AUC data of ICL protein. The figure shows 40 absorbance scans recorded at 280 nm for a protein 
sample of 0.1 mg/mL. The rmsd of the scans is of 0.0069, significantly higher than the noise rmsd. The single peak 
with a molecular mass of 231 kDa indicates that ICL is a tetramer. The frictional ratio (1.17), closer to 1, suggests a 
more globular assembly. 
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5.4. Gene expression of aceA 
The expression of aceA was investigated by cloning the promoter of the gene into pLP170 
(PaceA::lacZ reporter gene construct). The construct was then introduced into PAO1. As with the 
Picd::lacZ and Pidh::lacZ reporter constructs described in earlier chapters, PAO1 cells were grown in 
minimal medium supplemented with acetate or glucose as a carbon source. The expression of aceA 
was assessed using a fluorescent β-galactosidase assay. Growth of the cells was monitored as OD600.  
As shown in figure 45 (pink 
line), the growth rate of the cells 
containing the PaceA::lacZ reporter 
construct is not affected whether the 
cells were grown in minimal medium 
supplemented with acetate or glucose. 
When compared with the control line 
in black, the growth rate is similar. 
This confirms that the PaceA::lacZ 
construct introduced into PAO1 does 
not impair growth of the cells. One 
noticeable aspect is the difference in 
the results of the optical density 
measurements between the two media: 
growth in acetate was lower as the 
highest value is 0.2 OD600 while the 
highest value in glucose is 0.6 OD600. 
Glucose remains the preferred carbon 
source over acetate. 
The data in figure 45A show 
that aceA expression is up-regulated 
during growth in minimal medium 
supplemented with acetate. After 5h, 
the levels of β-galactosidase activity 
increase significantly. The highest β-
galactosidase activity for PaceA::lacZ 
construct reaches 5,000 nmol.min-1.A600-1 before entering stationary phase. Then, β-galactosidase 
activity decreases throughout the stationary phase. In figure 45B, the β-galactosidase assay reveals 
low expression of aceA during growth in minimal medium supplemented with glucose. The β-
galactosidase activity of the Pacea::lacZ construct remains low throughout the entire time of growth. 
The maximum value attained was 300 nmol.min-1.A600-1 after 6h of growth. Taken together, these 
ACETATE 
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Figure 45: Gene expression results of Pacea::lacZ fusion (A) MOPS 
+ acetate (B) MOPS + glucose. Black coloured results are the wild-
type (empty vector), blue is the Picd::lacZ construct, green is the 
Pidh::lacZ construct and pink is the PaceA::lacZ construct. The b-
galactosidase assay shows up-regulation of aceA when the cells are 
grown in acetate which reinforces that there is indeed rerouting of 
carbon flux through the glyoxylate shunt. 
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data indicate low expression of the aceA gene during growth on glucose, and increased expression of 
the aceA gene during growth on acetate. 
In conclusion, when the cells are grown in acetate, the glyoxylate shunt is activated by 
transcriptional induction of the gene encoding isocitrate lyase. This demonstrates that P. aeruginosa 
growing on C2-units sources use the glyoxylate shunt for anaplerosis of the TCA cycle while 
maintaining oxidative TCA cycle activity for the production of energy and gluconeogenic precursors 
as the expression of ICD and IDH persists307. However, the growth rate of the strain containing the 
PaceA::lacZ construct is different compared with the strain containing the Picd::lacZ construct or 
the Pidh::lacZ construct. I speculate that there is another form of transcriptional regulation of icd 
and idh but not of aceA. A candidate effector is the CbrA-CbrB two-component system. Indeed, 
studies performed by Nishijyo et al. found that in a cbrB mutant PAO4455, glucose was used with 
reduced efficiency but little or no growth defect was observed with acetate134. The expression of the 
TCA cycle enzymes is regulated by Crc (section 1.2.1.2) and a connection between the Cbr system 
and the catabolite repression exerted through Crc has been reported recently in P. aeruginosa132. It 
indicates that CbrB involvement in regulation of carbon catabolism may be extended to central 
carbon catabolic pathways. So, this adaptation to a C2-units nutrient source is comparable to E. coli 
in which there is a switch to the glyoxylate shunt in case of limited carbon source145,308. In E. coli, 
there is essentially no expression of the glyoxylate shunt enzymes during growth on glucose, whereas 
in P. aeruginosa, aceA is always expressed at low levels in these conditions. Interestingly, fungi have 
the same ability to rewire their metabolism as the cells overexpress ICL when acetate is the sole 
carbon source309,310.  
5.5. Kinetic analyses 
5.5.1. Michaelis-Menten data 
Isocitrate lyase is a co-factor- 
independent enzyme, the direct assay used 
monitors the formation rate of the 
glyoxylate-phenylhydrazine complex at 
324 nm. The kinetic studies at variable 
concentrations of isocitrate revealed that 
Km is 12 µM and Vmax is 0.048 mM.min-1 
(figure 46). The tetrameric quaternary 
structure of ICL indicates that the kcat 
value is 1,128 min-1 (19 s-1). The catalytic 
efficiency of ICLPa is kcat/Km = 1.55 s-1.µM-
1. In comparison to ICL in E. coli, there is 
a noticeable difference as the latter has a 
Figure 46: Kinetic analysis of ICL. Michaelis-Menten data and 
Lineweaver-Burk plot indicate that Km = 12 µM and Vmax = 
0.048 mM.min-1 
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kcat/Km = 0.37 s-1.µM-1. The catalytic efficiency of ICLPa is greater than that of ICLEc, which is 
consistent with the difference of Km between ICLPa and ICLEc. 
These values are remarkably different from the well-studied Escherichia coli enzyme. An 
extensive study of the branchpoint in this microorganism clearly established carbon flux partitioning. 
In E. coli, the affinity of ICL for isocitrate is Km = 604 µM153; hence a lower kcat/Km. Other 
microorganisms have a similar disparity with Km ranging from 23 µM, 50 µM to 280 µM for Chlorella 
sp.311, Neurospora crassa312 and Corynebacterium glutamicum207 respectively. M. tuberculosis encodes 
two isocitrate lyases jointly required for Mtb survival, ICL1 and ICL2 have a lower affinity for 
isocitrate. The Km are respectively 130 µM and 1.3 mM for ICL1 and ICL2313. In Pseudomonas 
aeruginosa, ICL has a slightly lower Km for isocitrate than the isocitrate dehydrogenases. The low 
Km of ICL for isocitrate means that flux through the TCA cycle enzymes does not need to be 
significantly decreased to get flux through the glyoxylate shunt. This also indicates that the control 
of flux through the TGB in P. aeruginosa is far more finely balanced. The coordination of metabolic 
flux in P. aeruginosa includes key regulators which affect IDH and subsequently ICL activity to 
redirect carbon flux through the TCA cycle or glyoxylate shunt. These compounds feature relatively 
little in the control mechanisms reported for other microorganisms characterised to date. 
The activity of ICL is tightly linked to the presence of magnesium cation. In Mycobacterium 
tuberculosis for example, absence of magnesium leads to negligible ICL activity313. It is supposed that 
the actual substrate in Pseudomonas ICL is a complex of isocitrate with magnesium and that 
magnesium acts as a non-essential activator. ICL is therefore to be considered, at least kinetically, a 
metal-ion-activated enzyme. The importance of magnesium is primordial for the cleavage of isocitrate; 
as long as magnesium is complexed, the non-activated and the activated enzyme forms are 
catalytically active193,314,315. 
5.5.2. Screening for regulators 
The effect of gluconeogenic precursors on IDH activity revealed a new regulation of the 
enzyme in P. aeruginosa. I investigated the effect of the same subset of metabolic intermediates on 
ICL of P. aeruginosa. However, note that for molecules containing a ketone or aldehyde group I 
needed to employ the coupled assay with LDH to circumvent the formation of a phenylhydrazine 
complex that would interfere with the readings. 
No activators of ICL activity were identified. However, I found that several compounds inhibit 
ICL activity (figure 47). Only glyoxylate activates ICL; however glyoxylate is also a substrate of 
LDH316 (used in the coupled assay). ICL was effectively inhibited by citrate, coenzyme A, glycolate, itaconate, maleate, malate, malonate, 3-nitropropionate, oxaloacetate, PEP, pyruvate, succinate, malate + oxaloacetate, glyoxylate + oxaloacetate and succinate + glyoxylate. Itaconate, maleate, 
3-nitropropionate, oxaloacetate and pyruvate most potently inhibit ICL activity. The percentage of 
inhibition varies from 93 to 98% compared with the control. Some of these inhibitors are known from 
studies on ICL from other organisms, and are synthetic compounds200. For example, itaconate317, 3-
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nitropropionate318, and 3-
bromopyruvate319 are all well-
established inhibitors of ICL. These 
compounds are analog of succinate 
(itaconate, 3-nitropropionate) or 
glyoxylate (3-bromopyruvate). The 
effect of 1 mM of itaconate has been 
extensively studied in ICL from 
Pseudomonas indigofera as it inhibits 
ICL activity by 96%320 which is 
similar to my observations here with 
the ICL of P. aeruginosa. Maleic 
acid320,321, oxaloacetate229,311 and 
pyruvate314,322 are also known 
inhibitors of ICL from Escherichia 
coli, Neurospora crassa, 
Brevibacterium flavium and 
Pseudomonas indigofera. However, the magnitude of the inhibitory effect is variable. Oxaloacetate 1 
mM, for example, has been reported to inhibit ICL activity by 70% in Brevibacterium flavium229, 
whereas pyruvate (1 mM) has a more limited effect on ICLEc with an inhibition of 7% only323. 
Another subset of milder inhibitors includes citrate, coenzyme A, glycolate, malate, malonate, 
PEP and succinate. Citrate, glycolate, malate, PEP and succinate are known inhibitors of ICL from 
E. coli, P. indigofera, Chlorella pyrenoidosa324 and Brevibacterium flavum. Citrate inhibition of ICL 
is mild in other organisms, ranging from 6% to 16% in Chlorella and Brevibacterium respectively229,324. 
In P. aeruginosa however, it has a more pronounced effect with 50% inhibition. Glycolate inhibition 
of ICL in P. indigofera (35%) and P. aeruginosa (34%) is similar. Malate inhibition of ICL in P. 
aeruginosa is more pronounced with a drop of ICL activity to 50%. In Chlorella and Brevibacterium 
ICL, malate shows a milder inhibition by 5 to 24% respectively229,324. PEP and succinate are known 
inhibitors of ICL from E. coli, C. pyrenoidosa, P. indigofera and B. flavum. The inhibition of ICL by 
PEP in these species ranges from 1 to 20%, the effect on ICLPa is more pronounced with a loss of 
activity of 72%. Succinate has a stronger effect on ICL activity with a reported inhibition ranging 
from 13 to 56% in Chlorella and Brevibacterium respectively. In P. aeruginosa, succinate decreases 
ICL activity by 85%. Coenzyme A and malonate have not been reported as ICL inhibitors before. 
They are potent inhibitors, coenzyme A decreases ICL activity by 66%, while malonate reduces the 
enzyme activity by 75%. It is unsurprising that P. aeruginosa ICL activity is modulated by certain 
metabolites. The potent effect of these demonstrates that ICL regulation is more nuanced; the 
glyoxylate shunt regulation responds to metabolic cues. Oxaloacetate and pyruvate, two emerging 
Figure 47: Results of screening of potential regulators on ICL. Several 
compounds inhibit ICL activity compared with control. Glyoxylate 
activatory effect is a false positive as glyoxylate is also a substrate for 
LDH used in the coupled assay. Values marked with * are significantly 
different compared with control (p<0.05 and n=3). All compounds 
were tested at a 1 mM concentration. 
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key regulators, reciprocally regulate IDH and ICL. By activating IDH and inhibiting ICL, this ensures 
flux through the TCA cycle. 
5.5.3. Inhibition kinetic study 
The inhibitors of ICL fell into three categories: non-competitive inhibitors, uncompetitive 
inhibitors and ‘mixed’ inhibitors (figure 48, see appendix 2D-G for the corresponding Michaelis-
Menten plots). Citrate, coenzyme A, glycolate, malate, oxaloacetate and pyruvate non-competitively 
inhibit ICL from P. aeruginosa. This means that the inhibitor is capable of binding to the free enzyme 
or more likely to the enzyme-substrate complex. The Km is not affected by the presence of the 
inhibitor, but the Vmax is altered. Table 19 compiles the kinetic parameters for the inhibitors of ICL, 
all had a pronounced effect on kcat with little effect on Km. The Vmax varies depending on the potency 
of that compound.  
For example, citrate, malate and coenzyme A have a moderate effect. More potent inhibitors 
such as glycolate, oxaloacetate and pyruvate feature a more reduced Vmax of ICL. This is consistent 
with the double-reciprocal plot in which the lines for citrate, malate and coenzyme A derive further 
from the control. In the case of non-competitive inhibition, the Ki was calculated according to the 
following equation: 
Ki=
[I]%Vm Vm(obs)⁄ )-1 
with [I] = 1 mM. The strongest physiological inhibitors were oxaloacetate and pyruvate. They 
inhibit ICL with a Ki of 1.41 mM and 1.68 mM respectively. The reported intracellular concentrations 
of pyruvate and oxaloacetate are up to 10 mM325 for the former and 0.03 mM326 for the latter. A more 
moderate inhibitor, citrate, has a Ki of 15.79 mM while the intracellular concentration can be up to 
2 mM in glucose-fed, exponentially growing E. coli327. 
 Table 19: Kinetic parameters of ICL in presence of inhibitors 
 Km (µM) Vmax (ΔmM/min) kcat (s-1) kcat/Km (s-1/µM) Ki (mM) Effect 
isocitrate 18.29 0.048 18.81 1.55 n/a n/a 
     citrate 18.80 0.045 17.69 0.94 15.79 non competitive 
     coenzyme A 22.56 0.038 14.94 0.66 3.85 non competitive 
     glycolic acid 18.20 0.031 12.15 0.67 1.82 non competitive 
     malic acid 16.61 0.039 15.33 0.92 4.41 non competitive 
     oxaloacetate 18.42 0.028 11.01 0.60 1.41 non competitive 
     pyruvate 18.22 0.030 11.79 0.65 1.68 non competitive 
     itaconic acid 6.27 0.022 8.67 1.38 0.92 uncompetitive 
     maleic acid 3.57 0.016 6.29 1.76 n/a mixed 
     malonic acid 12.01 0.031 12.19 1.01 2.85 uncompetitive 
     nitropropionic acid 6.86 0.019 7.47 1.09 0.96 uncompetitive 
     PEP 6.04 0.023 8.88 1.47 n/a mixed 
     succinate 7.82 0.018 7.09 0.91 0.92 uncompetitive 
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Itaconate, maleate, malonate, 3-nitropropionate, PEP and succinate show an uncompetitive 
or mixed inhibition of ICL. Here, the inhibitor binds to a subsite of the enzyme-substrate complex. 
In the presence of uncompetitive inhibitors, the Km and Vmax decrease upon binding of the compounds. 
As seen in Table 19, the values of Km and Vmax vary greatly depending on the inhibitor. Due to the 
uncompetitiveness of these compounds, Ki is replaced by Ki’. Ki’ was determined from the y-intersect 
of the Lineweaver-Burk plot:  
Ki'=
[I](Yintersect×Vmax)-1 
with [I] = 1 mM. Itaconate and 3-nitropropionate (synthetic compounds analog of succinate) 
are similar; Ki’ is on average 0.93 mM. Malonate, a more moderate inhibitor, has a higher Ki’ of 2.85 
mM. Potent inhibitors such as itaconate and 3-nitropropionate show parallel lines increasingly shifted 
(figure 48C) compared with control. On the other hand, maleic acid and PEP show a mixed 
inhibition. PEP has been previously reported to be an uncompetitive inhibitor of isocitrate lyase from 
E. coli with a Ki’ value of 0.89 mM328. The mixed inhibition of ICL from P. aeruginosa by maleate 
and PEP supposes that the compound has an unequal affinity for the free enzyme and the enzyme-
substrate complex, hence a mixture of competitive and uncompetitive phenotypes. The rate equation 
considers Kic (competitive part) and Kiu (uncompetitive part). However, in order to determine these 
two parameters, further investigation would require the kinetic analysis of ICL with variable 
concentrations of substrate and inhibitor. 
5.5.4. Thermal shift assay 
To investigate the binding of these inhibitors further, I conducted a thermal shift assay. This 
approach is predicated on the assumption that if a low molecular weight ligand binds to the enzyme, 
this leads to a "tightening up" of the structure and consequent stabilization against thermal 
Figure 48: Kinetic analysis of ICL in presence of inhibitors (A) Non-competitive inhibition by milder regulators 
citrate, coenzyme A, glycolate (B) Potent non-competitive inhibition by malate, oxaloacetate, pyruvate (C) 
Uncompetitive inhibition by synthetic compounds includes itaconate and 3-nitropropionate (D) Uncompetitive or 
mixed profile exhibited by stronger inhibitors such as maleate, PEP and succinate 
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denaturation. The TSA determines a ∆Tm that 
indicates the increased temperature stability of ICL 
with the regulator bound compared with the 
control. 
The bar chart in figure 49 compiles the 
results from the assay. The binding of isocitrate 
demonstrates a significant shift of 4.5°C. However, 
all the compounds tested also affected protein 
stability. Non-regulatory molecules, for example 
acetate, ADP, D-glucose-6-P, have a ∆Tm similar 
to the substrate. I have no explanation for this since 
these molecules do not influence ICL activity, so do 
not bind to ICL. Uncompetitive as well as non-
competitive inhibitors would be expected to show 
larger Tm shifts in the presence of substrate as the 
effect would be dependent upon the additivity of 
the individual binding. However, oxaloacetate and 
pyruvate, two potent non-competitive regulators 
have a similar ∆Tm than the substrate. I have no further explanation for this as the TSA experiment 
investigated the enzyme and the regulator alone, no substrate was added to the experimental 
conditions. So uncompetitive and non-competitive inhibitors would not be able to bind to a subsite. 
5.6. Crystal structure of ICL 
5.6.1. Structure description 
The three-dimensional structure of ICL was solved by molecular replacement using the 
Burkholderia pseudomallei structure (PDB 3I4E) as a template. The structure was refined to 1.9 Å 
with a Rcryst of 18.32% and a Rfree of 21.17%. The analysed crystal contains one molecule in the 
asymmetric unit, the polypeptide chain contains 486 residues (ICL is 531-residue long) along with 
182 water molecules. No electron density was detected for the last 45 residues at the C-terminus of 
the protein. The core of the enzyme is very well conserved and provides molecular insights regarding 
the active site pocket. The active site of the protein contained a calcium ion coordinated with 
glyoxylate and three water molecules (red circle figure 50A). 
Each monomer of ICL contains 17 α-helices and 14 β-strands, together with a small number 
of helical turns (figure 50A). The N-terminal region of the polypeptide chain comprises three 
consecutive α-helices, with the first two lying on the periphery of the molecule (α1 and α2). The 
structure then adpots a TIM-barrel like structure composed of 8 β-strands (β1-4, β6, β12-14), 
alternating with either one or two α-helices. The five remaining β-strands (β7-11) form a third 
Figure 49: Thermal shift assay of ICL in presence of 
inhibitors. All compounds tested indicate a significant 
difference in the denaturation temperature of ICL. 
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domain, the head-domain (figure 50A) (see appendix 10 for a structure/sequence alignment). ICL 
polypeptide is related by a crystallographic two-fold axis to yield a tetrameric structure (figure 50B) 
with extensive contact between each protomer.  
5.6.2. Structural comparison and contact analysis 
Investigation on ICL lead to the characterization of the crystal structure in known bacterial 
pathogens (E. coli195, M. tuberculosis196, B. pseudomallei (to be published), B. melitensis (to be 
published) and Y. pestis (to be published)). However, these are shorter than ICL from P. aeruginosa. 
Only one microorganism (Aspergillus nidulans) has an enzyme comparable to ICLPa with 538 residues, 
whereas there are 531 residues in P. aeruginosa ICL. 
The superposition of ICLPa, ICLBp, ICLEc and ICLMt (figure 51A) demonstrates that despite 
the shorter sequences of ICLEc, ICLMt and ICLBp, the rmsd is similar for the three with 1.35 Å, 1.30 
Å and 1.31 Å respectively. Most of the secondary structure elements are conserved. The core of the 
Figure 51: Superposition of ICLPa with other species (A) Bacterial ICL are shorter than ICLPa but the secondary 
structure proves to be similar (B) Eukaryotic ICLAn is similar in length to ICLPa. They have in common the presence 
of a head-domain 
Figure 50: ICL crystal structure (A) The solved structure accounted one monomer per asymmetric unit (B) The 
tetrameric polypeptide is related by a crystallographic two-fold axis operation 
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enzyme is structurally conserved, including the TIM-barrel like structure. However, alignment of the 
amino acid sequence of ICL from P. aeruginosa, E. coli and M. tuberculosis indicates differences 
between the longer and the shorter ICL enzymes (see section 5.2.2). The shorter version of ICL (e.g. 
ICLEc and ICLMt) lacks blocks of sequence that are present in the sequence of ICLPa as Leu145-Ala163 
(green in figure 51A), Ile272-Ile306 (yellow figure 51A) and Ala398-Arg433 (magenta figure 51A). 
The superposition of ICLPa with other ICL from microorganisms (ICLEc, ICLMt, and ICLAn) shows 
that the overall fold of ICLPa is distinct from the other species. The first two α-helices at the N-
terminus are flipped by a 180° angle relative to the axis of α3 as seen in figure 51A. The first missing 
block of sequence in ICLEc (Leu145-Ala163 in P. aeruginosa) is the extension of α6 by an additional 
four helical turns and of α7 by an additional helical turn. The second block of sequence (Ala398-
Arg433 in P. aeruginosa) is the extension of α13 and α14. These two α-helices extend away from the core of the protomer, giving the tetramer a star-like shape. The superposition of ICLPa with 
ICLAn (figure 51B) shows a similar conservation of the core of the enzyme. The rmsd is 1.43 Å. The 
most obvious difference in P. aeruginosa ICL compared with all other ICL relates to the third block 
of sequence (Ile272-Ile306 in P. aeruginosa). This forms a relatively unstructured “head-domain” in 
ICLPa reminiscent of the “head-domain” present in A. nidulans329 (figure 51B). The head-domain in 
A. nidulans is somehow bulkier with five α-helices, whereas in P. aeruginosa this domain is comprised 
of four β-strands and loops. The extensive interaction of these “head-domains” generates intimate 
contacts for the tetramer formation. Figure 51A shows that the shorter ICLEc and ICLMt do not 
have this “head-domain”. ICLPa therefore features traits from both prokaryotic and eukaryotic ICL. 
Protein-protein interactions play crucial roles in many biological functions. The analysis of 
the characteristics of protein-protein interfaces is to search for the factors that contribute to the 
affinity and specificity of protein-protein interactions. Further investigation on ICLPa using QtPISA 
revealed the residues comprising the interfaces between the four subunits. This analysis was further 
supported by COCOMAPS and InterfaceResidues script for PyMOL. The QtPISA interface summary 
concluded that there are six potential interfaces with the following chains pairing: A-B, A-C, A-D, 
B-C, B-D and C-D. 
The first pairing between chains A and B produces similar results when analysing it with 
COCOMAPS and InterfaceResidues. There are 50 residues forming the interface between the two 
chains as seen in figure 52A. Its symmetrical counterpart between chains C and D shows the same 
results flipped 180° on the x-axis (figure 52B). Most of the residues are located around position 300. 
Figure 52C, which is the distance map resulting from the analysis, shows a strong cluster of contact 
around position 300 corresponding to the “head-domain”. Three smaller clusters appear at the 
intersection of positions 100 and 200. The overall ∆ASA (accessible surface area) is the same for both 
A-B and C-D interfaces and is of 1,854.5 Å2. However, the distribution of the interface residues 
between polar and non-polar favourably tilts towards polar residues with an ∆ASA of 1,114.65 Å2 
against 739.85 Å2 for the non-polar residues. 
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Another pairing is between chains A and C and again its symmetry between chains B and D 
(figures 52D-E). According to the analysis conducted by InterfaceResidues and COCOMAPS, there 
are 38 residues involved in the formation of the interface. The distance map (figure 52F) shows two 
clusters formed by 23 residues situated in the first 50 of chain A interacting with the remaining 15 
residues situated around position 250 of chain C. The reverse happens between the first residues in 
the 50th of chain C interacting with position 250 of chain A. The same occurs between chain B and 
Figure 52: Analysis of ICLPa interfaces (A,B,C) Respectively, chains A-B interface, chains C-D interface, distance 
map of the A-B interface (D,E,F) Respectively, chains A-C interface, chains B-D interface, distance map of A-C 
interface (G,H,I) Respectively, chains A-D interface, chains B-C interface, distance map of A-D interface (J) Space-
filling view of the reconstructed interfaces (K) Side chain view of the residues onto the ICL tetramer 
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D as the distance map is exactly the same (see appendix 11 for complete results). With fewer 
residues, the parameters of the interface are reduced and show that indeed the ∆ASA is reduced to 
1,368.45 Å2. Same results are observed regarding the B-D interface. With respect to the balance 
between polar and non-polar residues, there are more polar residues with an ASA of 904.05 Å2 while 
non-polar residues represent 464.4 Å2.  
Finally, the last set of interfaces is between the chains A and D and the symmetry B and C. 
The number of residues differs between InterfaceResidues for PyMOL, COCOMAPS and QtPISA 
with 72, 70 and 76 residues respectively. Figures 52G-H show the symmetrical view of the two 
interfaces relative to the x-axis of the tetramer (frontal view figure 52J). The arrangement of the 
interfaces as seen in figure 52I highlights four clusters. There is contact of a subset of 27 residues 
scattered around position 100 starting from Gln69 to Gln139. Another cluster is visible along the 
truncated C-terminus, composed of 35 residues between Gln436 and Gln485. The last two clusters 
are symmetrical to each other as the N-terminal region of one chain interacts with the C-terminal 
region of the other. This includes the remaining 8 residues between positions 100 and 450 of each 
chain. Such a larger interface has a wider ∆ASA of 2,953.1 Å2 which represents 12.23% of the 
protomer surface. Polar residues are preponderant with a ∆ASA of 2,105.8 Å2, while non-polar ∆ASA 
is 847.35 Å2. 
In conclusion, the protein-protein interface of ICLPa is complex as the enzyme is a tetramer 
in solution. The reconstruction of the multiple contacts between the four chains in figures 52J-K 
demonstrates the complexity of the interface. There are in total 316 residues involved in stabilizing 
the tetramer. The total ∆ASA is of 12,352.1 Å2. The assembly of oligomers ideally responds to a 
power law relationship330: ASA = 5.3 x M0.76 where ASA is in Å2 and M is the molecular mass in 
Daltons331. Considering the truncated ICLPa solved here (M = 54,000 Da estimated by Expasy), the 
expected ASA for a monomer would be 20,936 Å2. The formation of the tetramer is presumably based 
on two dimers coming together. Each dimer (AD and BC interfaces) is characterised by an inter-
subunit helix-swapping of α12 and α13 between two crystallographically related subunits332– 334. So, if 
that protein forms dimers and tetramers, their expected ASA will be 35,455 Å2 for a dimer (5.3 x 
(2x54,000)0.76) and 60,042 Å2 for a tetramer (5.3 x (4x54,000)0.76). The expected area buried in the 
formation of the tetramer is 2 x 35,455 –  60,042 = 10,868 Å2. This estimation is similar to the observed 
total ASA which corroborates the results presented. 
5.6.3. Active site analysis of ICLPa 
The crystallisation conditions of ICL included CaCl2 supplemented with 1 mM glyoxylate. 
The data collection and solving was successful in finding suitable electron density for both ligands 
(figure 53A). The coordination of Ca2+ with glyoxylate and three water molecules was validated 
using CheckMyMetal335. In the active site of the structure I present here, glyoxylate and Ca2+ are 
displaced. This is reflected by a significant shift of the glyoxylate moiety by 5.7 Å towards the  β4-β5 loop (Glu213-Val231) and the Ca2+ is also shifted by 1.8 Å. 
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Table 20: Residues comparison of ICL active site 
 Substrate binding Mg2+ binding b4-5 loop 
ICLPa Y99 S101 W103 R260 E352 N380 T451 D184 D186 E213-V231 
ICLBm Y82 S84 W86 R222 E281 N309 T343 D147 E149 E176-I194 
ICLBp Y86 S88 W90 R229 E286 N314 T348 D154 E156 E183-V201 
ICLEc Y89 S91 W93 R232 E289 N317 T351 D149 E159 E186-V204 
ICLMt Y89 S91 W93 R228 E285 N313 T347 D153 E155 E182-I200 
ICLAn Y95 S97 W99 R243 E395 N423 T457 D168 D170 E197-V215 
Further investigation of the binding mechanistic in the active site of ICLPa involved 
superposition with ICLBm (Brucella melitensis PDB 3P0X, to be published) as the latter was co-
crystallised with isocitrate. Despite the low amino acid sequence identity between the two enzymes 
(28%), ICLPa and ICLBm overlay with a low rmsd of 1.31 Å. The core of the protein and the TIM-
barrel like structure are similar. The active site is located at the entrance of the TIM-barrel. It is 
comprised of two distinct parts. Most of the residues are located on the β-strands and loops around 
the rim of the TIM barrel, and there is a flexible loop between β4 and β5. The binding of isocitrate 
involves interaction of the substrate with the triad Tyr99-Ser101-Trp103, supported by Arg260, 
Glu352, Asn380 and Thr451. Catalysis is possible only with the participation of another triad Cys222-
Gly223-His224 as part of the β4-β5 loop. The latter is a very flexible structure that caps the active 
Figure 53: Active site analysis of ICLPa (A) Substrate and metal binding residues. The electron density satisfies a 
contouring of 1.2σ	for glyoxylate and 2σ for Ca2+ (B) Superposition of the active site cleft with other bacterial 
species (C) Overlay of the active site residues with ICL from Aspergillus nidulans (D) Amino acid sequence 
alignment of the catalytic loop 
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site upon binding of the substrate. Two additional residues, Asp184 and Asp186 might bind to the 
magnesium before catalysis. This preliminary investigation with B. melitensis also included ICL from 
E. coli195, M. tuberculosis196 and B. peudomallei (to be published) as these structures display different 
state of activation upon the presence of the substrate or products. As seen in figure 53B, it is evident 
that all of the residues discussed above are conserved. The table 20 aligns the binding residues and 
catalytic residues of all species. The Mg2+ binding residue Asp186 in ICLPa differs from other bacterial 
species but is similar to Asp170 in A. nidulans ICL. The conformation of the active site is comparable, 
the TIM-barrel-like structure provides a rigid anchor for binding, while the flexible loop flutters 
depending on the presence of isocitrate.  
Of the several residues involved in binding isocitrate, three are of particular interest: Cys222-
Gly223-His224. They constitute the end of the  β4-β5 loop (Glu213-Val231) in ICLPa. This loop is 
well conserved in all isocitrate lyases, ICLPa, ICLBm, ICLBp, ICLEc, ICLMt and ICLAn (figure 53B-C). 
The amino acid sequence alignment of this section demonstrates that out of the 19 residues, 9 are 
fully conserved and 5 are of strongly similar categories (figure 53D). For example, that loop 
corresponds in P. aeruginosa (ICL-Pa in figure 53D) to Glu213-Val231 or in E. coli (ICL-Ec in 
figure 53D) to Glu186-Val204. The loop itself has been extensively studied in M. tuberculosis ICL 
and is known to play a major role in the mechanism of action of ICL196,336. As seen in figure 53B-C, 
the loop is systematically present in bacterial species, and its spatial disposition depends on the 
crystallisation conditions. In the case of ICLBm and ICLMt, the loop is in a closed configuration since 
ICLBm is bound to isocitrate whereas ICLMt is bound to the reaction products, succinate and 
glyoxylate. On the other hand, in ICLBp, ICLEc and ICLPa, the loop points away from the active site. 
ICLBp is an apo structure. ICLEc was co-crystallised with pyruvate, the latter does not apparently 
faithfully mimic the true substrate or product of the reaction and therefore resembles the apo 
structure. Similarly, in ICLPa, glyoxylate is also not recognised which means that the loop stays in 
this open conformation. When the substrate is embedded in the active site, the motion of the loops 
becomes evident; it swings inwards to cap the active site, as determined in Mycobacterium 
tuberculosis196. The cysteine and histidine residues are essential for the catalytic activity of the enzyme 
as part of the KKCGH sequence motif. The superposition of the same active site residues of P. 
aeruginosa with A. nidulans (figure 53C) demonstrates the conservation of the substrate binding 
residues. Despite the low identity between the two amino acid sequences (26%), the isocitrate binding 
residues and more importantly the catalytic loop conservation indicates that the mechanism of action 
of ICL is apparently similar in prokaryotes and eukaryotes. 
5.7. Discussion 
Fatty acids or acetate metabolism is an important feature of the pathogenicity of 
Pseudomonas aeruginosa during infection. Consumption of fatty acids, converted into acetyl-CoA, 
involves regulation of carbon flux bifurcation between the oxidative TCA cycle and the glyoxylate 
shunt. The mechanisms that regulate the partitioning of metabolite fluxes at the bifurcation of the 
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TCA cycle and glyoxylate shunt were unknown in Pseudomonas aeruginosa. The regulation 
maintaining carbon flux at the TGB is essential during catabolism of C2-units in order to balance 
anaplerotic fluxes and to conserve atoms of carbon (glyoxylate shunt aka. ICL), and to conserve 
energy-generating fluxes (TCA cycle aka. ICD/IDH). The glyoxylate shunt becomes centrally-
important for biomass growth of Pseudomonas aeruginosa. The driver behind this work is that P. 
aeruginosa is incapable of surviving solely on C2-units catabolism without a functional glyoxylate 
shunt. Indeed, a double mutant of P. aeruginosa in which ICL and MS (malate synthase) are absent 
is cleared from a mouse pulmonary infection model in 48h165. This suggests that no other mechanism 
can circumvent the loss of the glyoxylate shunt, indicating the great potential for therapeutic agents 
which target both enzymes of the shunt in P. aeruginosa. Furthermore, as presented in section 5.1, 
an aceA mutant of P. aeruginosa showed a pronounced loss of T3SS-related virulence factors. This 
means that therapeutic agents targeting the glyoxylate shunt would also tackle virulence, a powerful 
tool against the proliferation of Pseudomonas aeruginosa. Investigation of the TGB, and in this 
chapter ICL, provides a better understanding of the enzymology of the branchpoint which is essential 
before any step further towards drug-design is to be made.  
ICL is a tetramer in solution. This is consistent with other bacterial species in which ICL has 
been characterized. Beforehand, however, I investigated the effect of acetate and glucose as sole 
carbon sources on the expression of aceA. The growth of PAO1 carrying the PaceA::lacZ construct 
was not impaired when the cells were grown in acetate-supplemented or glucose-supplemented 
minimal medium. This revealed a net up-regulation of ICL transcription when PAO1 is grown on 
acetate. This suggests that C2-unit catabolism efficiently promotes central carbon metabolism to 
divert isocitrate through the glyoxylate shunt instead of the TCA cycle. However, there is also a 
remarkable low aceA expression when PAO1 is grown on glucose, suggesting a more graded metabolic 
response. This ability of P. aeruginosa to rewire its gene expression profile is a remarkable trait for 
bacterial survival during infection as intermediates of the TCA cycle must be replenished by 
anaplerotic reactions66,151,164. 
In Pseudomonas aeruginosa, three enzymes compete for isocitrate. ICL affinity for isocitrate 
is similar, even slightly better, than its TCA cycle counterparts, ICD and IDH. ICL Km is 12 µM, 
while ICD Km is 25 µM and IDH Km is 18 µM. The enzymology in P. aeruginosa, however, is more 
complex as it also involves AceK. The regulation at the TGB of Pseudomonas is managed by AceK-
dependent phosphorylation of ICD, a partly rheostatic regulation of IDH and a more finely balanced 
regulation of ICL. A number of metabolic intermediates have a significant effect on ICL activity, and 
more importantly, all compounds are inhibitors (figure 54). None of the compounds show competitive 
inhibition of ICL which suggests that there is allosteric regulation of the enzyme. Non-competitive, 
uncompetitive and mixed inhibition of ICL are the three profiles seen in P. aeruginosa. Two key 
regulators emerged, oxaloacetate and pyruvate, which reciprocally inhibit ICL and activate IDH. 
They finely coordinate metabolic flux partitioning between the TCA cycle and the glyoxylate shunt. 
When these two intermediates are abundant, suggesting that there are enough gluconeogenic 
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precursors for biomass production, IDH is activated while ICL is inhibited leading to the rerouting of 
flux through the TCA cycle. In contrast, when the levels of oxaloacetate and pyruvate decrease, IDH 
becomes deactivated and ICL is disinhibited leading to greater carbon flux through the glyoxylate 
shunt. The same paradigm can be applied to PEP; higher levels of the compound suggests there are 
sufficient gluconeogenic precursors, so ICL is inhibited to redirect flux through ICD and IDH. The 
architecture of the regulatory circuit that controls partitioning of fluxes at the TGB is strikingly 
different in P. aeruginosa compared with the established paradigm in E. coli. In the latter, carbon 
flux partitioning is mediated by AceK-dependent inhibition of ICD, which diverts flux from the TCA 
cycle to the glyoxylate shunt. This is reinforced by the higher affinity of ICD from E. coli with a Km 
of 11 µM while ICL affinity for isocitrate is 604 µM.  
The preliminary steps of the ICL structure solving (Matthews coefficients calculations, 
phasing and molecular replacement) were straightforward. With a resolution of 1.9 Å, the ligands 
(glyoxylate and calcium) were detectable. However, the coordination of the ligands in presence of 
water did not match the usual conformation seen in other ICL structures. A typical coordination 
geometry for Ca2+ is octahedral, however in this case CheckMyMetal validated a square antiprism 
geometry. The shorter bond lengths characteristic of calcium, and the requirement of at least six 
Figure 54: Schematic of all ICL inhibitors compared with isocitrate. Colour coding: non-competitive, uncompetitive 
and mixed inhibitors. Coenzyme A is a distinct inhibitor of ICL, as a non-competitive regulator, it binds to a 
subsite of the enzyme, however there is no structural homology with any other compound. All other inhibitors 
have a similar structure indicating allocation to a subsite of ICL. 
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oxygen atoms to coordinate it, significantly shifted the location of the ligands in the active site337,338. 
The core of the ICL structure showed great similarity with other bacterial and fungal species 
characterized, as the TIM-barrel like fold is preciously conserved. There are several differences, 
however, that make ICLPa unique. ICLPa is 100-residue longer than the common “shorter” bacterial 
ICL, this means a few α-helices are elongated giving ICLPa tetramer its star-like shape and, more 
importantly, there is a “head-domain” increasing contact between each protomer of the tetramer. 
Comparing ICLPa and ICLAn (similar length, but enkaryotic ICLAn), most of the differences in ICLPa 
concentrate in the “head-domain”, which places ICLPa as an intermediate enzyme between prokaryotic 
ICL and eukaryotic ICL. The quaternary structure however remains unchanged and the protein-
protein contact between the four subunits is a complex arrangement.  
Further investigation on the active site of ICL from P. aeruginosa helps understanding the 
mechanism of action of the enzyme. All residues binding isocitrate are conserved in all ICL enzymes 
whether it is a bacterial or a fungal species; it is common to observe constant conservation of the 
catalytic residues and binding residues among enzymes even though they have low sequence identity. 
A detailed study of the active site highlighted the presence of a flexible catalytic loop (the β4-β5 
loop). The phenomenon of catalytic flexibility is also presented as plasticity. Conformational changes 
are frequently observed as part of enzyme mechanisms, according to which substrate and specific 
ligand binding is associated with a conformational change. Loops participating in the active sites of 
enzymes are an exception. These loops are often referred to as lids, turns or flaps, and their location 
at the entry of the active site plays a major role in substrate selectivity, and the recognition and 
facilitation of substrate binding into the binding cleft. Upon substrate binding, the disordered, 
solvent-exposed loop adopts a more compact and ordered conformation making interaction with 
subsites of the ligand and/or other residues of the protein. The closing of the cap the ligand in the 
active site cleft and protects the ligand from the aqueous environment. Moreover, access of the active 
site to other molecules is prevented339,340. This aspect of ICL catalysis structurally features the 
uncompetitive and non-competitive regulation of the enzyme in Pseudomonas aeruginosa. In the 
presence of the substrate and inhibitor, the substrate might bind first, closing the active cleft. The 
only option for the inhibitor is to bind to a secondary location on the enzyme and stop isocitrate 
cleavage. 
The exact mechanism by which ICL converts isocitrate into glyoxylate and succinate is not 
fully understood yet. It has been inferred that the ICL reaction mechanism involves a Claisen-type 
condensation via the formation of an enolic intermediate196. The first step involves deprotonation of 
the isocitrate hydroxyl group followed by fragmentation of the isocitrate to form glyoxylate and 
succinate341,342. This has been studied in Mycobacterium tuberculosis199,336, but could reasonably be 
applied to Pseudomonas aeruginosa considering the high conservation of the active site. The catalytic 
residue Cys222 serves as a general acid to aid the formation of the succinate co-product, whereas the 
residue His224 interacts with the catalytic Cys222 aiding the formation of the aci-carboxylate 
intermediate that forms upon C(2)-C(3) bond cleavage. The reaction could not take place without a 
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general base essential to deprotonate the C(2) hydroxyl group of the isocitrate substrate. This would 
be Arg260 as it is within range and already forms hydrogen bonds with the hydroxyl group. The 
mechanism of action would follow this step-by-step process as shown in figure 55 (adapted from 
Bhusal et al.199). In addition, magnesium is important for the catalysis. Isocitrate binds to ICL by 
chelating the Mg2+ via the C(1) carboxylic group and C(2) hydroxyl group. It has been demonstrated 
that Mg2+ is required for optimal activity of the enzyme. Replacement by Mn2+ does not support the 
same catalytic efficiency and other divalent cations would simply abolish the activity of the enzyme313.  
To conclude, isocitrate lyase is of major interest in Pseudomonas aeruginosa. The enzyme is 
vital for replenishing intermediates of the TCA cycle using anaplerosis. Without a functional 
glyoxylate shunt, P. aeruginosa is unable to grow on fatty acids or acetate that are the main nutrient 
sources during infection scenarios. The regulation mechanism proposed here involves metabolite-
mediated enzyme activation (IDH) and inhibition (ICL) to achieve a balanced bifurcation of fluxes 
between two pathways. In future, it will be important to establish the binding affinity of the regulators 
of ICL to further determine the “druggability” of isocitrate lyase. The current well-studied inhibitors 
in Mycobacterium tuberculosis are 3-nitropropionate, itaconate and 3-bromopyruvate. Although these 
compounds are potent inhibitors of M. tuberculosis ICL and P. aeruginosa ICL, they are nonselective 
and possess high toxicity, rendering them unsuitable as potential drug candidates. Effects on the 
growth of rats were reported against itaconate343, 3-nitropropionate caused neurotoxicity344 and 3-
bromopyruvate seems to be an energy blocker (glycolytic pathway enzymes in mammalian cells)345. 
Figure 55: Suggested catalytic mechanism of isocitrate lyase. Figure adapted from Bhusal et al.,2017199. 
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Therefore, these inhibitors were often used as control experiments in ICL inhibitors studies only. The 
interest of the research in isocitrate lyase became more decisive with the first structure solved from 
M. tuberculosis. Since then, it has been suggested as an alluring drug-target not only in bacteria 
(principally P. aeruginosa and Mycobacteria) but also in fungi163. The research I did on P. aeruginosa 
ICL should provide a preliminary ground for downstream development.  
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6. Conclusion 
The adaptation of Pseudomonas aeruginosa to its environment has proven to be important 
during infections. The limited access to rich nutrient sources such as glucose, notably in cystic fibrosis 
lungs, obliges the microorganism to a metabolic rewiring. Increased transcription of isocitrate lyase 
encoded by aceA in P. aeruginosa CF isolates indicates the importance of the glyoxylate shunt 
typically used during growth on fatty acids and acetate as sole carbon sources346. The use of these 
substrates involves metabolic regulatory mechanisms to ensure a balance between metabolite 
oxidation for energy gain and metabolite conservation for biomass production. To conserve 
metabolites for biomass production, Pseudomonas is capable of redirecting the carbon flux through 
the glyoxylate shunt to bypass the two CO2-forming steps and utilizes this anaplerotic pathway to 
replenish gluconeogenic precursors. This is where the pivotal isocitrate branchpoint between the TCA 
cycle and the glyoxylate shunt is of particular interest. At this point, three enzymes compete for the 
same substrate, two isocitrate dehydrogenases (ICD and IDH) and isocitrate lyase (ICL). In 
comparison with the well-studied model of E. coli, in which there are only two competitors for 
isocitrate and a detailed understanding of fluxes partitioning, the molecular mechanisms that control 
partitioning of carbon fluxes between the TCA cycle and glyoxylate shunt were poorly studied in P. 
aeruginosa. 
In P. aeruginosa, all three enzymes have a similar affinity for the substrate. All three Km are 
within the same range with 18 µM, 25 µM and 12 µM for ICD, IDH and ICL respectively. This 
diverges significantly from what we know in E. coli. In enteric bacteria, when the cells evolve in an 
acetate rich environment, the glyoxylate shunt is activated by transcriptional induction of the 
catabolite-repressed ICL-encoding gene and MS-encoding gene. After such transcriptional activation, 
the flux ratio between the TCA cycle and the glyoxylate shunt is controlled by post-translational 
regulation mediated by AceK. The architecture of the E. coli TGB is simple, in case of adaptation to 
acetate in the environment, phosphorylation-driven inactivation of ICD redirects isocitrate through 
the glyoxylate shunt. This means that the bacteria are able to conserve two atoms of carbon. If 
glucose is reintroduced into the environment, AceK dephosphorylates ICD that becomes active, fluxes 
through the glyoxylate shunt is reduced to be redirected towards the TCA cycle. The Km of ICD and 
ICL in E. coli reinforce this understanding as ICD has a higher affinity for isocitrate with a Km of 11 
µM while ICL has a Km of 604 µM. In P. aeruginosa, this AceK-dependent inactivation of ICD is 
functional, even though it does not fully abolish ICD activity. However, the multiplicity of isocitrate 
dehydrogenases and the highly competing isocitrate lyase in P. aeruginosa undermine the E. coli 
model and supposes a more finely tuned architecture of the TGB. 
I have demonstrated that ICD is regulated by AceK-mediated phosphorylation but IDH is 
not. Despite the similarity of ICD and IDH active sites, AceK is incapable of accessing and recognising 
the phosphorylation site Ser133 in IDH. Here, I show that branchpoint partitioning at the TGB is 
6. Conclusion 
114 
controlled by metabolite-mediated activation of IDH alongside inhibition of ICL. Investigation on 
potential regulators of IDH found that glyoxylate, oxaloacetate and pyruvate are potent activators 
of IDH. In contrast, ICL is inhibited by oxaloacetate and pyruvate. This means that the latter two 
compounds emerge as key regulators tuning an elegant balance of carbon fluxes at the P. aeruginosa 
TGB. Glyoxylate, as a unique product of isocitrate lyase, functions as a “rheostat” of IDH activity. 
So, according to this paradigm, when glyoxylate levels increase, IDH is activated while ICL is 
inhibited, this ensures carbon fluxes through the TCA cycle, leading to a decline of glyoxylate levels 
but also securing replenishment of the NADPH/NADH homeostasis to circumvent the increasing 
levels of ROS. Alternatively, when glyoxylate levels decrease, IDH becomes deactivated, ICL becomes 
disinhibited, and carbon flux is driven towards the glyoxylate shunt, leading to a recovery of 
glyoxylate levels. Oxaloacetate and pyruvate finely regulate the balance of carbon fluxes between the 
TCA cycle and glyoxylate shunt. When the levels of these two compounds increase, this means that 
the cells have sufficient gluconeogenic precursors for biomass production, activating IDH and 
inhibiting ICL to ensure again flux through the TCA cycle. By doing so, the cells also secure flux 
through the NADPH-forming step that is isocitrate dehydrogenase as NADPH supplies the reductive 
power necessary to quell the oxidative potential of ROS. This is consistent with a study performed 
on Pseudomonas fluorescens that revealed the importance of NADH/NADPH homeostasis to 1) 
provide ATP via the process of oxidative phosphorylation and 2) nullify the oxidative environment 
after the former phosphorylation248. When the levels of oxaloacetate and pyruvate decrease, IDH 
becomes deactivated and ICL becomes disinhibited which restores fluxes through the glyoxylate 
shunt. Sufficient levels of another gluconeogenic precursor, PEP, inhibits ICL which is consistent with 
the previous paradigm. PEP is a product of glycolysis, and by inhibiting ICL, PEP redirects fluxes 
towards the TCA cycle.  
This elegant regulatory mechanism of the TGB in P. aeruginosa is in contrast with the well-
studied E. coli and Mycobacterium smegmatis. In the former, post-translational AceK-mediated 
inhibition of ICD redirects fluxes through the glyoxylate shunt after up-regulation of ICL-encoding 
gene transcription. Work performed by Dr. Stephen Dolan (Martin Welch laboratory) indicates that 
in E. coli, AceK phosphatase activity is stimulated by α-ketoglutarate, pyruvate and oxaloacetate. 
This reinforces activation of ICD and greater flux through the TCA cycle as gluconeogenic precursors 
levels are sufficient for biomass production. In the latter species, M. smegmatis, the rheostatic control 
of IDH by glyoxylate ensures increased flux through the TCA cycle as levels of glyoxylate increase. 
In contrast, decreased levels of glyoxylate deactivate IDH to ensure that flux go through the 
glyoxylate shunt again regaining levels of glyoxylate. The architecture of the bifurcation in P. 
aeruginosa partially conserves this rheostat that is glyoxylate on IDH. P. aeruginosa also conserves 
the effect of AceK on ICD, phosphorylation of ICD deactivates ICD and dephosphorylation by the 
same AceK activates ICD. However, IDH and ICL are remarkably regulated by a subset of compounds 
that both activate and inhibit the two enzymes. P. aeruginosa mechanistic regulation at the 
bifurcation between the TCA cycle and the glyoxylate shunt resembles aspects seen in other species, 
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however it remains strikingly different compared with the established paradigm in E. coli (figure 56 
adapted from Crousilles. et al.347). 
The structural data of all three enzymes are a major step to characterise the branchpoint in 
Pseudomonas. Despite the fact that the glyoxylate shunt was first discovered in Pseudomonas strain 
KB1, we knew very little about the enzymology of the bifurcation between the TCA cycle and the 
glyoxylate shunt. I presented here three novel structures of ICD, IDH and ICL. ICD is a very 
conserved enzyme among bacteria. Structure solving of P. aeruginosa ICD based on E. coli ICD 
demonstrated high levels of similarity between the two enzymes. The active site is similar, and 
superposition work of ICDPa with ICDEc (co-crystallised with isocitrate and thio-NADP+) 
demonstrated that binding of the substrate and co-factor triggers a hinge motion that closes the 
active site. This also demonstrated how AceK recognises its substrate (ICD); because the active site 
of ICDPa and ICDEc is conserved, the two motifs recognized by AceK (P-loop and ARS) are present 
in ICDPa and there is indeed phosphorylation-mediated regulation of ICD activity. IDHPa was solved 
with NADP+ and α-ketoglutarate in one of the two chains present in the asymmetric unit. The 
crystallographic data demonstrated high levels of similarity of IDHPa compared with IDH from other 
Figure 56: Comparison of the TGB architecture in E. coli, M. smegmatis and P. aeruginosa. Interactions that activate 
the target enzyme are shown in red, interactions that inhibit the enzyme are shown in blue. The rheostat 
mechanism of glyoxylate is present in P. aeruginosa as well as the effect of AceK. However, the architecture of the 
TGB in P. aeruginosa is remarkably different. Figure adapted from Crousilles et al.,2018347 
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species (i.e. Mycobacterium tuberculosis, Corynebacterium glutamicum). Despite the low identity with 
the mycobacterial species, the secondary structure and active site are similar. Like in ICD, IDH 
substrate and co-factor binding residues are similar across several species. When IDH binds isocitrate 
and NADP+, there is a hinge motion that pulls the smaller domain of the enzyme to close the active 
site. In contrast to the first chain of IDH bound to α-ketoglutarate and NADP+, the smaller domain 
of the second chain of P. aeruginosa IDH (not bound to the ligands) showed flexibility and static 
disorder. This suggests that binding of the ligands greatly stabilizes the protein during crystallisation. 
IDH is not phosphorylated by AceK, although Ser133 in IDH resembles Ser115 in ICD 
(phosphorylation site). It is interesting to capture the evolution of IDH from ICD, rendering it immune 
to AceK as the substrate recognition loop of AceK cannot anchor to the IDH site. Finally, ICL in P. 
aeruginosa presented in this work features some remarkable structural observations. The TIM-barrel 
like structure of P. aeruginosa ICL is similar to several bacterial species; however, a significant 
number of additional residues manifest themselves as structural features projecting away from the 
globular core of the enzyme. One speculation is that they are involved in protein-protein interactions 
tightening the tetramer. One of the more remarkable observation is the presence of a catalytic loop 
in ICL that swings inwards upon binding of the substrate. I speculate that the non-competitive and 
uncompetitive inhibition of ICL is aided by this mechanism. In presence of isocitrate, the regulator 
cannot bind to the active site, hence an allostery-mediated inhibition of ICL. 
In conclusion, I have shown that the bifurcation between the TCA cycle and the glyoxylate 
shunt in P. aeruginosa has a complex enzymology profoundly different to that in all other organisms 
characterised to date. The driver behind the study of TGB is its potential as a drug-target. Ongoing 
research work on Mycobacterium tuberculosis and Pseudomonas aeruginosa demonstrated the 
importance of the glyoxylate shunt to survive in a murine lung model of infection199,293,336. 
Furthermore, an alternative screening using a glyoxylate shunt-promoting medium to grow bacteria 
lead to the identification of eight different compounds that had impressive MICs against multiple 
clinically-relevant Gram-negative pathogens165. Furthermore, metabolism and virulence are 
intrinsically related348. The down-regulation of expression of T3SS components in a ∆acea mutant 
PAO1 is an example. The physiological importance of the shunt in infection is not solely due for the 
survival of the bacteria but also for the virulence and ability of the bacteria to colonize a niche. 
Therapeutic agents with the ability to inhibit flux through the glyoxylate shunt or to redirect flux 
through the TCA cycle, would potentially deliver a “double punch” by targeting both metabolic 
defect and virulence. Considering that P. aeruginosa is listed by the WHO in the most critical group 
of pathogens that require new antibiotics, targeting a core component of the cell that is central 
metabolism is surely worth more research. 
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Appendixes 
Appendix 1: Michaelis-Menten plots 
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Appendix 2: SDS-PAGE analysis of His6-tagged proteins 
The analysis after the purification of His6-tagged ICD, IDH and ICL indicates that the products correspond to the 
estimated molecular mass. ICD band is between the 50 kDa and 37 kDa ladder bands, coherent with an estimated 
molecular mass of 46 kDa. IDH molecular mass is estimated to be 82 kDa, the band on the gel seems slightly 
underestimated, however the previous idh insert sequencing was correct. ICL has an estimated molecular mass of 
59 kDa, the third band on the gel is also coherent compared with the molecular mass ladder. Finally, AceK is 
predicted to be 67 kDa, which is coherent with the band seen on the gel. Overall, the proteins purified are correct 
and the purification yielded a highly concentrated solution of each protein. The smearing bands below the main 
ones were indicative of degradation products that did not interfere in any downstream experiment. 
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Appendix 3: Full gel filtration results of IID 
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Appendix 4: ESPript representation of P. aeruginosa ICD 
 
 
 
 
 
 
 
 
 
 
 
        TT           .                                      Escherichia_coli/1-416      
 1       10        20         30        40        50        
Escherichia_coli/1-416          K  VPA G KIT      L VP NPIIP IEGDGIGVD  P M KVVDAAVEKAYKS V    Q    LQ  N       Y         VT A L            .ME V K NGK. E
Pseudomonas_aeruginosa/1-418     K  VPA G KIT      L VP NPIIP IEGDGIGVD  P M KVVDAAVEKAYKQ I    T    VN  S       F         IS V I            MGY Q D ADMS K
                     TT                                     Escherichia_coli/1-416      
60        70        80        90       100       110        
Escherichia_coli/1-416      GERKI WME Y GEK TQVY QD WLP ETLD  R Y V IKGPLTTPVGGGIRSLNVAL        I                 LI E                      S T S G V A R A
Pseudomonas_aeruginosa/1-418 GERKI WME Y GEK TQVY QD WLP ETLD  R Y V IKGPLTTPVGGGIRSLNVAL        V                 AV D                      A A A D T Q V S
                TT                                          Escherichia_coli/1-416      
120       130       140       150       160       170        
Escherichia_coli/1-416      RQ LDLY C RPVR   G PSPVK P   DMVIFRENSEDIYAG EWKA S  AEKVIKF      I     YY       H                I     D       E L Q T ELT D A
Pseudomonas_aeruginosa/1-418 RQ LDLY C RPVR   G PSPVK P   DMVIFRENSEDIYAG EWKA S  AEKVIKF      V     WF       K                V     E       Q Q E V GDV G P
                                                            Escherichia_coli/1-416      
180       190       200       210       220       230        
Escherichia_coli/1-416      L EEMGVKKIRF E CGIGIKP S EGTKRLVR A  YA  NDR SVTLVHKGNIMKFTE                             I   I                   R P H C E A E A D
Pseudomonas_aeruginosa/1-418 L EEMGVKKIRF E CGIGIKP S EGTKRLVR A  YA  NDR SVTLVHKGNIMKFTE                             L   V                   T T N V Q K Q D S
                              TTT                           Escherichia_coli/1-416      
240       250       260       270       280       290        
Escherichia_coli/1-416      GAFKDWGY  AR EFG EL DGGPW   KNP TGK  V KDVIADA LQQILLRPAEYDV        L  E     I     L       I I                    Q G KV N E F
Pseudomonas_aeruginosa/1-418 GAFKDWGY  AR EFG EL DGGPW   KNP TGK  V KDVIADA LQQILLRPAEYDV        V  D     L     M       V V                    E A QF K N M
                                                            Escherichia_coli/1-416      
300       310       320       330       340       350        
Escherichia_coli/1-416      IA  NLNGDY SDALAA VGGIGIAPGAN  D  A FEATHGTAPKYAGQDKVNPGS IL  M      I                 I   L                     I  C Q G EC
Pseudomonas_aeruginosa/1-418 IA  NLNGDY SDALAA VGGIGIAPGAN  D  A FEATHGTAPKYAGQDKVNPGS IL  L      L                 L   M                     L  T E S SV
                                                            Escherichia_coli/1-416      
360       370       380       390       400       410        
Escherichia_coli/1-416      SAEMMLRHMGWTEAADLI KG  GAI AKTVTYDFERLMDGA LL CSEFGDA I  M                    V                             I  ME N K K EN
Pseudomonas_aeruginosa/1-418 SAEMMLRHMGWTEAADLI KG  GAI AKTVTYDFERLMDGA LL CSEFGDA I  M                    I                             M  TN A T S AK
β1 η1 β2 β3 α1 
β4 α2 α3 β5 α4 
β6 η2 β7 η3 β8 α5 
β9 α6 β10 
α7 β11 β12 β13 α8 η4 
β14 α9 η5 β15 β16 η6 
α10 α11 β17 α12 β18 α13 
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Appendix 5: Extracted information from the validation report of ICD PDB deposition 
The percentile ranks, Ramachandran plot and Polygon chart show the final results of structure solving of ICD after 
deposition to the PDB.  
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Appendix 6: Full gel filtration results of IDH 
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Appendix 7: ESPript representation of P. aeruginosa IDH 
 
                                                            P.aeruginosa/1-741  
 1       10        20        30        40        50         
P.aeruginosa/1-741         I  T TDEAP LATY   P   AF    GI  E  DIS A R  A F   L  K Y      A    SLL IVK  A SA  V T    L G IL N D  .MSIRS T F A D S A R EA
M.tuberculosis/1-745        I  T TDEAP LATY   P   AF    GI  E  DIS A R  A F   L   IY      L    L IVR  A A  I    V  IL  PD  TEMSAEQPT L AF EP K AS A E Y
A.vinelandii/1-741         I  T TDEAP LATY   P   AF    GI  E  DIS A R  A F   L  K IY      A    SLL IIK  S   V T    L G LI T PE  TD..MSTP L TG S A R Y
C.glutamicum/1-738         I  T TDEAP LATY   P   AF    GI  E  DIS A R  A F   L  K IW      L    SL  VV   A TA  V T    L G IL Q PE  TE....MA R K E A E R R
                 TT                                         P.aeruginosa/1-741  
60        70        80        90       100       110         
P.aeruginosa/1-741   Q     LA L  L   P  NIIKLPNISASVPQL  AI ELQ  GY  P  P    TD D RI D     ATS DA               K        V DF EDP   E D R AV G A GL K Q E
M.tuberculosis/1-745  Q     LA L  L   P  NIIKLPNISASVPQL  AI ELQ  GY  P  P    TD E RV D   E G  Q  D                A  K     V DY DP   P N R T L T V DK A A K Q
A.vinelandii/1-741   Q     LA L  L   P  NIIKLPNISASVPQL  AI ELQ  GY  P  P    TD  KI D   E G  ATT DA               KA  K     L DY EEP   T S D K QQ K K T
C.glutamicum/1-738   Q     LA L  L   P  NIIKLPNISASVPQL  AI ELQ  GY  P  P    TD D KV   E G  A T EA               KA  K     I E  D   GNA E K DQ D L NAT E
                                                TT          P.aeruginosa/1-741  
120       130       140       150       160       170         
P.aeruginosa/1-741  EK    RY    GSAVNPVLR GNSDRRAP  VK    K PH MG WS  S      M    EVRA  KI          E        AA  YAR H      M  RSHA  A L A S K A DY RG
M.tuberculosis/1-745 EK    RY    GSAVNPVLR GNSDRRAP  VK    K PH MG WS  S      M    IK   R                  A  YAR H      M  RTHVA  A E A CL Q K E S E A H RH
A.vinelandii/1-741  EK    RY    GSAVNPVLR GNSDRRAP  VK    K PH MG WS  S      M    DVKA  KI          E        L   YAR H      A  KSHVA  D K S N K A D H DN
C.glutamicum/1-738  EK    RY    GSAVNPVLR GNSDRRAP  VK    K PH MG WS  S      M    DI A  V          E        IA  FVK       A  KT VA  L NA K N F R E D N T DA
                              .        TT                   P.aeruginosa/1-741  
180       190       200        210       220       230        
P.aeruginosa/1-741   DF   E          V        G     K       G   D    S   L  F   G  F S SI M A  RIE V KD V L L E EVL S M   S Q T AK GD F G KVE. KQ S Q MF CGK RD FEK
M.tuberculosis/1-745  DF   E          V        G     K       G   D    S   L  F   G  Y  KSM L A  RME LAK  VL V L D DVI S M A  AG T DR RN L S KTI PE P D MF KK CD YEE
A.vinelandii/1-741   DF   E          V        G     K       G   D    S   L  F   G  Y S K A I  KIE IAKD VL V  EII S M A  G A L GAPGS L SST AKTS QA SV KN RN IAA
C.glutamicum/1-738   DF   E          V        G     K       G   D    S   L  F     N KSI L A  I IA D IL L L E EVL L A  N RH I DA DE Q KH A TET DS K L GTV AK DA LLE
                 TTT                                        P.aeruginosa/1-741  
240       250       260       270       280       290        
P.aeruginosa/1-741          G   S H KATMMK S PI FG  V     D            G    NG  TL D K T VMW L V      I   V  HA VYYK VF K L L VN N  IQ C E H S D WGQ FEE P S
M.tuberculosis/1-745         G   S H KATMMK S PI FG  V     D            G    NG  QM DA T VMF L V      V   V  HA IFYK AF K EL L VN N  LQ FE H R A HQ FDD V S
A.vinelandii/1-741          G   S H KATMMK S PI FG  V     D            G    NG  I DAK Q VL  V L      V   M  I FYK A K EV I N  IE E K L D Q SE LT HA LKQ FDV G
C.glutamicum/1-738          G   S H KATMMK S PI FG  V     D            G    NG  QV AK  ILF A L      V   I  HV AYF  VF E A LN   LAR AE D R A AQYG QLLA GE A
                                         TT  TT             P.aeruginosa/1-741  
300       310       320       330       340       350        
P.aeruginosa/1-741          L      EI           P  AMV S  GI N H PSDVIVDASMPAMIRVY KI S P E  DI R EM    VK  T L I               S D K ASQQ LH HEVYSH D
M.tuberculosis/1-745         L      EI           P  AMV S  GI N H PSDVIVDASMPAMIRLY KI S P D  DL R EL    AR  S                 D S E ASQR IE HRCHEH D F S
A.vinelandii/1-741          L      EI           P  AMV S  GI N H PSDVIVDASMPAMIRLY RI T P   DI R L    K  T L V               D A K EAKQK EA QAVYAQ Q N D
C.glutamicum/1-738          L      EI           P  AMV S  GI N H PSDVIVDASMPAMIRI L S E   DL    AR  T L V               A LSG E DN..G KAAFEKGLEDG N
       TT                                 TTT               P.aeruginosa/1-741  
360       370       380       390       400       410        
P.aeruginosa/1-741    G M   D    DT A  P       YQ  I  C   G FDPTTMG VPNVGLMAQ AES  WG  GK K  K VM ESTYA I  M  KTN A       S         K  N Q K Q R E NF
M.tuberculosis/1-745   G M   D    DT A  P       YQ  I  C   G FDPTTMG VPNVGLMAQ AE K YG  GK K  K V  ESTF I  I  KTN        T           AG A L N SR E NF Q Q
A.vinelandii/1-741    G M   D    DT A  P       YQ  I  C   G FDPTTMG VPNVGLMAQ AES K WG  GK H  K VI D YA V  V  KQ  A       S         K  D P L RC G V ED H
C.glutamicum/1-738    G M   D    DT A  P       YQ  I  C   G FDPTTMG VPNVGLMAQ AES H W     II DSSYA V  V  R N A       T         K  T NK DQEQ L G T ED K
     TT                           TT                        P.aeruginosa/1-741  
420       430        440       450       460       470       
P.aeruginosa/1-741  EYGSHDKTF    DG         G  L    VE  DIWR C  KDAPI DWVKLAV R          M A  M VV  V M   G    A Q             T AE T T R .LAD S QHK T T R
M.tuberculosis/1-745 EYGSHDKTF    DG         G  L    VE  DIWR C  KDAPI DWVKLAV R          I   VA IV T V L   AG    M V            T AE PE N DVA E TEN I R
A.vinelandii/1-741  EYGSHDKTF    DG         G  L    VE  DIWR C  KDAPI DWVKLAV R          I A  VV V S L L   AG    M QA            N AQ P R TD.E K EQS Q
C.glutamicum/1-738  EYGSHDKTF    DG         G  L    VE  DIWR C  KDAPI DWVKLAV R          I A  VV VV N V I   A     A QV            T R E Q S.S D EHD N Q S
                                  TT                        P.aeruginosa/1-741  
480       490       500       510       520       530       
P.aeruginosa/1-741  R    P  FWLDP R H       V  YL D D  GLDI I            R   G D S  AI      A D L K E   K H     S M EA R SME L R  Q DT E RE RK L LT GYN I V I K
M.tuberculosis/1-745 R    P  FWLDP R H       V  YL D D  GLDI I            R   G D IS  VL       E LI K   K H T     Q MS V R T E L R  GM Y P NE K KT E Q RSM Y C V L
A.vinelandii/1-741  R    P  FWLDP R H       V  YL D D  GLDI I            R   G D AT  AV      A D VI K E   K  T      LS VEA R SL  I   NT A AQ A R Y S R P T F A RE K
C.glutamicum/1-738  R    P  FWLDP R H       V  YL D D  GLDI I            R   G D LS  AV      A D LA  E    H T     Q LS VEA SID I R  GM E RN SL K A E P TQL R E
                                  TT                        P.aeruginosa/1-741  
540       550       560       570       580       590       
P.aeruginosa/1-741  TI  TGN LRDY TDLFPI ELGTSAKMLS VPLM GGG  ETGAGGSAPKHV Q  EE   SV   V    L      M          I    A   MY            Q LV  N
M.tuberculosis/1-745 TI  TGN LRDY TDLFPI ELGTSAKMLS VPLM GGG  ETGAGGSAPKHV Q  EE   A   I    L      L          V    A   MY             LV  NA K
A.vinelandii/1-741  TI  TGN LRDY TDLFPI ELGTSAKMLS VPLM GGG  ETGAGGSAPKHV Q  EE   SV   V    L      M          I       LF            Q L  S F G
C.glutamicum/1-738  TI  TGN LRDY TDLFPI ELGTSAKMLS VPLM GGG  ETGAGGSAPKHV Q  EE   SV   V          L          V    A   LF            Q V   NN Q
β1 α1 β2 α2 η1 
η2 α3 β3 α4 
α5 α6 β4 α7 β5 
α8 β6 β7 β8 β9 α9 
β10 α10 α11 α12 η3 
α13 η4 α14 β11 β12 α15 
β13 β14 α16 β15 
η5 β16 β17 β18 β19 α17 
β20 α18 η6 β21 α19 
β22 α20 η7 β23 β24 α21 
                                                     TT     P.aeruginosa/1-741  
600       610       620       630       640       650       
P.aeruginosa/1-741   LRWDSLGEFLAL            N  A  L   LD A  K L   KSP RK G  DNR            AVS E G TG K L    TG L DN    S  V DI   Y L ET IK A K GKA E N
M.tuberculosis/1-745  LRWDSLGEFLAL            N  A  L   LD A  K L   KSP RK G  DNR            A E G TG R L    G L DN    S   EL   H G GF DI IK E K GKT A I D T
A.vinelandii/1-741   LRWDSLGEFLAL            N  A  L   LD A  K L   KSP RK G  DNR            AAS E G  K V    TG I DN      V EI   Y L HL NAYK P L AST Q N A
C.glutamicum/1-738   LRWDSLGEFLAL            N  A  L   LD A  K L   KSP RK G  DNR            A S NG K V    T  L    S  V EI   H E FRHELNN T G ADA K E NEE
                                                            P.aeruginosa/1-741  
660       670       680       690       700       710       
P.aeruginosa/1-741  GS F L   WA  LAAQ  D  L   F   A  L      I   L   QG      GYY   H Y AMY  Q     NE E A  APL A T QE  V E AV  PAEIG   A A K H K E AT A N K R
M.tuberculosis/1-745 GS F L   WA  LAAQ  D  L   F   A  L      I   L   QG      GYY    Y AMY  Q     TD   A L V T NE  V E V  PVDIG   Q E QQ AEH S D K DV R TE E A
A.vinelandii/1-741  GS F L   WA  LAAQ  D  L   F   A  L      I   L   QG      GYY   H Y ALY  Q     TE E A  GI A T NE  V E AA  PVDI    A K Q Q T K D TK G A K A H
C.glutamicum/1-738  GS F L   WA  LAAQ  D  L   F   A  L      I   L   QG      GYY   H W F      TE D A  APV A N   AV  DLG   TK DE A A T E TGAAD DAA L GAT S
                                                            P.aeruginosa/1-741  
720       730       740                                     
P.aeruginosa/1-741           MRP   FN                                           N ELTS V   SAT  AAID LS P K S A.
M.tuberculosis/1-745          MRP   FN                                           P DMTT V   S T  AALE VDS A K A QG
A.vinelandii/1-741           MRP   FN                                           PN DLTS A   SAT  AAL LT K AP A.
C.glutamicum/1-738           MRP   FN                                           PN E T I   AQ  IVD LE KL N V E A KK
α22 α23 
α24 α25 α26 
α27 α28 
 
 140 
Appendix 8: Extracted information from the validation report of IDH PDB deposition 
The percentile ranks, Ramachandran plot and Polygon chart show the final results of structure solving of IDH after 
deposition to the PDB. 
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Appendix 9: Full gel filtration results of ICL 
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Appendix 10: ESPript representation of ICL 
 
 
 
 
              ..                                            P.aeruginosa/1-531  
1       10          20        30          40        50      
P.aeruginosa/1-531                         W      Y A                A   A      A V L N  IN   I I  MMS YQNEIKA AA ..KEK GSS SA PE A RMR Q..NRFKTGLD KYT AI RKD
E.coli/1-434                               W      Y A                A   A      M I L T  IT   V L  M.. KTR.TQQ EE QKEW. QPR EG RP S EDV KLRGSVNPECT QLG AK WRL
M.tuberculosis/1-428                        W      Y A                A   A      V A I T  VT   V L  LMS VGT.PKS EQ QQEWD NPR KD RT S EDV ALQGSVVEEHT RRG EV WEQ
   TT                                   TT                  M.tuberculosis/1-428
                                     TT                     P.aeruginosa/1-531  
  60        70        80        90       100       110      
P.aeruginosa/1-531                LG   G                      YLSGW VA          M Y Q    L S L       SAEYDADSSV T S CWH FIGQQK I IKKHLKTTNKRY M ALR DF.GPL
E.coli/1-434                      LG   G                      YLSGW VA          L Y N    L Q V       NH..GESKKG I S ALT GQA... Q .....AKAGIEA Q ADA LAASMY
M.tuberculosis/1-428               LG   G                      YLSGW VA          L W N    V Q I       NH..D...LE V A ALT NMA... Q .....VRAGLKA Q GDA LSGHTY
  ..                   ...   .....                    TT    M.tuberculosis/1-428
                                                            P.aeruginosa/1-531  
  120       130       140       150       160       170     
P.aeruginosa/1-531  PDQS      V             AD                                      M T  LI L T   HEK A SG EE Y FLRQ ARELDLLFTGLDAARAAGDKAKEAELLAQIDNFE
E.coli/1-434        PDQS      V             AD                                      L N  VV I N   YPA S PA ER N TFRR QIQ..................WSAGIEPGDPRYV
M.tuberculosis/1-428 PDQS      V             AD                                      L N  VV I N   YPA S PQ RR N ALQR QIA..................KI....EGDTSVE
                             ..................  ....       M.tuberculosis/1-428
          TT                                  TT TT         P.aeruginosa/1-531  
  180       190       200       210       220       230     
P.aeruginosa/1-531      PI AD  AGFG       L K  I AG      E Q    K CGH  GKV  P   V  I  D    A Y   M   A   V        V THV I N EAT L A K E CCIQI N SDE Q QD T HID
E.coli/1-434            PI AD  AGFG       L K  I AG      E Q    K CGH  GKV  P   L  V  E    V F   M   A   L        V DYF A G LNA E M A E AAVHF D ASV K MG L TQE
M.tuberculosis/1-428     PI AD  AGFG       L K  I AG      E Q    K CGH  GKV  P   A  V  E    A Y   L   V   L        I NWL G G LNV E Q A A AGSHW D ASE K LG L TQQ
                                               TT           M.tuberculosis/1-428
                                                            P.aeruginosa/1-531  
  240       250       260       270       280       290     
P.aeruginosa/1-531          R A     V      ARTD   A L                     D     L I V   VIV       EF AK NA Y FLELG DDG SLG G TKQIAVTNEPGDLGDLYNSFL C EIS
E.coli/1-434                R A     V      ARTD   A L                     D     I L A   LLV       DA QK VA L ADVTG P.T ADA D IT..................S C PY.
M.tuberculosis/1-428         R A     V      ARTD   A L                     D     I L A   VVI       DH RT TS L ADVAD P.T AEA T IT..................S V ER.
                                                            
M.tuberculosis/1-428
     TT      TT        TT                                   P.aeruginosa/1-531  
  300       310       320       330       340       350     
P.aeruginosa/1-531                       R        R   G               ADL W ET  E L P  F  D V    L   ESELGNGDVVIKR GKL R K LASNLFQ KGT E RC LDCITSLQNG I EK
E.coli/1-434                             R        R   G               ADL W ET  D I G  F  E I    V   ............. SEF T E TSEGF.. THA I QA SRG.LAYAPY C ST
M.tuberculosis/1-428                      R        R   G               ADL W ET  D I G  Y  E I    I   ............. QPF T E TREGF.. TKN I PC ARA.KAYAPF M GT
                       TT                  .                M.tuberculosis/1-428
                           TT                               P.aeruginosa/1-531  
  360       370       380       390       400       410     
P.aeruginosa/1-531  P                P   L YN SPSFNW           F                 V IK IR   V         H GQ AMVDR EVI NAK N TLNFRQQVFDA VAEGKDVSAYDRNKLM
E.coli/1-434        P                P   L YN SPSFNW           F                 L AR IH   A         D EL RFAQA AKY GKL C QKNLDDKTIAS QQQ.............
M.tuberculosis/1-428 P                P   L YN SPSFNW           F                 L AR VK   A         D EA QFSEA AEY DQM C KKHLDDATIAK QKE.............
                           TT                  .............M.tuberculosis/1-428
                                                            P.aeruginosa/1-531  
  420       430       440       450       460       470     
P.aeruginosa/1-531                              G     ITL   H        LA  Y     MA     A S     SVEYDDTELAKVADEKIRTFQRDGSAH IFHHL PTY T AL TDN KG FADEG
E.coli/1-434                                    G     ITL   H        LA  Y     MM     M N     ........................LSD YKFQF AGI S WF MFD NA AQGEG
M.tuberculosis/1-428                             G     ITL   H        LA  Y     MM     L S     ........................LAA FKFQF AGF A NY MFD YG AQNQ.
........................                                    M.tuberculosis/1-428
                                                            P.aeruginosa/1-531  
  480          490       500       510        520       530 
P.aeruginosa/1-531    YV   Q  E      G     HQ   G    D              A        QF   V     A  G  N   LA KG RQ LR...Q IACVK NM SDIG NHKEYFA .EAALK SGKD TMN H
E.coli/1-434          YV   Q  E      G     HQ   G    D              A        QF   V     V  G  T   KH EK QP FAAAKD YTFVS QE TGYF KVTTIIQ GTSSVT LTGS EES .
M.tuberculosis/1-428   YV   Q  E      G     HQ   G    D              A        QF   L     V  P  T   SA .E ER FAAEER YTATK RE AGYF RIATTVD .NSSTT LTGS EEG H
    .                                                       M.tuberculosis/1-428
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Appendix 11: Full results from COCOMAPS analysis on ICL 
Equivalent interfaces AB = CD, AC = BD, AD = BC  
The first column of graphs presents a black dot at the crossover of two residues i and j, belonging to Molecule 1 and 
Molecule 2, respectively, if any atom of the two residues are closer than the cut-off distance chosen by the user 
(default value being 8 Å). The second column of graphs with each contact colored according to the physico-chemical 
nature of the two interacting residues, violet = hydropohilic-hydrophilic, green = hydrophobic-hydrophobic, 
yellow = hydrophilic-hydropholic. The corresponding Accessible Surface Area (ASA) Table for each mirrored 
interface specifies all the characteristics of the said interface. 
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Appendix 12: Extracted information from the validation report of ICL PDB deposition 
The percentile ranks, Ramachandran plot and Polygon chart show the final results of structure solving of ICL after 
deposition to the PDB. 
 
